Home The Word Brain My Amedeo FAQ Privacy About Flying Publisher   


COVID Reference, 4th edition, 372 pages

+ the daily Top 10


  Diabetes

  Free Subscription


Articles published in Diabetes Obes Metab

Retrieve available abstracts of 640 articles:
HTML format



Single Articles


    August 2020
  1. ZACCARDI F, Jacquot E, Cortese V, Tyrer F, et al
    Comparative effectiveness of gliclazide modified release vs sitagliptin as second-line treatment after metformin monotherapy in patients with uncontrolled type 2 diabetes.
    Diabetes Obes Metab. 2020 Aug 5. doi: 10.1111/dom.14169.
    PubMed     Abstract available


  2. ADINOLFI LE, Petta S, Fracanzani AL, Nevola R, et al
    Reduced incidence of type 2 diabetes in patients with chronic hepatitis C virus infection cleared by direct-acting antivirals therapy. A prospective study.
    Diabetes Obes Metab. 2020 Aug 5. doi: 10.1111/dom.14168.
    PubMed     Abstract available


  3. VERMA S, McGuire DK, Bain SC, Bhatt DL, et al
    Effects of glucagon-like peptide-1 receptor agonists liraglutide and semaglutide on cardiovascular and renal outcomes across body mass index categories in type 2 diabetes: results of the LEADER and SUSTAIN 6 trials.
    Diabetes Obes Metab. 2020 Aug 3. doi: 10.1111/dom.14160.
    PubMed     Abstract available


  4. WAN EYF, Yu EYT, Chen JY, Wong ICK, et al
    Associations between usual glycated haemoglobin A1c and Cardiovascular Disease in Patients with Type 2 Diabetes Mellitus: A 10-year Diabetes cohort study.
    Diabetes Obes Metab. 2020 Aug 3. doi: 10.1111/dom.14157.
    PubMed     Abstract available


  5. MIURA H, Sakaguchi K, Otowa-Suematsu N, Yamada T, et al
    Effects of Insulin Degludec and Insulin Glargine U300 on Glycemic Stability in Individuals with Type 1 Diabetes: a Multicenter, Randomized Controlled Crossover Study.
    Diabetes Obes Metab. 2020 Aug 3. doi: 10.1111/dom.14161.
    PubMed     Abstract available


  6. MCEWAN P, Bennett H, Khunti K, Wilding J, et al
    Assessing the cost-effectiveness of SGLT2i in type 2 diabetes mellitus: a comprehensive economic evaluation using clinical trial and real-world evidence.
    Diabetes Obes Metab. 2020 Aug 3. doi: 10.1111/dom.14162.
    PubMed     Abstract available


  7. LI X, Zhu X, Liu J, Li Q, et al
    Pharmacokinetics, Pharmacodynamics, and Tolerability of Single- and Multiple-Doses of Janagliflozin, a Sodium-Glucose Cotransporter 2 Inhibitor, in Chinese Subjects with Type 2 Diabetes Mellitus.
    Diabetes Obes Metab. 2020 Aug 3. doi: 10.1111/dom.14156.
    PubMed     Abstract available


  8. WANNER C, Inzucchi SE, Zinman B, Koitka-Weber A, et al
    Consistent Effects of Empagliflozin on Cardiovascular and Kidney Outcomes Irrespective of Diabetic Kidney Disease Categories - Insights from the EMPA-REG OUTCOME trial.
    Diabetes Obes Metab. 2020 Aug 3. doi: 10.1111/dom.14158.
    PubMed     Abstract available


    July 2020
  9. MENEGHINI LF, Sullivan SD, Oster G, Busch R, et al
    A pragmatic randomized clinical trial of insulin glargine 300 U/mL versus first-generation basal insulin analogues in insulin-naive adults with type 2 diabetes: 6-month outcomes of ACHIEVE Control.
    Diabetes Obes Metab. 2020 Jul 30. doi: 10.1111/dom.14152.
    PubMed     Abstract available


  10. PRATLEY R, Dagogo-Jack S, Charbonnel B, Patel S, et al
    Efficacy and safety of ertugliflozin in older patients with type 2 diabetes mellitus: A pooled analysis of phase III studies.
    Diabetes Obes Metab. 2020 Jul 23. doi: 10.1111/dom.14150.
    PubMed     Abstract available


  11. HOME P, Blonde L, Kalra S, Ji L, et al
    Insulin glargine/lixisenatide fixed-ratio combination (iGlarLixi) compared to premix or addition of meal-time insulin to basal insulin in people with type 2 diabetes: A systematic review and Bayesian network meta-analysis.
    Diabetes Obes Metab. 2020 Jul 22. doi: 10.1111/dom.14148.
    PubMed     Abstract available


  12. LEE DH, Chun EJ, Moon JH, Yun HM, et al
    Effect of cilostazol on carotid plaque volume measured by 3D ultrasound in patients with type 2 diabetes: FANCY study.
    Diabetes Obes Metab. 2020 Jul 22. doi: 10.1111/dom.14147.
    PubMed     Abstract available


  13. MATHIEU C, Dandona P, Birkenfeld AL, Krarup Hansen T, et al
    Benefit:Risk Profile of Dapagliflozin 5 mg in the DEPICT-1 and -2 Trials in Individuals with Type 1 Diabetes and BMI >/=27 kg/m(2).
    Diabetes Obes Metab. 2020 Jul 20. doi: 10.1111/dom.14144.
    PubMed     Abstract available


  14. MORIERI ML, Bonora BM, Longato E, Di Camilo B, et al
    Exposure to DPP-4 inhibitors and risk of pneumonia among people with type 2 diabetes. Retrospective cohort study and meta-analysis.
    Diabetes Obes Metab. 2020 Jul 20. doi: 10.1111/dom.14142.
    PubMed     Abstract available


  15. VERMA S, Bain SC, Honore JB, Mann JFE, et al
    Impact of microvascular disease on cardiovascular outcomes in type 2 diabetes: Results from the LEADER and SUSTAIN 6 clinical trials.
    Diabetes Obes Metab. 2020 Jul 9. doi: 10.1111/dom.14140.
    PubMed     Abstract available


  16. ZHOU X, Zhou Y, Li X, Xiao X, et al
    Safety concerns of SGLT-2 inhibitors in type 1 diabetes: a real-world study from the perspective of FAERS.
    Diabetes Obes Metab. 2020 Jul 6. doi: 10.1111/dom.14138.
    PubMed    


  17. VAS P, Hopkins D, Feher MD, Rubino F, et al
    Diabetes, Obesity and COVID-19: A Complex Interplay.
    Diabetes Obes Metab. 2020 Jul 6. doi: 10.1111/dom.14134.
    PubMed     Abstract available


  18. HOME PD, Aroda VR, Blonde L, Guyot P, et al
    Efficacy and safety of iGlarLixi versus IDegLira in adults with type 2 diabetes inadequately controlled by glucagon-like peptide-1 receptor agonists (GLP-1RAs): a systematic literature review and indirect treatment comparison.
    Diabetes Obes Metab. 2020 Jul 6. doi: 10.1111/dom.14136.
    PubMed     Abstract available


  19. NIELSEN R, Jorsal A, Tougaard RS, Rasmussen JJ, et al
    The impact of the Glucagon-Like Peptide-1 Receptor Agonist Liraglutide on Natriuretic Peptides in Heart Failure Patients with Reduced Ejection Fraction with and without Type 2 Diabetes.
    Diabetes Obes Metab. 2020 Jul 6. doi: 10.1111/dom.14135.
    PubMed     Abstract available


  20. AHERN AL, Griffin SJ, Wheeler GM, Sharp SJ, et al
    The effect of referral to an open-group behavioural weight management programme on the relative risk of normoglycaemia, non-diabetic hyperglycaemia and type 2 diabetes: secondary analysis of the WRAP trial.
    Diabetes Obes Metab. 2020 Jul 3. doi: 10.1111/dom.14123.
    PubMed     Abstract available


  21. RODBARD HW, Giaccari A, Lajara R, Stewart J, et al
    Sotagliflozin added to optimised insulin therapy leads to HbA1c reduction without weight gain in adults with type 1 diabetes: a pooled analysis of inTandem1 and inTandem2.
    Diabetes Obes Metab. 2020 Jul 3. doi: 10.1111/dom.14127.
    PubMed     Abstract available


    June 2020
  22. HEROLD KC, Reynolds J, Dziura J, Baidal D, et al
    Exenatide ER in patients with Type 1 diabetes with and without residual insulin production.
    Diabetes Obes Metab. 2020 Jun 23. doi: 10.1111/dom.14121.
    PubMed     Abstract available


  23. HAIDER KS, Haider A, Saad F, Doros G, et al
    Remission of type 2 diabetes following long-term treatment with injectable testosterone undecanoate in patients with hypogonadism and type 2 diabetes: 11-year data from a real-world registry study.
    Diabetes Obes Metab. 2020 Jun 19. doi: 10.1111/dom.14122.
    PubMed     Abstract available


  24. JOHANSEN NJ, Dejgaard TF, Lund A, Schluntz C, et al
    Effect of short-acting exenatide administered three times daily on markers of cardiovascular disease in type 1 diabetes: A randomized double-blind placebo-controlled trial.
    Diabetes Obes Metab. 2020 Jun 16. doi: 10.1111/dom.14078.
    PubMed     Abstract available


  25. MENEGHINI L, Blonde L, Gill J, Dauchy A, et al
    Insulin glargine 300 U/mL versus first-generation basal insulin analogues in insulin-naive adults with type 2 diabetes: 12-month outcomes of ACHIEVE Control, a prospective, randomised, pragmatic real-life clinical trial.
    Diabetes Obes Metab. 2020 Jun 15. doi: 10.1111/dom.14116.
    PubMed     Abstract available


  26. BROWN RE, Bech PG, Aronson R
    Semaglutide Once Weekly in Persons with Type 2 Diabetes: Real-world Analysis of the Canadian LMC Diabetes Registry (SPARE Study).
    Diabetes Obes Metab. 2020 Jun 15. doi: 10.1111/dom.14117.
    PubMed     Abstract available


  27. DANNE T, Matsuhisa M, Sussebach C, Goyeau H, et al
    Lower Risk for Severe Hypoglycaemia with Insulin Glargine 300 U/mL vs Glargine 100 U/mL in Participants with Type 1 Diabetes: a Meta-Analysis of 6-Month Phase 3 Clinical Trials.
    Diabetes Obes Metab. 2020 Jun 9. doi: 10.1111/dom.14109.
    PubMed     Abstract available


  28. WU J, Zhang J, Sun X, Wang L, et al
    Influence of diabetes mellitus on the severity and fatality of SARS-CoV-2 infection.
    Diabetes Obes Metab. 2020 Jun 4. doi: 10.1111/dom.14105.
    PubMed     Abstract available


  29. SVANE MS, Johannesen HH, Martinussen C, Bojsen-Moller KN, et al
    No effects of a six-week intervention with glucagon-like peptide-1 receptor analogue on pancreatic volume and edema in obese men without diabetes.
    Diabetes Obes Metab. 2020 Jun 4. doi: 10.1111/dom.14106.
    PubMed     Abstract available


  30. LADWA M, Bello O, Hakim O, Shojaee-Moradie F, et al
    Insulin clearance as the major player in the hyperinsulinaemia of black African men without diabetes.
    Diabetes Obes Metab. 2020 Jun 2. doi: 10.1111/dom.14101.
    PubMed     Abstract available


  31. KLAFF L, Cao D, Dellva MA, Tobian J, et al
    Ultra Rapid Lispro Improves Postprandial Glucose Control Compared With Lispro in Patients With Type 1 Diabetes: Results from the 26-Week PRONTO-T1D Study.
    Diabetes Obes Metab. 2020 Jun 2. doi: 10.1111/dom.14100.
    PubMed     Abstract available


  32. KRAAIJENHOF J, Muskiet MHA, Tonneijck L, Ouwens DM, et al
    Effects of DPP-4 inhibitor linagliptin versus sulfonylurea glimepiride on systemic haemodynamics in overweight patient with type 2 diabetes: a secondary analysis of an 8-week randomized controlled double-blind trial.
    Diabetes Obes Metab. 2020 Jun 1. doi: 10.1111/dom.14107.
    PubMed     Abstract available


  33. MANTSIOU C, Karagiannis T, Kakotrichi P, Malandris K, et al
    Glucagon-like peptide 1 receptor agonists and sodium glucose co-transporter 2 inhibitors as combination therapy for type 2 diabetes. A systematic review and meta-analysis.
    Diabetes Obes Metab. 2020 Jun 1. doi: 10.1111/dom.14108.
    PubMed     Abstract available


  34. COOMANS DE BRACHENE A, Castela A, Op de Beeck A, Mirmira RG, et al
    Pre-clinical evaluation of TYK2 inhibitors for human beta cell protection in type 1 diabetes.
    Diabetes Obes Metab. 2020 Jun 1. doi: 10.1111/dom.14104.
    PubMed     Abstract available


  35. OHKUMA T, Peters SAE, Jun M, Harrap S, et al
    Sex-specific associations between cardiovascular risk factors and myocardial infarction in patients with type 2 diabetes: the ADVANCE-ON study.
    Diabetes Obes Metab. 2020 Jun 1. doi: 10.1111/dom.14103.
    PubMed     Abstract available


  36. CONSOLI A, Czupryniak L, Duarte R, Jermendy G, et al
    Positioning sulfonylureas in a modern treatment algorithm for patients with type 2 diabetes: expert opinion from a European Consensus Panel.
    Diabetes Obes Metab. 2020 Jun 1. doi: 10.1111/dom.14102.
    PubMed     Abstract available


    May 2020
  37. LI H, Tian S, Chen T, Cui Z, et al
    Newly diagnosed diabetes is associated with a higher risk of mortality than known diabetes in hospitalized patients with COVID-19.
    Diabetes Obes Metab. 2020 May 29. doi: 10.1111/dom.14099.
    PubMed     Abstract available


  38. FADINI GP, Morieri ML, Longato E, Bonora BM, et al
    Exposure to DPP-4 inhibitors and COVID-19 among people with type 2 diabetes. A case-control study.
    Diabetes Obes Metab. 2020 May 28. doi: 10.1111/dom.14097.
    PubMed     Abstract available


  39. WAN EYF, Yu EYT, Chin WY, Barrett JK, et al
    Greater variability in lipid measurements associated with cardiovascular disease and mortality: 10-year diabetes cohort study.
    Diabetes Obes Metab. 2020 May 26. doi: 10.1111/dom.14093.
    PubMed     Abstract available


  40. WANG W, Zhang L, Pei X, Pan Q, et al
    Evaluation of the safety of SGLT-2 inhibitors for treating patients with type 1 diabetes.
    Diabetes Obes Metab. 2020 May 21. doi: 10.1111/dom.14092.
    PubMed     Abstract available


  41. KANETO H, Koshida R, Baxter M
    Fixed-ratio combination of basal insulin and glucagon-like peptide-1 receptor agonists in the treatment of Japanese people with type 2 diabetes: An innovative solution to a complex therapeutic challenge.
    Diabetes Obes Metab. 2020 May 20. doi: 10.1111/dom.14095.
    PubMed     Abstract available


  42. GHANIM H, Batra M, Green K, Abuaysheh S, et al
    Liraglutide Treatment in Overweight and Obese Patients with Type 1 Diabetes: A 26 weeks Randomized Controlled Trial.
    Diabetes Obes Metab. 2020 May 19. doi: 10.1111/dom.14090.
    PubMed     Abstract available


  43. BORNER T, Shaulson ED, Tinsley IC, Stein LM, et al
    A second generation GLP-1 receptor agonist mitigates vomiting and anorexia while retaining glucoregulatory potency in lean diabetic and emetic mammalian models.
    Diabetes Obes Metab. 2020 May 14. doi: 10.1111/dom.14089.
    PubMed     Abstract available


  44. ZHANG Y, Li H, Zhang J, Cao Y, et al
    The Clinical Characteristics and Outcomes of Diabetes Mellitus and Secondary Hyperglycaemia Patients with Coronavirus Disease 2019: a Single-center, Retrospective, Observational Study in Wuhan.
    Diabetes Obes Metab. 2020 May 14. doi: 10.1111/dom.14086.
    PubMed     Abstract available


  45. KIM SG, Kim KJ, Yoon KH, Chun SW, et al
    Efficacy and safety of lobeglitazone versus sitagliptin as an add-on to metformin in type 2 diabetes with metabolic syndrome over 24 weeks.
    Diabetes Obes Metab. 2020 May 14. doi: 10.1111/dom.14085.
    PubMed     Abstract available


  46. PRATTICHIZZO F, Giuliani A, Sabbatinelli J, Matacchione G, et al
    Prevalence of residual inflammatory risk and associated clinical variables in patients with type 2 diabetes mellitus.
    Diabetes Obes Metab. 2020 May 11. doi: 10.1111/dom.14081.
    PubMed     Abstract available


  47. MOSER O, Dietrich M, McCarthy O, Bracken RM, et al
    Bolus insulin dose depends on previous-day race intensity during 5 days of professional road-cycle racing in athletes with type 1 diabetes - a prospective observational study.
    Diabetes Obes Metab. 2020 May 8. doi: 10.1111/dom.14083.
    PubMed     Abstract available


  48. RAJPAL A, Ismail-Beigi F
    Intermittent Fasting and "Metabolic Switch": Effects on Metabolic Syndrome, Pre-diabetes and Type 2 Diabetes Mellitus.
    Diabetes Obes Metab. 2020 May 6. doi: 10.1111/dom.14080.
    PubMed     Abstract available


  49. LIU J, Li L, Li S, Wang Y, et al
    SGLT2 inhibitors and risk of diabetic ketoacidosis in patients with type 2 diabetes: systematic review and meta-analysis of randomized controlled trials.
    Diabetes Obes Metab. 2020 May 4. doi: 10.1111/dom.14075.
    PubMed     Abstract available


  50. ZHOU C, Liu M, Zhang Z, Zhang Y, et al
    Positive association of serum uric acid with new-onset diabetes in hypertensive Chinese females found in a retrospective analysis of the China Stroke Primary Prevention Trial (CSPPT).
    Diabetes Obes Metab. 2020 May 3. doi: 10.1111/dom.14072.
    PubMed     Abstract available


  51. BIRKELAND KI, Bodegard J, Eriksson JW, Norhammar A, et al
    Heart failure and chronic kidney disease manifestation and mortality risk associations in type 2 diabetes: a large multinational cohort study.
    Diabetes Obes Metab. 2020 May 3. doi: 10.1111/dom.14074.
    PubMed     Abstract available


  52. MOREA N, Retnakaran R, Vidal J, Aroda VR, et al
    iGlarLixi effectively reduces residual hyperglycemia in patients with type 2 diabetes on basal insulin: a post hoc analysis from the LixiLan-L study.
    Diabetes Obes Metab. 2020 May 3. doi: 10.1111/dom.14077.
    PubMed     Abstract available


    April 2020
  53. PERSSON S, Johansen P, Andersson E, Lindgren P, et al
    Days absent from work due to complications associated with type 2 diabetes: Evidence from 20 years of linked national registry data in Sweden.
    Diabetes Obes Metab. 2020 Apr 24. doi: 10.1111/dom.14070.
    PubMed     Abstract available


  54. SHAH VN, Grimsmann JM, Foster N, Dost A, et al
    Undertreatment of Cardiovascular Risk factors in the Type 1 Diabetes Exchange Clinic Network (USA) and the Prospective Diabetes Follow-up (Germany/Austria) Registries.
    Diabetes Obes Metab. 2020 Apr 24. doi: 10.1111/dom.14069.
    PubMed     Abstract available


  55. VAN DER AART-VAN DER BEEK AB, van Raalte DH, Guja C, Hoogenberg K, et al
    Exenatide once weekly decreases urinary albumin excretion in patients with type 2 diabetes and elevated albuminuria: pooled analysis of randomized active controlled clinical trials.
    Diabetes Obes Metab. 2020 Apr 23. doi: 10.1111/dom.14067.
    PubMed     Abstract available


  56. DEL PRATO S, Frias JP, Blonde L, Aroda VR, et al
    Impact of disease duration and beta-cell reserve on the efficacy of switching to iGlarLixi in adults with type 2 diabetes on GLP-1 receptor agonist therapy: Exploratory analyses from the LixiLan-G trial.
    Diabetes Obes Metab. 2020 Apr 23. doi: 10.1111/dom.14068.
    PubMed     Abstract available


  57. KIM G, Lim S, Kwon HS, Park IB, et al
    Efficacy and safety of evogliptin treatment in patients with type 2 diabetes: A multicenter, active-controlled, randomized, double-blind study with open-label extension (EVERGREEN study).
    Diabetes Obes Metab. 2020 Apr 21. doi: 10.1111/dom.14061.
    PubMed     Abstract available


  58. BOLLI GB, Landgraf W, Bosnyak Z, Melas-Melt L, et al
    Hypoglycaemia risk with insulin glargine 300 U/mL compared with glargine 100 U/mL across different baseline fasting C-peptide levels in insulin-naive people with type 2 diabetes: a post hoc analysis of the EDITION 3 trial.
    Diabetes Obes Metab. 2020 Apr 21. doi: 10.1111/dom.14065.
    PubMed     Abstract available


  59. KAHKOSKA AR, Geybels MS, Klein KR, Kreiner FF, et al
    Validation of distinct type 2 diabetes clusters and their association with diabetes complications in the DEVOTE, LEADER and SUSTAIN-6 cardiovascular outcomes trials.
    Diabetes Obes Metab. 2020 Apr 20. doi: 10.1111/dom.14063.
    PubMed     Abstract available


  60. KITAZAWA T, Seino H, Ohashi H, Inazawa T, et al
    Comparison of tofogliflozin versus glimepiride as the third oral agent added to metformin plus DPP-4 inhibitor in Japanese type 2 diabetes patients: a randomized, 24-week, open label, controlled trial (STOP-OB).
    Diabetes Obes Metab. 2020 Apr 20. doi: 10.1111/dom.14059.
    PubMed     Abstract available


  61. MATHIEU C, Rudofsky G, Phillip M, Araki E, et al
    Long-term efficacy and safety of dapagliflozin in patients with inadequately controlled type 1 diabetes (the DEPICT-2 study): 52-week results from a randomized controlled trial.
    Diabetes Obes Metab. 2020 Apr 20. doi: 10.1111/dom.14060.
    PubMed     Abstract available


  62. TERAUCHI Y, Nakama T, Spranger R, Amano A, et al
    Efficacy and safety of insulin glargine/lixisenatide fixed-ratio combination (iGlarLixi 1:1) in Japanese patients with type 2 diabetes mellitus inadequately controlled on oral antidiabetic drugs: A randomized, 26-week, open-label, multicenter study: T
    Diabetes Obes Metab. 2020 Apr 14. doi: 10.1111/dom.14036.
    PubMed     Abstract available


  63. GIORGINO F, Vora J, Fenici P, Solini A, et al
    Cardiovascular protection with SGLT2 inhibitors in type 2 diabetes mellitus: does it apply to all patients?
    Diabetes Obes Metab. 2020 Apr 14. doi: 10.1111/dom.14055.
    PubMed     Abstract available


  64. ZHANG XM, Ma Y, Chen H, Lou Y, et al
    A pragmatic study of mid-mixture insulin and basal insulin treatment in patients with type 2 diabetes uncontrolled with oral antihyperglycemic medications: A lesson from real-world experience.
    Diabetes Obes Metab. 2020 Apr 8. doi: 10.1111/dom.14052.
    PubMed     Abstract available


  65. THETHI TK, Pratley R, Meier JJ
    Efficacy, safety and cardiovascular outcomes of once-daily oral semaglutide in patients with type 2 diabetes: The PIONEER programme.
    Diabetes Obes Metab. 2020 Apr 8. doi: 10.1111/dom.14054.
    PubMed     Abstract available


  66. RUNESSON B, Xu Y, Qureshi AR, Lindholm B, et al
    Association between reduced kidney function and incident hypoglycemia in people with diabetes; the Stockholm CREAtinine Measurements (SCREAM) project.
    Diabetes Obes Metab. 2020 Apr 6. doi: 10.1111/dom.14051.
    PubMed     Abstract available


  67. HELLER S, Lingvay I, Marso SP, Philis-Tsimikas A, et al
    Risk of severe hypoglycaemia and its impact in type 2 diabetes in DEVOTE.
    Diabetes Obes Metab. 2020 Apr 6. doi: 10.1111/dom.14049.
    PubMed     Abstract available


  68. DUBE MC, D'Amours M, Weisnagel SJ
    Effect of liraglutide on food consumption, appetite sensations and eating behaviours in overweight subjects with type 1 diabetes.
    Diabetes Obes Metab. 2020 Apr 6. doi: 10.1111/dom.14050.
    PubMed     Abstract available


  69. BUTLER J, Januzzi JL, Rosenstock J
    Management of heart failure and type 2 diabetes mellitus: Maximizing complementary drug therapy.
    Diabetes Obes Metab. 2020 Apr 3. doi: 10.1111/dom.14042.
    PubMed     Abstract available


  70. CRESCI B, Cosentino C, Monami M, Mannucci E, et al
    Metabolic Surgery for the Treatment of Type 2 Diabetes: A Network Metanalysis of Randomized Controlled Trials.
    Diabetes Obes Metab. 2020 Apr 3. doi: 10.1111/dom.14045.
    PubMed     Abstract available


  71. HALUZIK M, Cheng A, Muller-Wieland D, Westerbacka J, et al
    Differential glycaemic control with basal insulin glargine 300 U/mL versus degludec 100 U/mL according to kidney function in type 2 diabetes - a subanalysis from the BRIGHT trial.
    Diabetes Obes Metab. 2020 Apr 3. doi: 10.1111/dom.14043.
    PubMed     Abstract available


  72. CAO JY, Waldman B, O'Connell R, Sullivan, et al
    Uric Acid Predicts Long-Term Cardiovascular Risk in Type 2 Diabetes but Does Not Mediate the Benefits of Fenofibrate: the FIELD Study.
    Diabetes Obes Metab. 2020 Apr 3. doi: 10.1111/dom.14046.
    PubMed     Abstract available


  73. CAHN A, Raz I, Bonaca M, Mosenzon O, et al
    Safety of dapagliflozin in a broad population of patients with type 2 diabetes - analyses from the DECLARE - TIMI 58 study.
    Diabetes Obes Metab. 2020 Apr 2. doi: 10.1111/dom.14041.
    PubMed     Abstract available


  74. SAEED MI, Eklof J, Achir I, Sivapalan P, et al
    Use of inhaled corticosteroids and the risk of developing type 2 diabetes in patients with chronic obstructive pulmonary disease.
    Diabetes Obes Metab. 2020 Apr 1. doi: 10.1111/dom.14040.
    PubMed     Abstract available


  75. SELBY NM, Taal MW
    An updated overview of diabetic nephropathy: Diagnosis, prognosis, treatment goals and latest guidelines.
    Diabetes Obes Metab. 2020;22 Suppl 1:3-15.
    PubMed     Abstract available


  76. STEPHENS JW, Brown KE, Min T
    Chronic kidney disease in type 2 diabetes: Implications for managing glycaemic control, cardiovascular and renal risk.
    Diabetes Obes Metab. 2020;22 Suppl 1:32-45.
    PubMed     Abstract available


  77. BARRERA-CHIMAL J, Jaisser F
    Pathophysiologic mechanisms in diabetic kidney disease: A focus on current and future therapeutic targets.
    Diabetes Obes Metab. 2020;22 Suppl 1:16-31.
    PubMed     Abstract available


  78. AL DHAYBI O, Bakris GL
    Non-steroidal mineralocorticoid antagonists: Prospects for renoprotection in diabetic kidney disease.
    Diabetes Obes Metab. 2020;22 Suppl 1:69-76.
    PubMed     Abstract available


  79. SEEGER JD, Nunes A, Loughlin AM
    Using RWE research to extend clinical trials in diabetes: An example with implications for the future.
    Diabetes Obes Metab. 2020;22 Suppl 3:35-44.
    PubMed     Abstract available


  80. ZACCARDI F, Davies MJ, Khunti K
    The present and future scope of real-world evidence research in diabetes: What questions can and cannot be answered and what might be possible in the future?
    Diabetes Obes Metab. 2020;22 Suppl 3:21-34.
    PubMed     Abstract available


  81. PATORNO E, Schneeweiss S, Wang SV
    Transparency in real-world evidence (RWE) studies to build confidence for decision-making: Reporting RWE research in diabetes.
    Diabetes Obes Metab. 2020;22 Suppl 3:45-59.
    PubMed     Abstract available


  82. MARRE M
    Importance of intensive blood pressure control in type 2 diabetes: Mechanisms, treatments and current guidelines.
    Diabetes Obes Metab. 2020;22 Suppl 2:33-42.
    PubMed     Abstract available


    March 2020
  83. JODAR E, Michelsen M, Polonsky WH, Rea R, et al
    Semaglutide improves health-related quality of life vs placebo when added to standard of care in patients with type 2 diabetes at high cardiovascular risk (SUSTAIN 6).
    Diabetes Obes Metab. 2020 Mar 30. doi: 10.1111/dom.14039.
    PubMed     Abstract available


  84. VERMA S, Sharma A, Zinman B, Ofstad AP, et al
    Empagliflozin reduces the risk of mortality and hospitalization for heart failure across Thrombolysis In Myocardial Infarction Risk Score for Heart Failure in Diabetes categories: Post hoc analysis of the EMPA-REG OUTCOME trial.
    Diabetes Obes Metab. 2020 Mar 29. doi: 10.1111/dom.14015.
    PubMed     Abstract available


  85. WAN EYF, Yu EYT, Chin WY, Yan FT, et al
    Age-specific Associations of HbA1c Variability with Cardiovascular Disease and Mortality in Type 2 Diabetes Mellitus Patients: A 10-year cohort study.
    Diabetes Obes Metab. 2020 Mar 20. doi: 10.1111/dom.14034.
    PubMed     Abstract available


  86. YOON KH, Kang J, Kwon SC, Trautmann ME, et al
    Pharmacokinetic and dose-finding studies of efpeglenatide in patients with type 2 diabetes.
    Diabetes Obes Metab. 2020 Mar 16. doi: 10.1111/dom.14032.
    PubMed     Abstract available


  87. DICEMBRINI I, Pala L, Caliri M, Minardi S, et al
    combined continuous glucose monitoring and subcutaneous insulin infusion versus self-monitoring of blood glucose with optimized multiple injections in type 1 diabetes: A randomized cross-over trial.
    Diabetes Obes Metab. 2020 Mar 12. doi: 10.1111/dom.14028.
    PubMed     Abstract available


  88. DE BOER SA, Reijrink M, Abdulahad WH, Hoekstra ES, et al
    Angiogenic T cells are decreased in people with type 2 diabetes mellitus and recruited by the dipeptidyl peptidase-4 inhibitor Linagliptin. A subanalysis from a randomized, placebo controlled trial (RELEASE study).
    Diabetes Obes Metab. 2020 Mar 12. doi: 10.1111/dom.14024.
    PubMed     Abstract available


  89. COUSSA A, Bassil M, Gougeon R, Marliss EB, et al
    Glucose and protein metabolic responses to an energy- but not protein- restricted diet in type 2 Diabetes.
    Diabetes Obes Metab. 2020 Mar 12. doi: 10.1111/dom.14026.
    PubMed     Abstract available


  90. BUZZETTI R, Zampetti S, Pozzilli P
    The Impact Of Obesity On The Increasing Incidence Of Type 1 Diabetes.
    Diabetes Obes Metab. 2020 Mar 10. doi: 10.1111/dom.14022.
    PubMed    


  91. WEBB DR, Htike ZZ, Swarbrick DJ, Brady EM, et al
    A randomised, open label, active comparator trial assessing the effects of 26 weeks of liraglutide or sitagliptin on cardiovascular function in young obese adults with type 2 diabetes.
    Diabetes Obes Metab. 2020 Mar 10. doi: 10.1111/dom.14023.
    PubMed     Abstract available


  92. DEL PRATO S, Kang J, Trautmann ME, Stewart J, et al
    Efficacy and safety of once-monthly efpeglenatide in patients with type 2 diabetes: Results of a phase 2 placebo-controlled, 16-week randomized dose-finding study.
    Diabetes Obes Metab. 2020 Mar 3. doi: 10.1111/dom.14020.
    PubMed     Abstract available


  93. MATSUHISA M, Takita Y, Nasu R, Nagai Y, et al
    Nasal Glucagon as a Viable Alternative to Treat Insulin-induced Hypoglycemia in Japanese Patients with Type 1 and Type 2 Diabetes: A Phase 3 Randomized Crossover Study.
    Diabetes Obes Metab. 2020 Mar 1. doi: 10.1111/dom.14019.
    PubMed    


  94. MULDER S, Hammarstedt A, Nagaraj SB, Nair V, et al
    A metabolomics based molecular pathway analysis for how the SGLT2-inhibitor dapagliflozin may slow kidney function decline in patients with diabetes.
    Diabetes Obes Metab. 2020 Mar 1. doi: 10.1111/dom.14018.
    PubMed     Abstract available


  95. DAVIDSON MB
    Second Generation Basal Insulins to Initiate Insulin Therapy in Type 2 Diabetes: Need for Clinical Evidence Before Incurring Increased Costs.
    Diabetes Obes Metab. 2020 Mar 1. doi: 10.1111/dom.14016.
    PubMed    


    February 2020
  96. SINCLAIR AJ, Heller SR, Pratley RE, Duan R, et al
    Evaluating glucose-lowering treatment in older people with diabetes: Lessons from the IMPERIUM trial.
    Diabetes Obes Metab. 2020 Feb 26. doi: 10.1111/dom.14013.
    PubMed     Abstract available


  97. DERUAZ-LUYET A, Raabe C, Garry EM, Brodovicz KG, et al
    Incidence of lower extremity amputations among patients with type 1 and type 2 diabetes in the United States between 2010 and 2014.
    Diabetes Obes Metab. 2020 Feb 23. doi: 10.1111/dom.14012.
    PubMed     Abstract available


  98. BAJAJ HS, Raz I, Mosenzon O, Murphy SA, et al
    Cardiovascular and renal benefits of dapagliflozin in patients with short and long-standing type 2 diabetes: analyses from the DECLARE-TIMI 58 trial.
    Diabetes Obes Metab. 2020 Feb 23. doi: 10.1111/dom.14011.
    PubMed     Abstract available


  99. WENTWORTH JM, Colman PG
    The methionine aminopeptidase 2 inhibitor ZGN-1061 improves glucose control and weight in overweight and obese individuals with type 2 diabetes: a randomized placebo-controlled trial.
    Diabetes Obes Metab. 2020 Feb 19. doi: 10.1111/dom.14009.
    PubMed     Abstract available


  100. CURTIN F, Champion B, Davoren P, Duke S, et al
    A Safety and Pharmacodynamics Study of Temelimab, an anti-HERV-W-Env Monoclonal Antibody, in Type 1 Diabetes Patients.
    Diabetes Obes Metab. 2020 Feb 19. doi: 10.1111/dom.14010.
    PubMed     Abstract available


  101. KANETO H, Takami A, Spranger R, Amano A, et al
    Efficacy and safety of insulin glargine/lixisenatide fixed-ratio combination (iGlarLixi) in Japanese patients with type 2 diabetes mellitus inadequately controlled on basal insulin and oral antidiabetic drugs: The LixiLan JP-L Randomized Clinical Tria
    Diabetes Obes Metab. 2020 Feb 19. doi: 10.1111/dom.14005.
    PubMed     Abstract available


  102. JOHANSSON L, Hockings PD, Johnsson E, Dronamraju N, et al
    Dapagliflozin plus saxagliptin add-on to metformin reduces liver fat and adipose tissue volume in patients with type 2 diabetes.
    Diabetes Obes Metab. 2020 Feb 18. doi: 10.1111/dom.14004.
    PubMed     Abstract available


  103. FRIAS JP, Gonzalez-Galvez G, Johnsson E, Maaske J, et al
    Efficacy and safety of dual add-on therapy with dapagliflozin plus saxagliptin versus glimepiride in patients with poorly controlled type 2 diabetes on a stable dose of metformin: Results from a 52-week, randomized, active-controlled trial.
    Diabetes Obes Metab. 2020 Feb 12. doi: 10.1111/dom.13997.
    PubMed     Abstract available


  104. MUNCH M, Meyer L, Hannedouche T, Kunz K, et al
    Effect of Adding Vildagliptin to Insulin in Hemodialyzed Patients with Type 2 Diabetes: A Randomized Multicentric Prospective Study-The VILDDIAL Study.
    Diabetes Obes Metab. 2020 Feb 11. doi: 10.1111/dom.13988.
    PubMed     Abstract available


  105. IRACE C, Cutruzzola A, Nuzzi A, Assaloni R, et al
    Clinical Use of a 180-Day Implantable Glucose Sensor Improves Glycated Hemoglobin and Time in Range in Patients with Type 1 Diabetes.
    Diabetes Obes Metab. 2020 Feb 9. doi: 10.1111/dom.13993.
    PubMed     Abstract available


  106. BENNETT H, Tank A, Evans M, Bergenheim K, et al
    Cost-effectiveness of dapagliflozin as an adjunct to insulin for the treatment of Type 1 Diabetes Mellitus in the UK.
    Diabetes Obes Metab. 2020 Feb 9. doi: 10.1111/dom.13992.
    PubMed     Abstract available


  107. COOPER ME, Rosenstock J, Kadowaki T, Seino Y, et al
    Cardiovascular and kidney outcomes of linagliptin treatment in older people with type 2 diabetes and established cardiovascular disease and/or kidney disease: A prespecified subgroup analysis of the randomized, placebo-controlled CARMELINA(R) trial.
    Diabetes Obes Metab. 2020 Feb 9. doi: 10.1111/dom.13995.
    PubMed     Abstract available


  108. SCHERNTHANER G, Groop PH, Kalra PA, Ronco C, et al
    SGLT-2 Inhibitor Renal Outcome Modification in Type-2 Diabetes: Evidence from Studies in Patients with High or Low Renal Risk.
    Diabetes Obes Metab. 2020 Feb 9. doi: 10.1111/dom.13994.
    PubMed    


  109. VERMA S, Ji Q, Bhatt DL, Mazer CD, et al
    The Association Between Uric Acid Levels and Cardio-renal Outcomes and Death in Patients with Type 2 Diabetes: A Subanalysis of EMPA-REG OUTCOME.
    Diabetes Obes Metab. 2020 Feb 6. doi: 10.1111/dom.13991.
    PubMed     Abstract available


  110. BOUTER KEC, van Bommel EJM, Jansen H, van Harskamp D, et al
    The effect of dapagliflozin on apolipoprotein B and glucose fluxes in patients with type 2 diabetes and well controlled plasma LDL cholesterol.
    Diabetes Obes Metab. 2020 Feb 5. doi: 10.1111/dom.13990.
    PubMed     Abstract available


  111. KATSIKI N, Ofori-Asenso R, Ferrannini E, Mazidi M, et al
    Fixed-dose combination of empagliflozin and linagliptin for the treatment of patients with type 2 diabetes mellitus: A systematic review and meta-analysis.
    Diabetes Obes Metab. 2020 Feb 5. doi: 10.1111/dom.13989.
    PubMed     Abstract available


  112. TUTTLE KR, McGill JB
    Evidence-based treatment of hyperglycemia with incretin therapies in patients with type 2 diabetes mellitus and advanced chronic kidney disease.
    Diabetes Obes Metab. 2020 Feb 3. doi: 10.1111/dom.13986.
    PubMed     Abstract available


  113. PETRIE JR, Rossing PR, Campbell IW
    Metformin and cardiorenal outcomes in diabetes: a reappraisal.
    Diabetes Obes Metab. 2020 Feb 3. doi: 10.1111/dom.13984.
    PubMed     Abstract available


    January 2020
  114. VILSBOLL T, Ekholm E, Johnsson E, Garcia-Sanchez R, et al
    Efficacy and safety of dapagliflozin plus saxagliptin versus insulin glargine over 52 weeks as add-on to metformin with or without sulfonylurea in patients with type 2 diabetes: A randomized, parallel-design, open-label, phase 3 trial.
    Diabetes Obes Metab. 2020 Jan 31. doi: 10.1111/dom.13981.
    PubMed     Abstract available


  115. ISMAIL HM, Becker DJ, Libman I, Herold KC, et al
    Early and Late C-peptide Responses during Oral Glucose Tolerance Testing are Oppositely Predictive of Type 1 Diabetes in Autoantibody Positive Individuals.
    Diabetes Obes Metab. 2020 Jan 31. doi: 10.1111/dom.13982.
    PubMed     Abstract available


  116. NEUMAN V, Pruhova S, Kulich M, Kolouskova S, et al
    Gluten-free diet in children with recent-onset type 1 diabetes: a 12-month intervention trial.
    Diabetes Obes Metab. 2020 Jan 27. doi: 10.1111/dom.13974.
    PubMed     Abstract available


  117. BLONDE L, Belousova L, Fainberg U, Garcia-Hernandez PA, et al
    Liraglutide as add-on to SGLT2 inhibitors in patients with inadequately controlled type 2 diabetes: LIRA-ADD2SGLT2i, a 26-week, randomized, double-blind, placebo-controlled trial.
    Diabetes Obes Metab. 2020 Jan 27. doi: 10.1111/dom.13978.
    PubMed     Abstract available


  118. FRIAS JP, Nauck MA, Van J, Benson C, et al
    Efficacy and Tolerability of Tirzepatide, a Dual GIP and GLP-1 Receptor Agonist in Patients with Type 2 Diabetes: A 12-Week, Randomised, Double-Blind, Placebo-Controlled Study to Evaluate Different Dose-Escalation Regimens.
    Diabetes Obes Metab. 2020 Jan 27. doi: 10.1111/dom.13979.
    PubMed     Abstract available


  119. GORDON J, Beresford-Hulme L, Bennett H, Tank A, et al
    The relationship between hypoglycaemia, body mass index and quality of life among patients with type 1 diabetes: observations from the DEPICT clinical trial programme.
    Diabetes Obes Metab. 2020 Jan 22. doi: 10.1111/dom.13972.
    PubMed     Abstract available


  120. JI L, Wan H, Wen B, Wang X, et al
    Higher versus standard starting dose of insulin glargine 100 U/mL in overweight or obese Chinese patients with type 2 diabetes: results of a multicentre, open-label, randomised controlled trial (BEYOND VII).
    Diabetes Obes Metab. 2020 Jan 15. doi: 10.1111/dom.13967.
    PubMed     Abstract available


  121. LING S, Sun P, Zaccardi F, Khosla S, et al
    Durability of glycaemic control in patients with type 2 diabetes after metformin failure: prognostic model derivation and validation using the DISCOVER study.
    Diabetes Obes Metab. 2020 Jan 15. doi: 10.1111/dom.13966.
    PubMed     Abstract available


  122. SCIANNAMEO V, Berchialla P, Orsi E, Lamacchia O, et al
    Enrolment criteria for diabetes cardiovascular outcome trials do not inform on generalizability to clinical practice. The case of GLP-1 receptor agonists.
    Diabetes Obes Metab. 2020 Jan 14. doi: 10.1111/dom.13962.
    PubMed     Abstract available


  123. SINGH P, Taufeeq M, Pesavento TE, Washburn K, et al
    Comparison of two glucagon-like-peptide-1 analogs (GLP -1) dulaglutide vs liraglutide for the management of diabetes in solid organ transplant (SOT): a retrospective study.
    Diabetes Obes Metab. 2020 Jan 13. doi: 10.1111/dom.13964.
    PubMed     Abstract available


  124. PACKER M
    Interplay of AMPK/SIRT1 Activation and Sodium Influx Inhibition Mediates the Renal Benefits of SGLT2 Inhibitors in Type 2 Diabetes: a Novel Conceptual Framework.
    Diabetes Obes Metab. 2020 Jan 9. doi: 10.1111/dom.13961.
    PubMed     Abstract available


  125. BURGGRAAF B, Pouw N, Fernandez Arroyo S, van Vark-van der Zee Lc LC, et al
    A Placebo-controlled Proof-of-Concept Study of Alirocumab on Postprandial Lipids and Vascular Elasticity in Insulin-treated patients with Type 2 Diabetes Mellitus.
    Diabetes Obes Metab. 2020 Jan 7. doi: 10.1111/dom.13960.
    PubMed     Abstract available


  126. KONG APS, Lew T, Lau ESH, Lim LL, et al
    Real-world data reveal unmet clinical needs in insulin treatment in Asians with type 2 diabetes - the Joint Asia Diabetes Evaluation (JADE) Register.
    Diabetes Obes Metab. 2020 Jan 5. doi: 10.1111/dom.13950.
    PubMed     Abstract available


  127. SESTI G, Bardtrum L, Dagdelen S, Halladin N, et al
    A greater proportion of participants with type 2 diabetes achieve treatment targets with IDegLira (insulin degludec/liraglutide) versus insulin glargine U100 at 26 weeks: DUAL VIII a randomized trial designed to resemble clinical practice.
    Diabetes Obes Metab. 2020 Jan 5. doi: 10.1111/dom.13957.
    PubMed     Abstract available


  128. DAWWAS GK, Leonard CE, Garg M, Vouri SM, et al
    12-Year Trends in Pharmacologic Treatment of Type 2 Diabetes among Patients with Heart Failure in the United States.
    Diabetes Obes Metab. 2020 Jan 5. doi: 10.1111/dom.13949.
    PubMed     Abstract available


  129. TSENG JY, Chen HH, Huang KC, Hsu SP, et al
    Effect of mean HbA1c on the association of HbA1c variability and all-cause mortality in patients with type 2 diabetes mellitus.
    Diabetes Obes Metab. 2020 Jan 5. doi: 10.1111/dom.13951.
    PubMed     Abstract available


  130. PHILIS-TSIMIKAS A, Lane W, Pedersen-Bjergaard U, Wysham C, et al
    The relationship between HbA1c and hypoglycaemia in patients with diabetes treated with insulin degludec versus insulin glargine 100 units/mL.
    Diabetes Obes Metab. 2020 Jan 5. doi: 10.1111/dom.13954.
    PubMed     Abstract available


  131. HUSAIN M, Bain SC, Jeppesen OK, Lingvay I, et al
    Semaglutide (SUSTAIN and PIONEER) reduces cardiovascular events in type 2 diabetes across varying cardiovascular risk.
    Diabetes Obes Metab. 2020 Jan 5. doi: 10.1111/dom.13955.
    PubMed     Abstract available


  132. BAASCH-SKYTTE T, Lemgart CT, Oehlenschlager MH, Petersen PE, et al
    Efficacy of 10-20-30 training versus moderate-intensity continuous training on HbA1c , body composition and maximum oxygen uptake in male patients with type 2 diabetes: A randomized controlled trial.
    Diabetes Obes Metab. 2020 Jan 5. doi: 10.1111/dom.13953.
    PubMed     Abstract available


  133. PFOHL M, Jornayvaz FR, Fritsche A, Pscherer S, et al
    Effectiveness and Safety of Insulin Glargine 300 U/mL in Insulin-Naive Patients with Type 2 Diabetes after Failure of Oral Therapy in a Real World Setting.
    Diabetes Obes Metab. 2020 Jan 5. doi: 10.1111/dom.13952.
    PubMed     Abstract available


  134. IDRIS I
    News and Views January 2020: Highlights from the European Association of the Study of Diabetes (EASD) Scientific Meeting 2019.
    Diabetes Obes Metab. 2020;22:135-137.
    PubMed    


    December 2019
  135. GRUNBERGER G, Bhargava A, Ly T, Zisser H, et al
    Human Regular U-500 Insulin via Continuous Subcutaneous Insulin Infusion vs. Multiple Daily Injections in Adults with Type 2 Diabetes: the VIVID Study.
    Diabetes Obes Metab. 2019 Dec 22. doi: 10.1111/dom.13947.
    PubMed     Abstract available


  136. KHUNTI K, Giorgino F, Berard L, Mauricio D, et al
    The importance of the initial period of basal insulin titration in people with diabetes.
    Diabetes Obes Metab. 2019 Dec 22. doi: 10.1111/dom.13946.
    PubMed     Abstract available


  137. PERKINS BA, Soleymanlou N, Rosenstock J, Skyler JS, et al
    Low-Dose Empagliflozin as Adjunct-to-Insulin Therapy in Type 1 Diabetes: A Valid Modeling and Simulation Analysis to Confirm Efficacy.
    Diabetes Obes Metab. 2019 Dec 19. doi: 10.1111/dom.13945.
    PubMed     Abstract available


  138. THIEU VT, Mitchell BD, Varnado OJ, Frier BM, et al
    Treatment and prevention of severe hypoglycaemia in people with diabetes: current and new formulations of glucagon.
    Diabetes Obes Metab. 2019 Dec 9. doi: 10.1111/dom.13941.
    PubMed     Abstract available


  139. VISENTIN R, Schiavon M, Gobel B, Riz M, et al
    Dual GLP-1R/GCGR Agonist SAR425899 Improves Beta-cell Function in Type 2 Diabetes.
    Diabetes Obes Metab. 2019 Dec 5. doi: 10.1111/dom.13939.
    PubMed     Abstract available


  140. DANIELE G, Tura A, Dardano A, Bertolotto A, et al
    Effects of Treatment With Metformin and/or Sitagliptin on Beta-cell Function and Insulin Resistance in Prediabetic Women With Previous Gestational Diabetes.
    Diabetes Obes Metab. 2019 Dec 4. doi: 10.1111/dom.13940.
    PubMed     Abstract available


  141. JI L, Kang ES, Dong X, Li L, et al
    Efficacy and Safety of Insulin Glargine 300 U/mL versus Insulin Glargine 100 U/mL in Asia Pacific Insulin-Naive People with Type 2 Diabetes: The EDITION AP Randomised Controlled Trial.
    Diabetes Obes Metab. 2019 Dec 3. doi: 10.1111/dom.13936.
    PubMed     Abstract available


  142. LIU J, Patel S, Cater NB, Wu L, et al
    Efficacy and safety of ertugliflozin in East/Southeast Asian patients with type 2 diabetes mellitus.
    Diabetes Obes Metab. 2019 Dec 3. doi: 10.1111/dom.13931.
    PubMed     Abstract available


  143. MEIER JJ, Menge BA, Schenker N, Erdmann S, et al
    Effects of sequential treatment with lixisenatide, insulin glargine, or their combination on meal-related glycaemic excursions, insulin and glucagon secretion, and gastric emptying in patients with type 2 diabetes.
    Diabetes Obes Metab. 2019 Dec 3. doi: 10.1111/dom.13935.
    PubMed     Abstract available


  144. ALSALIM W, Goransson O, Tura A, Pacini G, et al
    Persistent whole day meal effects of three dipeptidyl peptidase-4 inhibitors on glycemia and hormonal responses in metformin-treated type 2 diabetes.
    Diabetes Obes Metab. 2019 Dec 2. doi: 10.1111/dom.13934.
    PubMed     Abstract available


  145. AKTURK HK, Giordano D, Champakanath A, Brackett S, et al
    Long-term Real-life Glycemic Outcomes with Hybrid Closed-Loop System when Compared with Sensor-Augmented Pump Therapy in Patients with Type 1 Diabetes.
    Diabetes Obes Metab. 2019 Dec 2. doi: 10.1111/dom.13933.
    PubMed     Abstract available


  146. PETTUS JH, Zhou FL, Shepherd L, Mercaldi K, et al
    Differences between patients with type 1 diabetes with optimal and suboptimal glycaemic control: a real-world study of more than 30 000 patients in a United States electronic health record database.
    Diabetes Obes Metab. 2019 Dec 2. doi: 10.1111/dom.13937.
    PubMed     Abstract available


    November 2019
  147. HALVORSEN YD, Walford G, Thurber T, Russell H, et al
    A Twelve-Week, Randomized, Double-Blind, Placebo-Controlled, Four-Arm Dose-Finding Phase 2 Study Evaluating Bexagliflozin as a Monotherapy for Adults with Type 2 Diabetes.
    Diabetes Obes Metab. 2019 Nov 20. doi: 10.1111/dom.13928.
    PubMed     Abstract available


  148. ARAKI E, Watada H, Uchigata Y, Tomonaga O, et al
    Efficacy and safety of dapagliflozin in Japanese patients with inadequately controlled type 1 diabetes (DEPICT-5): 52-week results from a randomized, open-label, phase III clinical trial.
    Diabetes Obes Metab. 2019 Nov 19. doi: 10.1111/dom.13922.
    PubMed     Abstract available


  149. SCHOLTES RA, van Raalte DH, Correa-Rotter R, Toto RD, et al
    The effects of dapagliflozin on cardio-renal risk factors in patients with type 2 diabetes with or without renin-angiotensin inhibitor treatment: a post hoc analysis.
    Diabetes Obes Metab. 2019 Nov 19. doi: 10.1111/dom.13923.
    PubMed     Abstract available


  150. KNUDSEN ST, Cooper ME
    Renal Protection: What Have We Learnt From ADVANCE About Kidney Disease in Type 2 Diabetes?
    Diabetes Obes Metab. 2019 Nov 14. doi: 10.1111/dom.13917.
    PubMed     Abstract available


  151. HEISE T, Donnelly C, Barve A, Aubonnet P, et al
    Pharmacokinetic and Pharmacodynamic Bioequivalence of Proposed Biosimilar MYL-1501D With US and EU Insulin Glargine Formulations in Patients With Type 1 Diabetes Mellitus.
    Diabetes Obes Metab. 2019 Nov 13. doi: 10.1111/dom.13919.
    PubMed     Abstract available


  152. VIANNA AGD, Lacerda CS, Pechmann LM, Polesel MG, et al
    Improved Glycemic Variability and Time in Range with Dapagliflozin versus Gliclazide Modified Release among Adults with Type 2 Diabetes Evaluated by Continuous Glucose Monitoring: A 12-week Randomized Controlled Trial.
    Diabetes Obes Metab. 2019 Nov 10. doi: 10.1111/dom.13913.
    PubMed     Abstract available


  153. DUFFUS SH, Al Ta'ani Z, Slaughter JC, Niswender KD, et al
    Increased Proportion of Time in Hybrid Closed-Loop "Auto Mode" is Associated with Improved Glycemic Control for Adolescent and Young Adult Type 1 Diabetes Patients Using the MiniMed 670G Insulin Pump.
    Diabetes Obes Metab. 2019 Nov 10. doi: 10.1111/dom.13912.
    PubMed     Abstract available


  154. MORRIS E, Aveyard P, Dyson P, Noreik M, et al
    A food-based low-energy, low-carbohydrate diet for people with type 2 diabetes in primary care: a randomised controlled feasibility trial.
    Diabetes Obes Metab. 2019 Nov 10. doi: 10.1111/dom.13915.
    PubMed     Abstract available


  155. DEJGAARD TF, Schmidt S, Frandsen CS, Vistisen D, et al
    Liraglutide reduces hyperglycaemia and body weight in overweight, dysregulated insulin-pump-treated patients with type 1 diabetes: The Lira Pump trial - a randomized, double-blinded, placebo-controlled trial.
    Diabetes Obes Metab. 2019 Nov 6. doi: 10.1111/dom.13911.
    PubMed     Abstract available


  156. XIE C, Wang X, Jones KL, Horowitz M, et al
    Role of endogenous glucagon-like peptide-1 enhanced by vildagliptin in the glycaemic and energy expenditure responses to intraduodenal fat infusion in type 2 diabetes.
    Diabetes Obes Metab. 2019 Nov 6. doi: 10.1111/dom.13906.
    PubMed     Abstract available


  157. SONE H, Kaneko T, Shiki K, Tachibana Y, et al
    Efficacy and safety of empagliflozin as add-on to insulin in Japanese patients with type 2 diabetes: a randomised, double-blind, placebo-controlled trial.
    Diabetes Obes Metab. 2019 Nov 6. doi: 10.1111/dom.13909.
    PubMed     Abstract available


  158. GASTALDELLI A, Repetto E, Guja C, Hardy E, et al
    Exenatide and dapagliflozin combination improves markers of liver steatosis and fibrosis in patients with type 2 diabetes.
    Diabetes Obes Metab. 2019 Nov 6. doi: 10.1111/dom.13907.
    PubMed     Abstract available


  159. BLEVINS TC, Barve A, Raiter Y, Aubonnet P, et al
    Efficacy and Safety of MYL-1501D Versus Insulin Glargine in Patients With Type 1 Diabetes Mellitus: Results of the INSTRIDE 3 Phase 3 Switch Study.
    Diabetes Obes Metab. 2019 Nov 5. doi: 10.1111/dom.13904.
    PubMed     Abstract available


    October 2019
  160. AVGERINOS I, Michailidis T, Liakos A, Karagiannis T, et al
    Oral semaglutide for type 2 diabetes: a systematic review and meta-analysis.
    Diabetes Obes Metab. 2019 Oct 21. doi: 10.1111/dom.13899.
    PubMed     Abstract available


  161. HANAIRE H, Franc S, Borot S, Penfornis A, et al
    Efficacy of Diabeloop closed-loop to improve glycaemic control in patients with type 1 diabetes exposed to copious dinners or to sustained physical exercise.
    Diabetes Obes Metab. 2019 Oct 16. doi: 10.1111/dom.13898.
    PubMed     Abstract available


  162. LANDGRAF W, Owens DR, Frier BM, Zhang M, et al
    Fasting C-peptide, a biomarker for hypoglycaemia risk in insulin-naive people with type 2 diabetes initiating basal insulin glargine 100 U/mL.
    Diabetes Obes Metab. 2019 Oct 13. doi: 10.1111/dom.13897.
    PubMed     Abstract available


  163. GHOUSE J, Isaksen JL, Skov MW, Lind B, et al
    Effect of diabetes duration on the relationship between glycaemic control and risk of death in older adults with type 2 diabetes.
    Diabetes Obes Metab. 2019 Oct 9. doi: 10.1111/dom.13891.
    PubMed     Abstract available


  164. DOUROS A, Dell'Aniello S, Yu OHY, Suissa S, et al
    Comparative cardiovascular and hypoglycemic safety of glimepiride in type 2 diabetes: A population-based cohort study.
    Diabetes Obes Metab. 2019 Oct 9. doi: 10.1111/dom.13893.
    PubMed     Abstract available


  165. ABERER F, Pferschy PN, Tripolt NJ, Sourij C, et al
    Hypoglycaemia leads to a delayed increase in platelet and coagulation activation markers in people with type 2 diabetes treated with metformin only: Results from a stepwise hypoglycaemic clamp study.
    Diabetes Obes Metab. 2019 Oct 8. doi: 10.1111/dom.13889.
    PubMed     Abstract available


  166. DING Y, Zhu X, Li X, Chen H, et al
    Pharmacokinetics and pharmacodynamics of rongliflozin, a novel selective inhibitor of sodium-glucose co-transporter-2, in people with type 2 diabetes mellitus.
    Diabetes Obes Metab. 2019 Oct 6. doi: 10.1111/dom.13887.
    PubMed     Abstract available


  167. ZABALA A, Darsalia V, Holzmann MJ, Franzen S, et al
    Risk of first stroke in patients with type 2 diabetes and the relation to glycaemic control: a nationwide observational study.
    Diabetes Obes Metab. 2019 Oct 1. doi: 10.1111/dom.13885.
    PubMed     Abstract available


  168. PETRUSKI-IVLEVA N, Schneeweiss S, Eapen S, Rajan A, et al
    Fournier's gangrene in type-2 diabetic patients using second-line anti-diabetic medications.
    Diabetes Obes Metab. 2019 Oct 1. doi: 10.1111/dom.13886.
    PubMed     Abstract available


    September 2019
  169. JI L, Sun N, Zhang Y, Zhang L, et al
    Efficacy of metformin in preventing progression to diabetes in Chinese subjects with impaired glucose regulation: Protocol for a multicenter, open-label, randomized, controlled clinical study.
    Diabetes Obes Metab. 2019 Sep 12. doi: 10.1111/dom.13884.
    PubMed     Abstract available


  170. KWAK SH, Hwang YC, Won JC, Bae JC, et al
    Comparison of Gemigliptin and Dapagliflozin Effects on Glycemic Variability in Type 2 Diabetes: A Randomized, Open-Label, Active-Controlled, 12-Week Study (STABLE II Study).
    Diabetes Obes Metab. 2019 Sep 10. doi: 10.1111/dom.13882.
    PubMed     Abstract available


  171. GIUGLIANO D, Ceriello A, De Nicola L, Perrone-Filardi P, et al
    Primary versus secondary cardiorenal prevention in type 2 diabetes: Which newer antihyperglycaemic drug matters?
    Diabetes Obes Metab. 2019 Sep 9. doi: 10.1111/dom.13881.
    PubMed     Abstract available


  172. KE C, Shah BR, Luk AO, Di Ruggiero E, et al
    Cardiovascular Outcomes Trials in Type 2 Diabetes: Time to Include Young Adults.
    Diabetes Obes Metab. 2019 Sep 4. doi: 10.1111/dom.13874.
    PubMed     Abstract available


  173. RADHOLM K, Zhou Z, Clemens K, Neal B, et al
    Effects of SGLT2 inhibitors in type 2 diabetes, comparing women to men.
    Diabetes Obes Metab. 2019 Sep 4. doi: 10.1111/dom.13876.
    PubMed     Abstract available


  174. SHAO SC, Chang KC, Chien RN, Lin SJ, et al
    Effects of Sodium Glucose Co-transporter 2 Inhibitors on Serum Alanine Aminotransferase Values in Type 2 Diabetes Patients: A Multi-Institutional Cohort Study.
    Diabetes Obes Metab. 2019 Sep 4. doi: 10.1111/dom.13875.
    PubMed     Abstract available


  175. CHO YM, Deerochanawong C, Seekaew S, Suraamornkul S, et al
    Efficacy and safety of gemigliptin as add-on therapy to insulin with or without metformin in patients with type 2 diabetes mellitus (ZEUS II study).
    Diabetes Obes Metab. 2019 Sep 3. doi: 10.1111/dom.13873.
    PubMed     Abstract available


  176. IDRIS I
    News and Views September 2019: American Diabetes Association (ADA) 79th scientific session Highlights.
    Diabetes Obes Metab. 2019;21:2183-2186.
    PubMed    


    August 2019
  177. MEN P, Qu S, Luo W, Li C, et al
    Comparison of lixisenatide in combination with basal insulin versus other insulin regimens for the treatment of patients with type 2 diabetes mellitus inadequately controlled by basal insulin: systematic review, network meta-analysis and cost-effectiv
    Diabetes Obes Metab. 2019 Aug 30. doi: 10.1111/dom.13871.
    PubMed     Abstract available


  178. SHIELDS BM, Hattersley AT, Farmer AJ
    Identifying routine clinical predictors of non-adherence to second line therapies in Type 2 diabetes: a retrospective cohort analysis in a large primary care database.
    Diabetes Obes Metab. 2019 Aug 29. doi: 10.1111/dom.13865.
    PubMed     Abstract available


  179. STEVENS JE, Buttfield M, Wu T, Hatzinikolas S, et al
    Effects of sitagliptin on gastric emptying of, and the glycaemic and blood pressure responses to, a carbohydrate meal in type 2 diabetes.
    Diabetes Obes Metab. 2019 Aug 29. doi: 10.1111/dom.13864.
    PubMed     Abstract available


  180. LANGFORD BE, Evans M, Haskins-Coulter T, O'Connor ME, et al
    Systematic Literature Review and Network Meta-Analysis of SGLT Inhibitors versus Metformin as Add-On to Insulin in Type 1 Diabetes.
    Diabetes Obes Metab. 2019 Aug 29. doi: 10.1111/dom.13863.
    PubMed     Abstract available


  181. SANSOME DJ, Xie C, Veedfald S, Horowitz M, et al
    Mechanism of glucose lowering by metformin in type 2 diabetes: role of bile acids.
    Diabetes Obes Metab. 2019 Aug 29. doi: 10.1111/dom.13869.
    PubMed     Abstract available


  182. KHUNTI K, Chen H, Cid-Ruzafa J, Fenici P, et al
    Glycaemic Control in Patients with Type 2 Diabetes Initiating Second-Line Therapy: Results From the Global DISCOVER Study Programme.
    Diabetes Obes Metab. 2019 Aug 29. doi: 10.1111/dom.13866.
    PubMed     Abstract available


  183. GUO C, Zhou Q, Zhang D, Qin P, et al
    Total sedentary behavior and TV viewing with risk of overweight/obesity, type 2 diabetes, and hypertension: a dose-response meta-analysis.
    Diabetes Obes Metab. 2019 Aug 29. doi: 10.1111/dom.13867.
    PubMed     Abstract available


  184. BALLY L, Herzig D, Ruan Y, Wilinska ME, et al
    Short-term fully closed-loop insulin delivery using faster insulin aspart compared to standard insulin aspart in type 2 diabetes.
    Diabetes Obes Metab. 2019 Aug 28. doi: 10.1111/dom.13861.
    PubMed     Abstract available


  185. NAGARAJ SB, Sidorenkov G, van Boven JFM, Denig P, et al
    Predicting Short-term and Long-term HbA1c Response after Insulin Initiation in Patients with Type 2 Diabetes Mellitus using Machine Learning.
    Diabetes Obes Metab. 2019 Aug 27. doi: 10.1111/dom.13860.
    PubMed     Abstract available


  186. WATADA H, Kaneko S, Komatsu M, Ross Agner B, et al
    Superior HbA1c control with the fixed-ratio combination of insulin degludec and liraglutide (IDegLira) compared with </=50 units insulin degludec in Japanese subjects with type 2 diabetes in a phase 3, double-blind, randomised trial.
    Diabetes Obes Metab. 2019 Aug 18. doi: 10.1111/dom.13859.
    PubMed     Abstract available


  187. CHILTON RJ
    Effects of Sodium-Glucose Cotransporter-2 Inhibitors on the Cardiovascular and Renal Complications of Type 2 Diabetes.
    Diabetes Obes Metab. 2019 Aug 13. doi: 10.1111/dom.13854.
    PubMed     Abstract available


  188. DEKKERS CCJ, Sjostrom CD, Greasley PJ, Cain V, et al
    Effects of the SGLT2 inhibitor dapagliflozin on estimated plasma volume in patients with type 2 diabetes.
    Diabetes Obes Metab. 2019 Aug 13. doi: 10.1111/dom.13855.
    PubMed     Abstract available


  189. KAKU K, Araki E, Tanizawa Y, Ross Agner B, et al
    Superior efficacy with the fixed-ratio combination of insulin degludec and liraglutide (IDegLira) compared with insulin degludec and liraglutide in insulin-naive Japanese subjects with type 2 diabetes in a phase 3, open-label, randomised trial.
    Diabetes Obes Metab. 2019 Aug 13. doi: 10.1111/dom.13856.
    PubMed     Abstract available


  190. GENTILELLA R, Sesti G, Vazquez L, Sapin H, et al
    Dulaglutide is an effective treatment for lowering HbA1c in patients with type 2 diabetes regardless of Body Mass Index.
    Diabetes Obes Metab. 2019 Aug 7. doi: 10.1111/dom.13853.
    PubMed     Abstract available


  191. NORHAMMAR A, Bodegard J, Nystrom T, Thuresson M, et al
    Dapagliflozin vs Non-SGLT-2i Treatment is Associated with Lower Hospital Care Costs in Type 2 Diabetes Patients Similar to the DECLARE-TIMI 58 Participants: A Nationwide Observational Study.
    Diabetes Obes Metab. 2019 Aug 5. doi: 10.1111/dom.13852.
    PubMed     Abstract available


  192. LIM S, Oh TJ, Dawson J, Sattar N, et al
    Diabetes drugs and stroke risk: intensive vs. conventional glucose-lowering strategies, and implications of recent cardiovascular outcome trials.
    Diabetes Obes Metab. 2019 Aug 5. doi: 10.1111/dom.13850.
    PubMed     Abstract available


  193. GIUGLIANO D, Maiorino MI, Bellastella G, Longo M, et al
    GLP-1 receptor agonists for prevention of cardiorenal outcomes in type 2 diabetes: an updated meta-analysis including the REWIND and PIONEER 6 trials.
    Diabetes Obes Metab. 2019 Aug 2. doi: 10.1111/dom.13847.
    PubMed     Abstract available


  194. KIETSIRIROJE N, Pearson S, Campbell M, Ariens RAS, et al
    Double diabetes: A distinct high-risk group?
    Diabetes Obes Metab. 2019 Aug 2. doi: 10.1111/dom.13848.
    PubMed     Abstract available


  195. DICEMBRINI I, Mannucci E, Monami M, Pala L, et al
    Impact of Technology on Glycemic Control in Type 2 Diabetes: A Meta-Analysis of Randomized Trials on Continuous Glucose Monitoring and Continuous Subcutaneous Insulin Infusion.
    Diabetes Obes Metab. 2019 Aug 1. doi: 10.1111/dom.13845.
    PubMed     Abstract available


    July 2019
  196. BAILEY CJ, Del Prato S, Wei C, Reyner D, et al
    Durability of Glycemic Control with Dapagliflozin, an SGLT2 Inhibitor, Compared with Saxagliptin, a DPP4 Inhibitor, in Patients with Inadequately Controlled Type 2 Diabetes.
    Diabetes Obes Metab. 2019 Jul 31. doi: 10.1111/dom.13841.
    PubMed     Abstract available


  197. WILMOT EG, Choudhary P, Leelarathna L, Baxter M, et al
    Glycaemic variability: The under-recognized therapeutic target in type 1 diabetes care.
    Diabetes Obes Metab. 2019 Jul 31. doi: 10.1111/dom.13842.
    PubMed     Abstract available


  198. GIORGINO F, Yu M, Haupt A, Milicevic Z, et al
    Effect of Once Weekly Dulaglutide versus Insulin Glargine in Patients with Type 2 Diabetes and Different Baseline Glycaemic Patterns: A Post-Hoc Analysis of the AWARD-2 Clinical Trial.
    Diabetes Obes Metab. 2019 Jul 31. doi: 10.1111/dom.13844.
    PubMed     Abstract available


  199. MORIERI ML, Rigato M, Frison V, Simioni N, et al
    Fixed versus flexible combination of GLP-1 receptor agonists with basal insulin in type 2 diabetes. A retrospective multicenter comparative effectiveness study.
    Diabetes Obes Metab. 2019 Jul 31. doi: 10.1111/dom.13840.
    PubMed     Abstract available


  200. SANTOS-LOZANO JM, Rada M, Lapetra J, Guinda A, et al
    Prevention of type 2 diabetes in prediabetic patients by using functional olive oil enriched in oleanolic acid: The prediabole study, a randomised controlled trial.
    Diabetes Obes Metab. 2019 Jul 31. doi: 10.1111/dom.13838.
    PubMed     Abstract available


  201. TURTON J, Brinkworth GD, Field R, Parker H, et al
    An evidence-based approach to developing low-carbohydrate diets for type 2 diabetes management: a systematic review of interventions and methods.
    Diabetes Obes Metab. 2019 Jul 26. doi: 10.1111/dom.13837.
    PubMed     Abstract available


  202. RENDELL MS
    COMMENTARY: SGLT inhibitors in type 1 diabetes: place in therapy and a risk mitigation strategy for preventing diabetic ketoacidosis - the STOP DKA Protocol.
    Diabetes Obes Metab. 2019 Jul 23. doi: 10.1111/dom.13836.
    PubMed     Abstract available


  203. MOSER O, Eckstein ML, McCarthy O, Deere R, et al
    Performance of the Freestyle(R) Libre flash glucose monitoring (flash GM) system in people with type 1 diabetes: a secondary outcome analysis of a randomised crossover trial.
    Diabetes Obes Metab. 2019 Jul 23. doi: 10.1111/dom.13835.
    PubMed     Abstract available


  204. LEDESMA G, Umpierrez GE, Morley JE, Lewis-D'Agostino D, et al
    Efficacy and safety of linagliptin to improve glucose control in older people with type 2 diabetes on stable insulin therapy: A randomized trial.
    Diabetes Obes Metab. 2019 Jul 12. doi: 10.1111/dom.13829.
    PubMed     Abstract available


  205. LI P, Geng Z, Ladage VP, Wu J, et al
    Early hypoglycaemia and adherence after basal insulin initiation in a nationally representative sample of Medicare beneficiaries with type 2 diabetes.
    Diabetes Obes Metab. 2019 Jul 12. doi: 10.1111/dom.13832.
    PubMed     Abstract available


  206. HALVORSEN YD, Walford GA, Massaro J, Aftring RP, et al
    A 96-Week Multinational Randomized Double-Blind Parallel-Group Clinical Trial Evaluating the Safety and Effectiveness of Bexagliflozin as a Monotherapy for Adults with Type 2 Diabetes.
    Diabetes Obes Metab. 2019 Jul 12. doi: 10.1111/dom.13833.
    PubMed     Abstract available


  207. NICOLUCCI A, Charbonnel B, Gomes MB, Khunti K, et al
    Treatment patterns and associated factors in 14 668 people with type 2 diabetes initiating a second-line therapy: results from the global DISCOVER study programme.
    Diabetes Obes Metab. 2019 Jul 12. doi: 10.1111/dom.13830.
    PubMed     Abstract available


  208. CHIRIACO M, Pateras K, Virdis A, Charakida M, et al
    Association Between Blood Pressure Variability, Cardiovascular Disease And Mortality In Type 2 Diabetes: A Systematic Review And Meta-Analysis.
    Diabetes Obes Metab. 2019 Jul 7. doi: 10.1111/dom.13828.
    PubMed     Abstract available


  209. BAKER C, Wason S, Banks P, Sawhney S, et al
    Dose-Dependent Glycometabolic Effects of Sotagliflozin on Type 1 Diabetes Over 12 Weeks: the inTandem4 Trial.
    Diabetes Obes Metab. 2019 Jul 2. doi: 10.1111/dom.13825.
    PubMed     Abstract available


  210. DEEROCHANAWONG C, Pheng CS, Matawaran BJ, Sheu WH, et al
    Use of SGLT-2 inhibitors in patients with type 2 diabetes mellitus and multiple cardiovascular risk factors: an Asian perspective and expert recommendations.
    Diabetes Obes Metab. 2019 Jul 2. doi: 10.1111/dom.13819.
    PubMed     Abstract available


  211. HOLLANDER PA, Kiljanski J, Spaepen E, Harris CJ, et al
    The Risk of Clinically Relevant Hypoglycaemia in Patients with Type 2 Diabetes Self-titrating Insulin Glargine U-100.
    Diabetes Obes Metab. 2019 Jul 2. doi: 10.1111/dom.13822.
    PubMed     Abstract available


  212. KENG MJ, Tsiachristas A, Leal J, Gray A, et al
    Impact of achieving primary care targets in Type 2 diabetes on health outcomes and healthcare costs.
    Diabetes Obes Metab. 2019 Jul 2. doi: 10.1111/dom.13821.
    PubMed     Abstract available


  213. MULDER S, Heerspink HJL, Darshi M, Kim JJ, et al
    The effects of dapagliflozin on urinary metabolites in patients with type 2 diabetes.
    Diabetes Obes Metab. 2019 Jul 2. doi: 10.1111/dom.13823.
    PubMed     Abstract available


  214. PRATLEY RE, Kang J, Trautmann ME, Hompesch M, et al
    Body weight management and safety with efpeglenatide in adults without diabetes: a phase II randomized study.
    Diabetes Obes Metab. 2019 Jul 2. doi: 10.1111/dom.13824.
    PubMed     Abstract available


  215. LEGA IC, Bronskill SE, Campitelli MA, Guan J, et al
    Sodium glucose cotransporter 2 inhibitors and risk of genital mycotic and urinary tract infections: a population-based study of older women and men with diabetes.
    Diabetes Obes Metab. 2019 Jul 2. doi: 10.1111/dom.13820.
    PubMed     Abstract available


  216. BAILEY TS, Wu J, Zhou FL, Gupta MTech RA, et al
    Switching to insulin glargine 300 units/mL in real-world older type 2 diabetes patients (DELIVER 3).
    Diabetes Obes Metab. 2019 Jul 2. doi: 10.1111/dom.13818.
    PubMed     Abstract available


    June 2019
  217. JENDLE J, Birkenfeld AL, Polonsky WH, Silver R, et al
    Improved treatment satisfaction in patients with type 2 diabetes treated with once-weekly semaglutide in the SUSTAIN trials.
    Diabetes Obes Metab. 2019 Jun 19. doi: 10.1111/dom.13816.
    PubMed     Abstract available


  218. KHUNTI K, Ji L, Medina J, Surmont F, et al
    Type 2 diabetes treatment and outcomes worldwide: A short review of the DISCOVER study programme.
    Diabetes Obes Metab. 2019 Jun 19. doi: 10.1111/dom.13817.
    PubMed     Abstract available


  219. HOLLAND JA, Martin WP, Docherty NG, le Roux CW, et al
    The Impact of Intentional Weight Loss on Diabetic Kidney Dixg104 10 sease.
    Diabetes Obes Metab. 2019 Jun 17. doi: 10.1111/dom.13813.
    PubMed     Abstract available


  220. GOLDENBERG RM, Gilbert JD, Hramiak IM, Woo VC, et al
    SGLT inhibitors in type 1 diabetes: place in therapy and a risk mitigation strategy for preventing diabetic ketoacidosis - the STOP DKA Protocol.
    Diabetes Obes Metab. 2019 Jun 10. doi: 10.1111/dom.13811.
    PubMed     Abstract available


  221. SABATINE MS, Giugliano RP, Leiter LA
    Correctly Understanding the Diabetes Data in FOURIER.
    Diabetes Obes Metab. 2019 Jun 10. doi: 10.1111/dom.13812.
    PubMed     Abstract available


  222. JOHANSEN ML, Schou M, Rossignol P, Holm MR, et al
    Effect of the mineralocorticoid receptor antagonist eplerenone on liver fat and metabolism in patients with type 2 diabetes: a randomized, double-blind, placebo-controlled trial (MIRAD trial).
    Diabetes Obes Metab. 2019 Jun 10. doi: 10.1111/dom.13809.
    PubMed     Abstract available


  223. MELMER A, Zuger T, Lewis DM, Leibrand S, et al
    Glycemic Control in Individuals with Type 1 Diabetes Using an Open Source Artificial Pancreas System (OpenAPS).
    Diabetes Obes Metab. 2019 Jun 10. doi: 10.1111/dom.13810.
    PubMed     Abstract available


  224. KAKU K, Isaka H, Sakatani T, Toyoshima J, et al
    Efficacy and safety of ipragliflozin add-on therapy to insulin in Japanese patients with type 1 diabetes mellitus: A randomized, double-blind, phase 3 trial.
    Diabetes Obes Metab. 2019 Jun 7. doi: 10.1111/dom.13807.
    PubMed     Abstract available


  225. FRANC S, Joubert M, Daoudi A, Fagour C, et al
    Efficacy of two telemonitoring systems to improve glycaemic control during basal insulin initiation in patients with type 2 diabetes: The TeleDiab-2 randomised controlled trial.
    Diabetes Obes Metab. 2019 Jun 7. doi: 10.1111/dom.13806.
    PubMed     Abstract available


  226. RIED-LARSEN M, Johansen MY, MacDonald CS, Hansen KB, et al
    Type 2 diabetes remission one year after an intensive lifestyle intervention: A secondary analysis of a randomized clinical trial.
    Diabetes Obes Metab. 2019 Jun 5. doi: 10.1111/dom.13802.
    PubMed     Abstract available


  227. ARODA VR, Saugstrup T, Buse JB, Donsmark M, et al
    Incorporating and Interpreting Regulatory Guidance on Estimands in Diabetes Clinical Trials: The PIONEER 1 Randomized Clinical Trial as an Example.
    Diabetes Obes Metab. 2019 Jun 5. doi: 10.1111/dom.13804.
    PubMed     Abstract available


  228. MARTONO DP, Heerspink HJL, Hak E, Denig P, et al
    No significant effect of type 2 diabetes-related genetic risk scores on HbA1c levels after initiating metformin or sulfonylurea derivatives.
    Diabetes Obes Metab. 2019 Jun 5. doi: 10.1111/dom.13803.
    PubMed     Abstract available


  229. MISHRIKY BM, Powell JR, Wittwer JA, Chu JX, et al
    Do GLP-1RA and SGLT-2i reduce cardiovascular events in black patients with type 2 diabetes? A systematic review and meta-analysis.
    Diabetes Obes Metab. 2019 Jun 5. doi: 10.1111/dom.13805.
    PubMed     Abstract available


  230. HALVORSEN YD, Lock JP, Zhou W, Zhu F, et al
    A 24-week, randomized, double-blind, active-controlled clinical trial comparing bexagliflozin to sitagliptin as an adjunct to metformin for the treatment of type 2 diabetes in adults.
    Diabetes Obes Metab. 2019 Jun 4. doi: 10.1111/dom.13801.
    PubMed     Abstract available


    May 2019
  231. HALS IK, Fleiner HF, Reimers N, Astor MC, et al
    Testing for optimal beta cell preserving treatment in Latent Autoimmune Diabetes in Adults (LADA). Results from a 21 month randomized trial.
    Diabetes Obes Metab. 2019 May 30. doi: 10.1111/dom.13797.
    PubMed     Abstract available


  232. SULLIVAN SD, Nicholls CJ, Gupta MTech RA, Meron AA, et al
    Comparable glycaemic control and hypoglycaemia in adults with type 2 diabetes after initiating insulin glargine 300 units/mL or insulin degludec: DELIVER Naive D real-world study.
    Diabetes Obes Metab. 2019 May 30. doi: 10.1111/dom.13793.
    PubMed     Abstract available


  233. PACKER M
    Critical Role of the Epicardium in Mediating Cardiac Inflammation and Fibrosis in Patients With Type 2 Diabetes.
    Diabetes Obes Metab. 2019 May 30. doi: 10.1111/dom.13792.
    PubMed     Abstract available


  234. ROSENSTOCK J, Perl S, Johnsson E, Garcia-Sanchez R, et al
    Triple Therapy With Low-Dose Dapagliflozin Plus Saxagliptin Versus Dual Therapy With Each Monocomponent, All Added to Metformin, in Uncontrolled Type 2 Diabetes.
    Diabetes Obes Metab. 2019 May 30. doi: 10.1111/dom.13795.
    PubMed     Abstract available


  235. YASHIRO H, Hamagami K, Hiyoshi H, Sugama J, et al
    SCO-792, an enteropeptidase inhibitor, improves disease status of diabetes and obesity in mice.
    Diabetes Obes Metab. 2019 May 30. doi: 10.1111/dom.13799.
    PubMed     Abstract available


  236. DAVIES MJ, Russell-Jones D, Barber TM, Lavalle-Gonzalez FJ, et al
    Glycaemic benefit of iGlarLixi in insulin-naive type 2 diabetes patients with high HbA1c or those with inadequate glycaemic control on two oral antihyperglycaemic drugs in the LixiLan-O randomized trial.
    Diabetes Obes Metab. 2019 May 24. doi: 10.1111/dom.13791.
    PubMed     Abstract available


  237. WEISMAN A, Tomlinson GA, Lipscombe LL, Perkins BA, et al
    Author's reply to 'The role of long-term effects of allopurinol on cardiovascular outcomes and all-cause mortality in diabetes'.
    Diabetes Obes Metab. 2019 May 21. doi: 10.1111/dom.13789.
    PubMed     Abstract available


  238. ABTAHI S
    The role of long-term effects of allopurinol on cardiovascular outcomes and all-cause mortality in diabetes.
    Diabetes Obes Metab. 2019 May 21. doi: 10.1111/dom.13790.
    PubMed    


  239. MADDALONI E, Coleman RL, Pozzilli P, Holman RR, et al
    Long-term Risk of Cardiovascular Disease in Individuals with Latent Autoimmune Diabetes of Adults (UKPDS nnn).
    Diabetes Obes Metab. 2019 May 17. doi: 10.1111/dom.13788.
    PubMed     Abstract available


  240. BAKER WL, Beyer-Westendorf J, Bunz TJ, Eriksson D, et al
    Effectiveness and Safety of Rivaroxaban and Warfarin for Prevention of Major Adverse Cardiovascular or Limb Events in Nonvalvular Atrial Fibrillation Patients with Type 2 Diabetes.
    Diabetes Obes Metab. 2019 May 17. doi: 10.1111/dom.13787.
    PubMed     Abstract available


  241. GARRY EM, Buse JB, Gokhale M, Lund JL, et al
    Study Design Choices for Evaluating Comparative Safety of Diabetic Medications: An Evaluation of Pioglitazone and Bladder Cancer Risk Among Older US Adults with Type-2 Diabetes.
    Diabetes Obes Metab. 2019 May 14. doi: 10.1111/dom.13774.
    PubMed     Abstract available


  242. TORIMOTO K, Okada Y, Goshima Y, Tokutsu A, et al
    Addition of canagliflozin to insulin improves glycemic control and reduces insulin dose in patients with type 2 diabetes mellitus: a randomized controlled trial.
    Diabetes Obes Metab. 2019 May 10. doi: 10.1111/dom.13770.
    PubMed     Abstract available


  243. HAKIM O, Bello O, Bonadonna RC, Mohandas C, et al
    Ethnic differences in intrahepatic lipid and its association with hepatic insulin sensitivity and insulin clearance between men of Black and White ethnicity with early type 2 diabetes.
    Diabetes Obes Metab. 2019 May 10. doi: 10.1111/dom.13771.
    PubMed     Abstract available


  244. PFOHL M, Pscherer S, Fritsche A, Anderten H, et al
    Predictors of treatment response in type-2 diabetes patients initiating basal-supported oral therapy with insulin glargine 100 U/mL - a sub-analysis of the Titration and OPtimisation (TOP) registry.
    Diabetes Obes Metab. 2019 May 8. doi: 10.1111/dom.13768.
    PubMed     Abstract available


  245. PIEBER TR, Svehlikova E, Brunner M, Halberg IB, et al
    Fast-acting insulin aspart in subjects with type 2 diabetes: Earlier onset and greater initial exposure and glucose-lowering effect compared with insulin aspart.
    Diabetes Obes Metab. 2019 May 8. doi: 10.1111/dom.13767.
    PubMed     Abstract available


  246. SHARIF S, Groenwold RH, van der Graaf Y, Berkelmans GF, et al
    Mediation analysis of the relationship between type 2 diabetes and cardiovascular events and all-cause mortality: findings from the SMART-cohort.
    Diabetes Obes Metab. 2019 May 7. doi: 10.1111/dom.13759.
    PubMed     Abstract available


  247. ANHOLM C, Kumarathurai P, Samkani A, Pedersen LR, et al
    Effect of liraglutide on estimates of lipolysis and lipid oxidation in obese patients with stable coronary artery disease and newly diagnosed type 2 diabetes: A randomized trial.
    Diabetes Obes Metab. 2019 May 3. doi: 10.1111/dom.13761.
    PubMed     Abstract available


  248. FRIAS JP, Wynne AG, Matyjaszek-Matuszek B, Bartaskova D, et al
    Efficacy and Safety of an Expanded Dulaglutide Dose Range: A Phase 2, Placebo-controlled Trial in Patients with Type 2 Diabetes on Metformin.
    Diabetes Obes Metab. 2019 May 3. doi: 10.1111/dom.13764.
    PubMed     Abstract available


  249. CHRISTENSEN RH, Hansen CS, von Scholten BJ, Jensen MT, et al
    Epicardial and pericardial adipose tissues are associated with reduced diastolic and systolic function in type 2 diabetes.
    Diabetes Obes Metab. 2019 May 3. doi: 10.1111/dom.13758.
    PubMed     Abstract available


  250. TIAN J, Jin, Qi B, Qiyou D, et al
    Evidence and Potential Mechanisms of Traditional Chinese Medicine for the Treatment of Type 2 Diabetes: A Systematic Review and Meta-analysis.
    Diabetes Obes Metab. 2019 May 3. doi: 10.1111/dom.13760.
    PubMed     Abstract available


  251. INOUE M, Lorenz M, Muto H, Wesch R, et al
    Effect of single dose of insulin glargine/lixisenatide fixed ratio combination (iGlarLixi) on postprandial glucodynamic response in Japanese patients with type 2 diabetes mellitus: A phase 1 randomized trial.
    Diabetes Obes Metab. 2019 May 3. doi: 10.1111/dom.13757.
    PubMed     Abstract available


  252. ZHOU FL, Watada H, Tajima Y, Berthelot M, et al
    Identification of subgroups of patients with type 2 diabetes with differences in renal function preservation between sglt2 inhibitors and dpp4 inhibitors using a supervised machine learning algorithm (profile study): A Retrospective analysis of a japa
    Diabetes Obes Metab. 2019 May 3. doi: 10.1111/dom.13753.
    PubMed     Abstract available


  253. BAILEY CJ
    FDA guidance on cardiovascular risk of antidiabetic therapies: One decade later.
    Diabetes Obes Metab. 2019;21:1079-1080.
    PubMed    


    April 2019
  254. KOSHIZAKA M, Ishikawa K, Ishibashi R, Maezawa Y, et al
    Comparing the effects of ipragliflozin versus metformin on visceral fat reduction and metabolic dysfunction in Japanese patients with type 2 diabetes treated with sitagliptin: A prospective, multicentre, open-label, blinded-endpoint, randomised contro
    Diabetes Obes Metab. 2019 Apr 17. doi: 10.1111/dom.13750.
    PubMed     Abstract available


  255. PETTUS J, Gill J, Paranjape S, Stewart J, et al
    Efficacy and safety of a morning injection of insulin glargine 300 units/mL versus insulin glargine 100 units/mL in adult patients with type 1 diabetes: A multicentre, randomized controlled trial using continuous glucose monitoring.
    Diabetes Obes Metab. 2019 Apr 17. doi: 10.1111/dom.13751.
    PubMed     Abstract available


  256. XIA J, Song Y, Rawal S, Wu J, et al
    Vitamin D Status during Pregnancy and the Risk of Gestational Diabetes Mellitus: A Longitudinal Study in a Multiracial Cohort.
    Diabetes Obes Metab. 2019 Apr 17. doi: 10.1111/dom.13748.
    PubMed     Abstract available


  257. ADIELS M, Taskinen MR, Bjornson E, Andersson L, et al
    Role of apolipoprotein C-III overproduction in diabetic dyslipidemia.
    Diabetes Obes Metab. 2019 Apr 10. doi: 10.1111/dom.13744.
    PubMed     Abstract available


  258. GIUGLIANO D, De Nicola L, Maiorino MI, Bellastella G, et al
    Type 2 diabetes and the kidney: insights from cardiovascular outcome trials.
    Diabetes Obes Metab. 2019 Apr 10. doi: 10.1111/dom.13743.
    PubMed     Abstract available


  259. WITTBRODT E, Chamberlain D, Arnold SV, Tang F, et al
    Eligibility of patients with type 2 diabetes for SGLT-2 inhibitor cardiovascular outcomes trials: an assessment using the Diabetes Collaborative Registry.
    Diabetes Obes Metab. 2019 Apr 10. doi: 10.1111/dom.13738.
    PubMed     Abstract available


  260. HALLBERG SJ, Dockter NE, Kushner JA, Athinarayanan SJ, et al
    Improving the Scientific Rigor of Nutritional Recommendations for Adults with Type 2 Diabetes: A Comprehensive Review of the American Diabetes Association Guidelines Recommended Eating Patterns.
    Diabetes Obes Metab. 2019 Apr 3. doi: 10.1111/dom.13736.
    PubMed     Abstract available


  261. TSUJIMOTO T, Kajio H
    No beneficial effects of aspirin on secondary cardiovascular prevention in patients with type 2 diabetes taking non-steroidal anti-inflammatory drugs.
    Diabetes Obes Metab. 2019 Apr 3. doi: 10.1111/dom.13737.
    PubMed     Abstract available


  262. PATORNO E, Gopalakrishnan C, Brodovicz KG, Meyers A, et al
    Cardiovascular safety of linagliptin compared to other oral glucose lowering agents in patients with type 2 diabetes: a sequential monitoring program in routine care.
    Diabetes Obes Metab. 2019 Apr 2. doi: 10.1111/dom.13735.
    PubMed     Abstract available


  263. SPANOPOULOS D, Okhai H, Zaccardi F, Tebboth A, et al
    Temporal variation of renal function in people with type 2 diabetes mellitus: a retrospective UK Clinical Practice Research Datalink cohort study.
    Diabetes Obes Metab. 2019 Apr 2. doi: 10.1111/dom.13734.
    PubMed     Abstract available


  264. SEIDU S, Topsever P, Hambling CE, Cos FX, et al
    Deintensification in older patients with type 2 diabetes: a systematic review of approaches, rates and outcomes.
    Diabetes Obes Metab. 2019 Apr 1. doi: 10.1111/dom.13724.
    PubMed     Abstract available


  265. ARONSON R, Abitbol A, Tweden KS
    First Assessment of the Performance of an Implantable CGM System Through 180 Days in a Primarily Adolescent Population with Type I Diabetes.
    Diabetes Obes Metab. 2019 Apr 1. doi: 10.1111/dom.13726.
    PubMed     Abstract available


  266. YANG W, Ma J, Yuan G, Li L, et al
    Determining the optimal fasting glucose target for patients with type 2 diabetes: results of the multicentre, open-label, randomized-controlled FPG GOAL trial.
    Diabetes Obes Metab. 2019 Apr 1. doi: 10.1111/dom.13733.
    PubMed     Abstract available


  267. DASH S, Leiter LA
    Residual cardiovascular risk among people with diabetes.
    Diabetes Obes Metab. 2019;21 Suppl 1:28-38.
    PubMed     Abstract available


  268. BENGALURU JAYANNA M, Robinson JG
    The extent to which statins have improved cardiovascular outcomes: Lessons from randomized trials and observational studies of "real world" practice in people with diabetes.
    Diabetes Obes Metab. 2019;21 Suppl 1:17-27.
    PubMed     Abstract available


  269. DIJK W, Cariou B
    Efficacy and safety of proprotein convertase subtilisin/kexin 9 inhibitors in people with diabetes and dyslipidaemia.
    Diabetes Obes Metab. 2019;21 Suppl 1:39-51.
    PubMed     Abstract available



  270. New frontiers in cardiovascular risk reduction: people with diabetes and dyslipidaemia.
    Diabetes Obes Metab. 2019;21 Suppl 1:5.
    PubMed    


  271. GONNA H, Ray KK
    The importance of dyslipidaemia in the pathogenesis of cardiovascular disease in people with diabetes.
    Diabetes Obes Metab. 2019;21 Suppl 1:6-16.
    PubMed     Abstract available


  272. BOEDER S, Edelman SV
    Sodium-glucose co-transporter inhibitors as adjunctive treatment to insulin in type 1 diabetes: A review of randomized controlled trials.
    Diabetes Obes Metab. 2019;21 Suppl 2:62-77.
    PubMed     Abstract available


  273. BIESTER T, Kordonouri O, Danne T
    Beyond type 2 diabetes: sodium glucose co-transporter-inhibition in type 1 diabetes.
    Diabetes Obes Metab. 2019;21 Suppl 2:53-61.
    PubMed     Abstract available


    March 2019
  274. POLLOCK RF, Heller S, Pieber TR, Woo V, et al
    Short-term cost-utility of degludec versus glargine U100 for patients with type 2 diabetes at high risk of hypoglycaemia and cardiovascular events - a Canadian setting (DEVOTE 9).
    Diabetes Obes Metab. 2019 Mar 29. doi: 10.1111/dom.13730.
    PubMed     Abstract available


  275. PETERS A, Piletic M, Ejstrud J, Salvesen-Sykes K, et al
    Baseline nocturnal glucose change: a predictor of the treatment effect of bolus intensification in insulin-treated type 2 diabetes.
    Diabetes Obes Metab. 2019 Mar 29. doi: 10.1111/dom.13729.
    PubMed     Abstract available


  276. KLOECKER DE, Zaccardi F, Baldry E, Davies MJ, et al
    Efficacy of Low- and Very-Low-Energy Diets in people with Type 2 Diabetes Mellitus: A systematic review and meta-analysis of interventional studies.
    Diabetes Obes Metab. 2019 Mar 29. doi: 10.1111/dom.13727.
    PubMed     Abstract available


  277. SCHMIDT S, Christensen MB, Serifovski N, Damm-Frydenberg C, et al
    Low versus High Carbohydrate Diet in Type 1 Diabetes: A 12-week randomized open-label crossover study.
    Diabetes Obes Metab. 2019 Mar 29. doi: 10.1111/dom.13725.
    PubMed     Abstract available


  278. KOSTEV K
    Longitudinal Changes in HbA1c following Therapy Intensification after Inadequate Response to Two Oral Antidiabetic Agents in Patients with Type 2 Diabetes in Germany.
    Diabetes Obes Metab. 2019 Mar 25. doi: 10.1111/dom.13707.
    PubMed     Abstract available


  279. FREEMANTLE N, Jourdan S
    Comment on "A comparative effectiveness study of degludec and insulin glargine 300 U/mL in insulin-naive patients with type 2 diabetes".
    Diabetes Obes Metab. 2019 Mar 22. doi: 10.1111/dom.13711.
    PubMed     Abstract available


  280. HELLER SR, DeVries JH, Wysham C, Hansen CT, et al
    Lower rates of hypoglycaemia in older people with type 2 diabetes when using insulin degludec versus insulin glargine U100: results from SWITCH 2.
    Diabetes Obes Metab. 2019 Mar 20. doi: 10.1111/dom.13708.
    PubMed     Abstract available


  281. YANG W, Ma J, Hong T, Liu M, et al
    Efficacy and safety of insulin degludec/insulin aspart versus biphasic insulin aspart 30 in Chinese adults with type 2 diabetes: a phase 3, open-label, 2:1 randomized, treat-to-target trial.
    Diabetes Obes Metab. 2019 Mar 14. doi: 10.1111/dom.13703.
    PubMed     Abstract available


  282. VERMA S, Bain SC, Monk Fries T, Mazer CD, et al
    Duration of Diabetes and Cardiorenal Efficacy of Liraglutide and Semaglutide: A Post Hoc Analysis of the LEADER and SUSTAIN 6 Clinical Trials.
    Diabetes Obes Metab. 2019 Mar 9. doi: 10.1111/dom.13698.
    PubMed     Abstract available


  283. CHEN Y, Yuan Z, Lu J, Eliaschewitz FG, et al
    Randomised study of Evolocumab in Patients With Type 2 Diabetes and Dyslipidaemia on Background Statin: Pre-Specified Analysis of the China Population From the BERSON Clinical Trial.
    Diabetes Obes Metab. 2019 Mar 9. doi: 10.1111/dom.13700.
    PubMed     Abstract available


  284. RUSSELL-JONES D, Dauchy A, Delgado E, Dimitriadis G, et al
    Take Control: A Randomized Trial Evaluating the Efficacy and Safety of Self- Versus Physician-Managed Titration of Insulin Glargine 300 U/mL (Gla-300) in Patients with Uncontrolled Type 2 Diabetes.
    Diabetes Obes Metab. 2019 Mar 8. doi: 10.1111/dom.13697.
    PubMed     Abstract available


  285. PRATLEY RE, Emerson SS, Franek E, Gilbert MP, et al
    Cardiovascular safety and severe hypoglycaemia benefit of insulin degludec versus insulin glargine U100 in patients with type 2 diabetes aged 65 years or older: results from DEVOTE (DEVOTE 7).
    Diabetes Obes Metab. 2019 Mar 8. doi: 10.1111/dom.13699.
    PubMed     Abstract available


  286. KIM K, Unni S, Brixner DI, Thomas SM, et al
    Longitudinal Changes in HbA1c following Treatment Intensification after Inadequate Response to Two Oral Antidiabetic Agents in Patients with Type 2 Diabetes.
    Diabetes Obes Metab. 2019 Mar 7. doi: 10.1111/dom.13694.
    PubMed     Abstract available


  287. BAILEY TS, Zhou FL, Gupta RA, Preblick R, et al
    Glycemic goal attainment and hypoglycemia outcomes in type 2 diabetes patients initiating insulin glargine 300 units/mL or 100 units/mL: Real-world results from the DELIVER Naive cohort study.
    Diabetes Obes Metab. 2019 Mar 6. doi: 10.1111/dom.13693.
    PubMed     Abstract available


  288. DUNKLEY AJ, Fitzpatrick C, Gray LJ, Waheed G, et al
    Incidence and severity of hypoglycaemia in type 2 diabetes by treatment regimen: a UK multi-site 12-month prospective observational study.
    Diabetes Obes Metab. 2019 Mar 6. doi: 10.1111/dom.13690.
    PubMed     Abstract available


  289. LAN NS, Fegan PG, Yeap BB, Rankin JM, et al
    Icosapent ethyl for dyslipidaemia in patients with diabetes and coronary artery disease: act now to reduce it.
    Diabetes Obes Metab. 2019 Mar 4. doi: 10.1111/dom.13689.
    PubMed     Abstract available


  290. ARAKI E, Yamashita S, Arai H, Yokote K, et al
    The Efficacy and Safety of Pemafibrate in Patients with Type 2 Diabetes and Elevated Triglyceride levels: 52-Week Data From The PROVIDE Study.
    Diabetes Obes Metab. 2019 Mar 4. doi: 10.1111/dom.13686.
    PubMed     Abstract available


  291. JI L, Liu Y, Miao H, Xie Y, et al
    Safety and efficacy of ertugliflozin in Asian patients with type 2 diabetes mellitus inadequately controlled with metformin monotherapy: VERTIS Asia.
    Diabetes Obes Metab. 2019 Mar 4. doi: 10.1111/dom.13681.
    PubMed     Abstract available


  292. DENNIS JM, Henley WE, McGovern AP, Farmer AJ, et al
    Time trends in prescribing of type 2 diabetes drugs, glycemic response and risk factors: a retrospective analysis of primary care data, 2010-2017.
    Diabetes Obes Metab. 2019 Mar 3. doi: 10.1111/dom.13687.
    PubMed     Abstract available


  293. MEIFFREN G, Herbrand T, Anastassiadis E, Klein O, et al
    Better glycemic control with BioChaperone Combo (BC Combo) than with insulin lispro Mix25 (LMix) or separate glargine & lispro (G+L) administrations after a test meal in subjects with type 2 diabetes (T2DM).
    Diabetes Obes Metab. 2019 Mar 3. doi: 10.1111/dom.13685.
    PubMed     Abstract available


  294. UNGER J, Allison DC, Carlton M, Lakkole K, et al
    Trial design and baseline data for LIRA-PRIME: a randomized trial investigating the efficacy of liraglutide in controlling glycemia in type 2 diabetes in a primary care setting.
    Diabetes Obes Metab. 2019 Mar 3. doi: 10.1111/dom.13682.
    PubMed     Abstract available


  295. LORENZATTI AJ, Eliaschewitz FG, Chen Y, Lu J, et al
    Randomised Study of Evolocumab in Patients With Type 2 Diabetes and Dyslipidaemia on Background Statin: Primary Results of the BERSON Clinical Trial.
    Diabetes Obes Metab. 2019 Mar 1. doi: 10.1111/dom.13680.
    PubMed     Abstract available


  296. KAKU K, Isaka H, Toyoshima J, Sakatani T, et al
    Clinical pharmacology study of ipragliflozin in Japanese patients with type 1 diabetes mellitus: A phase 2, randomized, placebo-controlled trial.
    Diabetes Obes Metab. 2019 Mar 1. doi: 10.1111/dom.13679.
    PubMed     Abstract available


    February 2019
  297. RUGGENENTI P, Trillini M, P Barlovic D, Cortinovis M, et al
    Effects of valsartan, benazepril and their combination in overt nephropathy of type 2 diabetes: A prospective, randomized, controlled trial.
    Diabetes Obes Metab. 2019 Feb 22. doi: 10.1111/dom.13639.
    PubMed     Abstract available


  298. VILSBOLL T, Blevins TC, Jodar E, Poulter N, et al
    Fixed-ratio combination of insulin degludec and liraglutide (IDegLira) improves cardiovascular risk markers in patients with type 2 diabetes uncontrolled on basal insulin.
    Diabetes Obes Metab. 2019 Feb 20. doi: 10.1111/dom.13675.
    PubMed     Abstract available


  299. JACOBI SF, Khajavi N, Kleinau G, Teumer A, et al
    Evaluation of a rare glucose-dependent insulinotropic polypeptide receptor variant in a patient with diabetes.
    Diabetes Obes Metab. 2019 Feb 19. doi: 10.1111/dom.13634.
    PubMed     Abstract available


  300. MENEGHINI LF, Mauricio D, Orsi E, Lalic NM, et al
    The Diabetes Unmet Need with basal insulin Evaluation (DUNE) study in type 2 diabetes: Achieving HbA1c targets with basal insulin in a real-world setting.
    Diabetes Obes Metab. 2019 Feb 15. doi: 10.1111/dom.13673.
    PubMed     Abstract available


  301. JOHNSTON SS, Ammann EM, Kashyap SR, Stokes A, et al
    Body Mass Index and Insulin Use as Identifiers of High-Cost Patients with Type 2 Diabetes: A Retrospective Analysis of Electronic Health Records Linked to Insurance Claims Data.
    Diabetes Obes Metab. 2019 Feb 15. doi: 10.1111/dom.13671.
    PubMed     Abstract available


  302. TUTTLE KR, Lakshmanan MC, Rayner B, Zimmermann AG, et al
    Body Weight and eGFR during Dulaglutide Treatment in Type 2 Diabetes and Moderate-to-Severe Chronic Kidney Disease (AWARD-7).
    Diabetes Obes Metab. 2019 Feb 14. doi: 10.1111/dom.13668.
    PubMed     Abstract available


  303. LYTVYN Y, Bjornstad P, Lovshin JA, Singh SK, et al
    The Association Between Uric Acid, Renal Hemodynamics and Arterial Stiffness Over the Natural History of Type 1 Diabetes.
    Diabetes Obes Metab. 2019 Feb 13. doi: 10.1111/dom.13665.
    PubMed     Abstract available


  304. PHILIS-TSIMIKAS A, Billings LK, Busch R, Morales Portillo C, et al
    Superior Efficacy of Insulin Degludec/Liraglutide versus Insulin Glargine U100 as Add-on to Sodium-Glucose Co-Transporter-2 Inhibitor Therapy: a Randomized Clinical Trial in Patients with Uncontrolled Type 2 Diabetes.
    Diabetes Obes Metab. 2019 Feb 13. doi: 10.1111/dom.13666.
    PubMed     Abstract available


  305. LEE DH, Chun EJ, Oh TJ, Kim KM, et al
    Effect of Cilostazol, a Phosphodiesterase-3 Inhibitor, on Coronary Artery Stenosis and Plaque Characteristics in Patients with Type 2 Diabetes (ESCAPE Study).
    Diabetes Obes Metab. 2019 Feb 13. doi: 10.1111/dom.13667.
    PubMed     Abstract available


  306. PARKINSON J, Tang W, Astrand M, Melin J, et al
    Model-based characterization of the relationship between dapagliflozin systemic exposure and HbA1c response in patients with type 1 diabetes mellitus.
    Diabetes Obes Metab. 2019 Feb 12. doi: 10.1111/dom.13664.
    PubMed     Abstract available


  307. CANIVELL S, Mata-Cases M, Real J, Franch-Nadal J, et al
    Glycemic Control after Treatment Intensification in Patients with Type 2 Diabetes Uncontrolled on Two or More Non-Insulin Antidiabetic Drugs in a Real-World Setting.
    Diabetes Obes Metab. 2019 Feb 12. doi: 10.1111/dom.13663.
    PubMed     Abstract available


  308. MEZQUITA RAYA P, Ampudia Blasco FJ, Hunt B, Martin V, et al
    Evaluating the Long-Term Cost-Effectiveness of ideglira for type 2 diabetes in spain based on Real-World clinical evidence.
    Diabetes Obes Metab. 2019 Feb 11. doi: 10.1111/dom.13660.
    PubMed     Abstract available


  309. WEISMAN A, Tomlinson GA, Lipscombe LL, Perkins BA, et al
    Association between allopurinol and cardiovascular outcomes and all-cause mortality in diabetes: A retrospective, population-based cohort study.
    Diabetes Obes Metab. 2019 Feb 8. doi: 10.1111/dom.13656.
    PubMed     Abstract available


  310. FUECHTENBUSCH M, Aberle J, Heitmann E, Nicolay C, et al
    Weight loss in patients with type 2 diabetes (T2D) mellitus receiving once-weekly dulaglutide plus insulin lispro or insulin glargine plus insulin lispro: An AWARD-4 post-hoc analysis across baseline body mass index subgroups.
    Diabetes Obes Metab. 2019 Feb 8. doi: 10.1111/dom.13658.
    PubMed     Abstract available


  311. BELL DSH, Goncalves E
    Heart Failure in the diabetic patient - epidemiology, etiology, prognosis, therapy and the effect of glucose lowering medications.
    Diabetes Obes Metab. 2019 Feb 5. doi: 10.1111/dom.13652.
    PubMed     Abstract available


  312. HE YL, Haynes W, Meyers CD, Amer A, et al
    The effects of licogliflozin, a dual SGLT1/2 inhibitor, on body weight in obese patients with or without diabetes.
    Diabetes Obes Metab. 2019 Feb 5. doi: 10.1111/dom.13654.
    PubMed     Abstract available


  313. GARIANI K, Lebowitz D, Kressmann B, von Dach E, et al
    Oral Amoxicillin/Clavulanate for Treating Diabetic Foot Infections.
    Diabetes Obes Metab. 2019 Feb 5. doi: 10.1111/dom.13651.
    PubMed     Abstract available


  314. BOYE KS, Riddle MC, Gerstein HC, Mody R, et al
    Generalizability of Glucagon-Like Peptide-1 Receptor Agonist Cardiovascular Outcome Trials to the Overall Type 2 Diabetes Population in the United States.
    Diabetes Obes Metab. 2019 Feb 3. doi: 10.1111/dom.13649.
    PubMed     Abstract available


    January 2019
  315. TOYAMA T, Neuen BL, Jun M, Ohkuma T, et al
    Effect of SGLT2 inhibitors on cardiovascular, renal and safety outcomes in patients with type 2 diabetes mellitus and chronic kidney disease: a systematic review and meta-analysis.
    Diabetes Obes Metab. 2019 Jan 29. doi: 10.1111/dom.13648.
    PubMed     Abstract available


  316. MCGUIRE DK, Marx N, Johansen OE, Inzucchi SE, et al
    FDA Guidance on Antihyperglycemic Therapies for Type 2 Diabetes: One Decade Later.
    Diabetes Obes Metab. 2019 Jan 28. doi: 10.1111/dom.13645.
    PubMed     Abstract available


  317. YU L, Li X, Zhang Z, Du P, et al
    Dimorphic autoantigenic and protective effects of Reg2 peptide in the treatment of diabetic beta-cell loss.
    Diabetes Obes Metab. 2019 Jan 28. doi: 10.1111/dom.13644.
    PubMed     Abstract available


  318. LEITE NC, Viegas BB, Villela-Nogueira CA, Carlos FO, et al
    Efficacy of Diacerein in Reducing Liver Steatosis and Fibrosis in Patients with Type 2 Diabetes and Nonalcoholic Fatty Liver Disease: a Randomized, Placebo-Controlled Trial.
    Diabetes Obes Metab. 2019 Jan 28. doi: 10.1111/dom.13643.
    PubMed     Abstract available


  319. CHARYTAN DM, Solomon SD, Ivanovich P, Remuzzi G, et al
    Metformin Use and Cardiovascular Events in Patients with Type 2 Diabetes and Chronic Kidney Disease.
    Diabetes Obes Metab. 2019 Jan 22. doi: 10.1111/dom.13642.
    PubMed     Abstract available


  320. ZOBEL EH, von Scholten BJ, Goldman B, Persson F, et al
    Pleiotropic effects of liraglutide in patients with type 2 diabetes and moderate renal impairment: individual effects of treatment.
    Diabetes Obes Metab. 2019 Jan 20. doi: 10.1111/dom.13638.
    PubMed     Abstract available


  321. JONES KL, Rigda RS, Buttfield MD, Hatzinikolas S, et al
    Effects of lixisenatide on postprandial blood pressure, gastric emptying and glycemia in health and type 2 diabetes.
    Diabetes Obes Metab. 2019 Jan 9. doi: 10.1111/dom.13633.
    PubMed     Abstract available


  322. BORG MJ, Jones KL, Sun Z, Horowitz M, et al
    Metformin attenuates the postprandial fall in blood pressure in type 2 diabetes.
    Diabetes Obes Metab. 2019 Jan 7. doi: 10.1111/dom.13632.
    PubMed     Abstract available


  323. GALLO S, Charbonnel B, Goldman A, Shi H, et al
    Long-term efficacy and safety of ertugliflozin in patients with type 2 diabetes mellitus inadequately controlled with metformin monotherapy: 104-week VERTIS MET trial.
    Diabetes Obes Metab. 2019 Jan 7. doi: 10.1111/dom.13631.
    PubMed     Abstract available


  324. NORHAMMAR A, Bodegard J, Nystrom T, Thuresson M, et al
    Dapagliflozin and Cardiovascular Mortality and Disease Outcomes in Type 2 Diabetes Patients Similar to the DECLARE-TIMI 58 Participants: A Nationwide Observational Study.
    Diabetes Obes Metab. 2019 Jan 4. doi: 10.1111/dom.13627.
    PubMed     Abstract available


  325. GIUGLIANO D, Meier JJ, Esposito K
    Heart failure and type 2 diabetes: From CVOTs, with hope.
    Diabetes Obes Metab. 2019 Jan 4. doi: 10.1111/dom.13629.
    PubMed     Abstract available


  326. FAN W, Song Y, Inzucchi SE, Sperling L, et al
    Composite Cardiovascular Risk Factor Target Achievement and its Predictors in US Adults with Diabetes: The Diabetes Collaborative Registry.
    Diabetes Obes Metab. 2019 Jan 4. doi: 10.1111/dom.13625.
    PubMed     Abstract available


  327. FRIAS JP, Zimmer Z, Lam RLH, Lic GA, et al
    Double-blind, randomized clinical trial assessing the efficacy and safety of early initiation of sitagliptin during metformin up-titration in treatment of patients with type 2 diabetes: the CompoSIT-M Study.
    Diabetes Obes Metab. 2019 Jan 4. doi: 10.1111/dom.13626.
    PubMed     Abstract available


    December 2018
  328. WANG C, Xiao Y, Wang J, Hou N, et al
    Dynamic Changes in Insulin and Glucagon During Disease Progression in Rhesus Monkeys with Obesity-Related Type 2 Diabetes Mellitus.
    Diabetes Obes Metab. 2018 Dec 21. doi: 10.1111/dom.13624.
    PubMed     Abstract available


  329. HEISE T, Meiffren G, Alluis B, Seroussi C, et al
    BioChaperone Lispro (BCLIS) vs faster aspart (FIA) and insulin aspart (ASP) in patients with type 1 diabetes on continuous subcutaneous insulin infusion: a randomized euglycemic clamp study.
    Diabetes Obes Metab. 2018 Dec 18. doi: 10.1111/dom.13621.
    PubMed     Abstract available


  330. PAWASKAR M, Pinar Bilir S, Kowal S, Gonzalez C, et al
    Cost-effectiveness of intensification with SGLT2i in Type 2 Diabetes patients on metformin and sitagliptin compared to direct intensification with insulin in the United Kingdom.
    Diabetes Obes Metab. 2018 Dec 18. doi: 10.1111/dom.13618.
    PubMed     Abstract available


  331. CHEN W, Zhou Y, Kong Z, Wang X, et al
    The Renoprotective Effects of SGLT2 Inhibitors versus Placebo in Patients with Type 2 Diabetes with or without Prevalent Kidney Disease: A Systematic Review and Meta-analysis.
    Diabetes Obes Metab. 2018 Dec 18. doi: 10.1111/dom.13620.
    PubMed     Abstract available


  332. SINGH P, Pesavento TE, Washburn K, Walsh D, et al
    Largest single-center experience of dulaglutide for the management of diabetes mellitus in solid organ transplant.
    Diabetes Obes Metab. 2018 Dec 18. doi: 10.1111/dom.13619.
    PubMed     Abstract available


  333. RETNAKARAN R, Ye C, Kramer CK
    Stability of Insulin and C-peptide Measurement with Long-term Frozen Storage of Serum: Implications for Diabetes Research Studies.
    Diabetes Obes Metab. 2018 Dec 18. doi: 10.1111/dom.13617.
    PubMed     Abstract available


  334. TIBALDI J, Hadley-Brown M, Liebl A, Haldrup S, et al
    A comparative effectiveness study of degludec and insulin glargine 300U/mL in insulin-naive patients with type 2 diabetes.
    Diabetes Obes Metab. 2018 Dec 15. doi: 10.1111/dom.13616.
    PubMed     Abstract available


  335. HOLMES RS, Crabtree E, McDonagh MS
    Comparative effectiveness and harms of long-acting insulins for Type 1 and Type 2 diabetes: a systematic review and meta-analysis.
    Diabetes Obes Metab. 2018 Dec 15. doi: 10.1111/dom.13614.
    PubMed     Abstract available


  336. ABDURRACHIM D, Teo XQ, Woo CC, Ong SY, et al
    Cardiac metabolic modulation upon low-carbohydrate low-protein ketogenic diet in diabetic rats studied in vivo using hyperpolarized (13) C pyruvate, butyrate, and acetoacetate probes.
    Diabetes Obes Metab. 2018 Dec 11. doi: 10.1111/dom.13608.
    PubMed     Abstract available


  337. BIRKELAND KI, Bodegard J, Norhammar A, Kuiper JG, et al
    How Representative are the Patients Included in the CV outcome Trials with SGLT2 Inhibitors of a General Type 2 Diabetes Population? A Large European Observational study.
    Diabetes Obes Metab. 2018 Dec 9. doi: 10.1111/dom.13612.
    PubMed     Abstract available


  338. KLONOFF DC, Evans ML, Lane W, Kempe HP, et al
    A randomized, multicentre trial evaluating the efficacy and safety of fast-acting insulin aspart in continuous subcutaneous insulin infusion in adults with type 1 diabetes (onset 5).
    Diabetes Obes Metab. 2018 Dec 9. doi: 10.1111/dom.13610.
    PubMed     Abstract available


  339. WU S, Gao L, Cipriani A, Huang Y, et al
    The effects of incretin-based therapies on beta-cell function and insulin resistance in type 2 diabetes: a systematic review and network meta-analysis combining 360 trials.
    Diabetes Obes Metab. 2018 Dec 9. doi: 10.1111/dom.13613.
    PubMed     Abstract available


  340. KUHADIYA ND, Prohaska B, Ghanim H, Dandona P, et al
    Addition of GLP-1RA therapy to Insulin in C-peptide Positive Patients With Type 1 Diabetes.
    Diabetes Obes Metab. 2018 Dec 9. doi: 10.1111/dom.13609.
    PubMed     Abstract available


  341. HALAMA A, Kahal H, Bhagwat AM, Zierer J, et al
    The metabolic and proteomic signatures of hypoglycemia in type 2 diabetes.
    Diabetes Obes Metab. 2018 Dec 7. doi: 10.1111/dom.13602.
    PubMed     Abstract available


  342. OWENS DR, Landgraf W, Frier BM, Zhang M, et al
    Commencing insulin glargine 100 U/mL therapy in people with type 2 diabetes: Determinants of achievement of HbA1c goal <7.0.
    Diabetes Obes Metab. 2018 Dec 6. doi: 10.1111/dom.13607.
    PubMed     Abstract available


  343. MODY R, Huang Q, Yu M, Zhao R, et al
    Adherence, Persistence, Glycemic Control and Costs Among Patients with Type 2 Diabetes Initiating Dulaglutide Compared with Liraglutide or Exenatide QW at 12 Months Follow-Up in a US Real-World Setting.
    Diabetes Obes Metab. 2018 Dec 5. doi: 10.1111/dom.13603.
    PubMed     Abstract available


  344. CHILTON RJ, Oliveros R, Gallegos KM, Pham S, et al
    PCSK9 inhibitors and diabetes: translational biology to clinical practice.
    Diabetes Obes Metab. 2018 Dec 5. doi: 10.1111/dom.13600.
    PubMed     Abstract available


  345. WATSON LE, Phillips LK, Wu T, Bound MJ, et al
    A whey/guar "preload" improves postprandial glycaemia and HbA1c in type 2 diabetes - a 12-week, single-blind, randomized, placebo-controlled trial.
    Diabetes Obes Metab. 2018 Dec 5. doi: 10.1111/dom.13604.
    PubMed     Abstract available


  346. WITTERT G, Atlantis E, Allan C, Bracken K, et al
    Testosterone therapy to prevent type 2 diabetes mellitus in at-risk men (T4DM): Design and implementation of a double-blind randomised controlled trial.
    Diabetes Obes Metab. 2018 Dec 5. doi: 10.1111/dom.13601.
    PubMed     Abstract available


    November 2018
  347. HANDELSMAN Y, Mathieu C, Del Prato S, Johnsson E, et al
    Sustained 52-week efficacy and safety of triple therapy with dapagliflozin plus saxagliptin versus dual therapy with sitagliptin added to metformin in patients with uncontrolled type 2 diabetes.
    Diabetes Obes Metab. 2018 Nov 30. doi: 10.1111/dom.13594.
    PubMed     Abstract available


  348. WATADA H, Shiramoto M, Ueda S, Tang W, et al
    Pharmacokinetics and Pharmacodynamics of Dapagliflozin in Combination with Insulin in Japanese Patients with Type 1 Diabetes.
    Diabetes Obes Metab. 2018 Nov 30. doi: 10.1111/dom.13593.
    PubMed     Abstract available


  349. MONAMI M, Sesti G, Mannucci E
    PCSK9 Inhibitor Therapy: A Systematic Review And Meta-Analysis of Metabolic And Cardiovascular Outcomes in Patients With Diabetes.
    Diabetes Obes Metab. 2018 Nov 28. doi: 10.1111/dom.13599.
    PubMed     Abstract available


  350. MOSER O, Pandis M, Aberer F, Kojzar H, et al
    A head-to-head comparison of personal and professional continuous glucose monitoring systems in people with type 1 diabetes: hypoglycaemia remains the weak spot.
    Diabetes Obes Metab. 2018 Nov 28. doi: 10.1111/dom.13598.
    PubMed     Abstract available


  351. BIESTER T, Nir J, Remus K, Farfel A, et al
    DREAM5: An open-label, randomized, cross-over study to evaluate the safety and efficacy of day and night closed-loop control using the MD-Logic automated insulin delivery system compared to sensor augmented pump therapy in patients with type 1 diabete
    Diabetes Obes Metab. 2018 Nov 26. doi: 10.1111/dom.13585.
    PubMed     Abstract available


  352. XIANG Y, Huang G, Zhu Y, Zuo X, et al
    Identification of autoimmune type 1 diabetes and multiple organ-specific autoantibodies in adult-onset non-insulin requiring diabetes in China: a population based multicenter national wide survey.
    Diabetes Obes Metab. 2018 Nov 24. doi: 10.1111/dom.13595.
    PubMed     Abstract available


  353. VELLANKI P, Rasouli N, Baldwin D, Alexanian S, et al
    Glycaemic Efficacy and Safety of Linagliptin compared to Basal-Bolus Insulin Regimen in Patients with Type 2 Diabetes Undergoing Non-Cardiac Surgery: A Multicenter Randomized Clinical Trial.
    Diabetes Obes Metab. 2018 Nov 20. doi: 10.1111/dom.13587.
    PubMed     Abstract available


  354. SOKOLOV V, Yakovleva T, Ueda S, Parkinson J, et al
    Urinary glucose excretion after dapagliflozin treatment: an exposure-response modeling comparison between Japanese and non-Japanese patients diagnosed with Type 1 Diabetes Mellitus.
    Diabetes Obes Metab. 2018 Nov 19. doi: 10.1111/dom.13586.
    PubMed     Abstract available


  355. CUSI K, Bril F, Barb D, Polidori D, et al
    Effect of Canagliflozin Treatment on Hepatic Triglyceride Content and Glucose Metabolism in Patients with Type 2 Diabetes.
    Diabetes Obes Metab. 2018 Nov 16. doi: 10.1111/dom.13584.
    PubMed     Abstract available


  356. JENSEN J, Schou M, Kistorp C, Faber J, et al
    Prevalence of heart failure and diagnostic value of MR-proANP in outpatients with type 2 diabetes.
    Diabetes Obes Metab. 2018 Nov 16. doi: 10.1111/dom.13583.
    PubMed     Abstract available


  357. BARER Y, Cohen O, Cukierman-Yaffe T
    The effect of glycemic control on cardiovascular disease in individuals with type 2 diabetes with pre-existing cardiovascular disease - a systematic review and meta-analysis.
    Diabetes Obes Metab. 2018 Nov 13. doi: 10.1111/dom.13581.
    PubMed     Abstract available


  358. BONADONNA RC, Yale JF, Brulle-Wohlhueter C, Boelle-Le Corfec E, et al
    Hypoglycaemia as a function of HbA1c in type 2 diabetes: Insulin glargine 300 U/mL in a patient-level pooled analysis of EDITION 1, 2 and 3.
    Diabetes Obes Metab. 2018 Nov 9. doi: 10.1111/dom.13578.
    PubMed     Abstract available


  359. JADAWJI C, Crasto W, Gillies C, Kar D, et al
    Prevalence and progression of diabetic nephropathy in South Asians, White Europeans and Afro-Caribbeans with Type 2 diabetes; a systematic review and meta-analysis.
    Diabetes Obes Metab. 2018 Nov 8. doi: 10.1111/dom.13569.
    PubMed     Abstract available


  360. VAN BRUGGEN FH, Luijendijk HJ
    What the diabetes data in FOURIER trial fail to show.
    Diabetes Obes Metab. 2018 Nov 8. doi: 10.1111/dom.13576.
    PubMed     Abstract available


  361. MASON SA, Rasmussen B, van Loon LJC, Salmon J, et al
    Ascorbic acid supplementation improves postprandial glycaemic control and blood pressure in people with type 2 diabetes: Findings of a randomized cross-over trial.
    Diabetes Obes Metab. 2018 Nov 4. doi: 10.1111/dom.13571.
    PubMed     Abstract available


  362. WOO V, Bell A, Clement M, Noronha L, et al
    CANadian CAnagliflozin Registry: Effectiveness and Safety of Canagliflozin in the treatment of Type 2 diabetes mellitus in Canadian Clinical Practice.
    Diabetes Obes Metab. 2018 Nov 4. doi: 10.1111/dom.13573.
    PubMed     Abstract available


  363. ITOH H, Komuro I, Takeuchi M, Akasaka T, et al
    Achieving LDL-C target levels less than 70 mg/dL may provide extra cardiovascular protection in high-risk patients: exploratory analysis of the Standard Versus Intensive Statin Therapy for Patients With Hypercholesterolemia and Diabetic Retinopathy St
    Diabetes Obes Metab. 2018 Nov 4. doi: 10.1111/dom.13575.
    PubMed     Abstract available


  364. ROUSSEL R, Duran Garcia S, Zhang Y, Shah S, et al
    Double-blind, randomized clinical trial comparing the efficacy and safety of continuing or discontinuing the dipeptidyl peptidase-4 inhibitor sitagliptin when initiating insulin glargine therapy in patients with type 2 diabetes: The CompoSIT-I Study.
    Diabetes Obes Metab. 2018 Nov 4. doi: 10.1111/dom.13574.
    PubMed     Abstract available


    October 2018
  365. BORG MJ, Bound M, Grivell J, Sun Z, et al
    Comparative effects of proximal and distal small intestinal administration of metformin on plasma glucose and glucagon-like peptide-1, and gastric emptying after oral glucose, in type 2 diabetes.
    Diabetes Obes Metab. 2018 Oct 28. doi: 10.1111/dom.13567.
    PubMed     Abstract available


  366. DAVIS TME, Bruce DG, Finn J, Curtis BH, et al
    Temporal changes in the incidence and predictors of severe hypoglycaemia in type 2 diabetes: The Fremantle Diabetes Study.
    Diabetes Obes Metab. 2018 Oct 28. doi: 10.1111/dom.13568.
    PubMed     Abstract available


  367. KIM Y, Kang ES, Jang HC, Kim DJ, et al
    Teneligliptin versus sitagliptin in Korean patients with type 2 diabetes inadequately controlled with metformin and glimepiride: A randomized, double-blind, non-inferiority trial.
    Diabetes Obes Metab. 2018 Oct 26. doi: 10.1111/dom.13566.
    PubMed     Abstract available


  368. DEVRIES JH, Bailey TS, Bhargava A, Gerety G, et al
    Day-to-day Fasting Self-monitored Blood Glucose Variability is Associated with Risk of Hypoglycaemia in Insulin-Treated Patients with Type 1 and Type 2 Diabetes: A Post Hoc Analysis of the SWITCH Trials.
    Diabetes Obes Metab. 2018 Oct 25. doi: 10.1111/dom.13565.
    PubMed     Abstract available


  369. VILJOEN A, Hoxer CS, Johansen P, Malkin S, et al
    Evaluation of the Long-Term Cost-Effectiveness of Once-Weekly semaglutide versus dulaglutide for the treatment of type 2 diabetes mellitus in the UK.
    Diabetes Obes Metab. 2018 Oct 25. doi: 10.1111/dom.13564.
    PubMed     Abstract available


  370. HOVELMANN U, Braendholt Olsen M, Mouritzen U, Lamers D, et al
    Low doses of dasiglucagon consistently increase plasma glucose levels from hypoglycaemia and euglycaemia in people with type 1 diabetes mellitus.
    Diabetes Obes Metab. 2018 Oct 23. doi: 10.1111/dom.13562.
    PubMed     Abstract available


  371. ABERER F, Lichtenegger KM, Smajic E, Donsa K, et al
    GlucoTab guided insulin therapy using insulin glargine U300 enables glycaemic control with low risk of hypoglycaemia in hospitalised patients with type 2 diabetes.
    Diabetes Obes Metab. 2018 Oct 16. doi: 10.1111/dom.13559.
    PubMed     Abstract available


  372. AL-QAISSI A, Papageorgiou M, Javed Z, Heise T, et al
    Environmental effects of ambient temperature and relative humidity on insulin pharmacodynamics in adults with type 1 diabetes mellitus.
    Diabetes Obes Metab. 2018 Oct 12. doi: 10.1111/dom.13555.
    PubMed     Abstract available


  373. BJORNSTAD P, Singh SK, Snell-Bergeon JK, Lovshin JA, et al
    The Relationships between Markers of Tubular Injury and Intrarenal Hemodynamic Function in Adults with and without Type 1 Diabetes: Results from the Canadian Study of Longevity in Type 1 Diabetes.
    Diabetes Obes Metab. 2018 Oct 12. doi: 10.1111/dom.13556.
    PubMed     Abstract available


  374. CHO KYG, Nakamura A, Omori K, Takase T, et al
    Effect of switching from pioglitazone to the SGLT2 inhibitor dapagliflozin on body weight and metabolism-related factors in patients with type-2 diabetes mellitus: An open-label, prospective, randomized, parallel-group comparison trial.
    Diabetes Obes Metab. 2018 Oct 12. doi: 10.1111/dom.13557.
    PubMed     Abstract available


  375. BAIN SC, Mosenzon O, Arechavaleta R, Bogdanski P, et al
    Cardiovascular safety of oral semaglutide in patients with type 2 diabetes: Rationale, design and patient baseline characteristics for the PIONEER 6 trial.
    Diabetes Obes Metab. 2018 Oct 4. doi: 10.1111/dom.13553.
    PubMed     Abstract available


  376. GARCIA-FINANA M, Hughes DM, Cheyne CP, Broadbent DM, et al
    Personalized risk-based screening for diabetic retinopathy: a multivariate approach vs. the use of stratification rules.
    Diabetes Obes Metab. 2018 Oct 3. doi: 10.1111/dom.13552.
    PubMed     Abstract available


  377. MAGALHAES JP, Judice PB, Ribeiro R, Andrade R, et al
    Effectiveness of high intensity interval training combined with resistance training vs. continuous moderate intensity training combined with resistance training in patients with type 2 diabetes - 1 year randomized controlled trial.
    Diabetes Obes Metab. 2018 Oct 3. doi: 10.1111/dom.13551.
    PubMed     Abstract available


  378. PEARCE I, Simo R, Lovestam-Adrian M, Wong DT, et al
    Association between diabetic eye disease and other complications of diabetes: implications for care. A systematic review.
    Diabetes Obes Metab. 2018 Oct 2. doi: 10.1111/dom.13550.
    PubMed     Abstract available


  379. MULDER S, Hamidi H, Kretzler M, Ju W, et al
    An integrative systems biology approach for precision medicine in diabetic kidney disease.
    Diabetes Obes Metab. 2018;20 Suppl 3:6-13.
    PubMed     Abstract available


  380. DE VRIES JK, Levin A, Loud F, Adler A, et al
    Implementing personalized medicine in diabetic kidney disease: Stakeholders' perspectives.
    Diabetes Obes Metab. 2018;20 Suppl 3:24-29.
    PubMed     Abstract available


  381. MOL PGM, Thompson A, Heerspink HJL, Leufkens HGM, et al
    Precision medicine in diabetes and diabetic kidney disease: Regulatory considerations.
    Diabetes Obes Metab. 2018;20 Suppl 3:19-23.
    PubMed     Abstract available


  382. HEERSPINK HJL, de Zeeuw D
    Treating diabetic complications; from large randomized clinical trials to precision medicine.
    Diabetes Obes Metab. 2018;20 Suppl 3:3-5.
    PubMed     Abstract available


  383. HEERSPINK HJL, List J, Perkovic V
    New clinical trial designs for establishing drug efficacy and safety in a precision medicine era.
    Diabetes Obes Metab. 2018;20 Suppl 3:14-18.
    PubMed     Abstract available


    September 2018
  384. AL-QAISSI A, Papageorgiou M, Deshmukh H, Madden LA, et al
    The effects of acute insulin-induced hypoglycaemia on endothelial microparticles in adults with and without type 2 diabetes.
    Diabetes Obes Metab. 2018 Sep 28. doi: 10.1111/dom.13548.
    PubMed     Abstract available


  385. NAUCK MA, Buse JB, Mann JFE, Pocock S, et al
    Health-related quality of life in people with type 2 diabetes participating in the LEADER trial.
    Diabetes Obes Metab. 2018 Sep 27. doi: 10.1111/dom.13547.
    PubMed     Abstract available


  386. BUSE JB, Carlson AL, Komatsu M, Mosenzon O, et al
    Fast-acting insulin aspart versus insulin aspart in the setting of insulin degludec-treated type 1 diabetes: efficacy and safety from a randomized double-blind trial.
    Diabetes Obes Metab. 2018 Sep 26. doi: 10.1111/dom.13545.
    PubMed     Abstract available


  387. LIAKOS A, Lambadiari V, Bargiota A, Kitsios K, et al
    Effect of liraglutide on ambulatory blood pressure in hypertensive patients with type 2 diabetes: randomized, double blind, placebo-controlled trial.
    Diabetes Obes Metab. 2018 Sep 22. doi: 10.1111/dom.13541.
    PubMed     Abstract available


  388. BAIN SC, Klufas MA, Ho A, Matthews DR, et al
    Worsening diabetic retinopathy with rapid improvement in systemic glucose control: a review.
    Diabetes Obes Metab. 2018 Sep 18. doi: 10.1111/dom.13538.
    PubMed     Abstract available


  389. SEUFERT J, Fritsche A, Pscherer S, Anderten H, et al
    Titration and optimization trial for the initiation of insulin glargine 100 U/mL in inadequately controlled type-2 diabetes patients on oral antidiabetic drugs.
    Diabetes Obes Metab. 2018 Sep 18. doi: 10.1111/dom.13535.
    PubMed     Abstract available


  390. ABDURRACHIM D, Teo XQ, Woo CC, Chan WX, et al
    Empagliflozin lowers myocardial ketone utilization while preserving glucose utilization in diabetic hypertensive heart disease: A hyperpolarized (13) C magnetic resonance spectroscopy study.
    Diabetes Obes Metab. 2018 Sep 17. doi: 10.1111/dom.13536.
    PubMed     Abstract available


  391. NICHOLS GA, Philip S, Reynolds K, Granowitz CB, et al
    Increased Residual Cardiovascular Risk in Patients with Diabetes and High vs. Normal Triglycerides Despite Statin-Controlled LDL Cholesterol.
    Diabetes Obes Metab. 2018 Sep 17. doi: 10.1111/dom.13537.
    PubMed     Abstract available


  392. MOSER O, Eckstein ML, Mueller A, Birnbaumer P, et al
    Reduction in insulin degludec dosing for multiple exercise sessions improves time spent in euglycaemia in people with type 1 diabetes: a randomised cross-over trial.
    Diabetes Obes Metab. 2018 Sep 17. doi: 10.1111/dom.13534.
    PubMed     Abstract available


  393. KUO S, Yang CT, Wu JS, Ou HT, et al
    Effects of intensifying triple oral antidiabetic drug therapy by initiating insulin versus enhancing oral antidiabetic drug therapy on clinical outcomes in patients with type 2 diabetes: a nationwide population-based, propensity score-matched cohort s
    Diabetes Obes Metab. 2018 Sep 5. doi: 10.1111/dom.13525.
    PubMed     Abstract available


  394. SINGH RG, Nguyen NN, DeSouza SV, Pendharkar SA, et al
    Comprehensive analysis of body composition and insulin traits associated with intra-pancreatic fat deposition in health and new-onset prediabetes/diabetes after acute pancreatitis.
    Diabetes Obes Metab. 2018 Sep 5. doi: 10.1111/dom.13523.
    PubMed     Abstract available


  395. YOSHIKAWA F, Kumashiro N, Shigiyama F, Uchino H, et al
    Efficacy of Intermittent Empagliflozin Supplementation on Dietary Self-Management and Glycemic Control in Patients With Poorly Controlled Type 2 Diabetes: A 24-Week Randomized Controlled Trial.
    Diabetes Obes Metab. 2018 Sep 5. doi: 10.1111/dom.13524.
    PubMed     Abstract available


  396. SHIMIZU M, Suzuki K, Kato K, Jojima T, et al
    Evaluation of the effects of dapagliflozin, an SGLT2 inhibitor, on hepatic steatosis and fibrosis by transient elastography in patients with type 2 diabetes and non-alcoholic fatty liver disease.
    Diabetes Obes Metab. 2018 Sep 3. doi: 10.1111/dom.13520.
    PubMed     Abstract available


  397. YU M, Shankar RR, Zhang R, Zhang Y, et al
    Efficacy and safety of sitagliptin added to treatment of patients with type 2 diabetes inadequately controlled with pre-mixed insulin.
    Diabetes Obes Metab. 2018 Sep 3. doi: 10.1111/dom.13517.
    PubMed     Abstract available


  398. NATALI A, Nesti L, Venturi E, Shore AC, et al
    Metformin is the key factor for elevated plasma GDF-15 levels in type 2 diabetes: a nested, case-control study.
    Diabetes Obes Metab. 2018 Sep 3. doi: 10.1111/dom.13519.
    PubMed     Abstract available


  399. KHUNTI K, Seidu S, Davies MJ
    Should sodium glucose co-transporter 2 inhibitors be considered as first line oral therapy for people with type 2 diabetes?
    Diabetes Obes Metab. 2018 Sep 3. doi: 10.1111/dom.13518.
    PubMed     Abstract available


  400. IDRIS I
    News and Views for September 2018: Highlights from the American Diabetes Association Scientific meeting, June 2018.
    Diabetes Obes Metab. 2018;20:2321-2324.
    PubMed    


  401. RIAHI Y, Israeli T, Cerasi E, Leibowitz G, et al
    Effects of proinsulin misfolding on beta-cell dynamics, differentiation and function in diabetes.
    Diabetes Obes Metab. 2018;20 Suppl 2:95-103.
    PubMed     Abstract available


  402. FOLLI F, La Rosa S, Finzi G, Davalli AM, et al
    Pancreatic islet of Langerhans' cytoarchitecture and ultrastructure in normal glucose tolerance and in type 2 diabetes mellitus.
    Diabetes Obes Metab. 2018;20 Suppl 2:137-144.
    PubMed     Abstract available


  403. MESZAROS G, Pasquier A, Vivot K, Goginashvili A, et al
    Lysosomes in nutrient signalling: A focus on pancreatic beta-cells.
    Diabetes Obes Metab. 2018;20 Suppl 2:104-115.
    PubMed     Abstract available


  404. LIU M, Weiss MA, Arunagiri A, Yong J, et al
    Biosynthesis, structure, and folding of the insulin precursor protein.
    Diabetes Obes Metab. 2018;20 Suppl 2:28-50.
    PubMed     Abstract available


  405. NAPOLITANO T, Silvano S, Vieira A, Balaji S, et al
    Role of ghrelin in pancreatic development and function.
    Diabetes Obes Metab. 2018;20 Suppl 2:3-10.
    PubMed     Abstract available


  406. ESGUERRA JLS, Nagao M, Ofori JK, Wendt A, et al
    MicroRNAs in islet hormone secretion.
    Diabetes Obes Metab. 2018;20 Suppl 2:11-19.
    PubMed     Abstract available


  407. WEI FY, Tomizawa K
    tRNA modifications and islet function.
    Diabetes Obes Metab. 2018;20 Suppl 2:20-27.
    PubMed     Abstract available


  408. THOMAIDOU S, Zaldumbide A, Roep BO
    Islet stress, degradation and autoimmunity.
    Diabetes Obes Metab. 2018;20 Suppl 2:88-94.
    PubMed     Abstract available


  409. PETRENKO V, Philippe J, Dibner C
    Time zones of pancreatic islet metabolism.
    Diabetes Obes Metab. 2018;20 Suppl 2:116-126.
    PubMed     Abstract available


  410. ALVELOS MI, Juan-Mateu J, Colli ML, Turatsinze JV, et al
    When one becomes many-Alternative splicing in beta-cell function and failure.
    Diabetes Obes Metab. 2018;20 Suppl 2:77-87.
    PubMed     Abstract available


    August 2018
  411. BOLLI GB, Wysham C, Fisher M, Chevalier S, et al
    A post hoc pooled analysis to evaluate hypoglycaemia risk with insulin glargine 300 U/mL (Gla-300) versus 100 U/mL (Gla-100) over wider nocturnal windows in people with type 2 diabetes on a basal-only insulin regimen.
    Diabetes Obes Metab. 2018 Aug 29. doi: 10.1111/dom.13515.
    PubMed     Abstract available


  412. GRANADOS A, Gebremariam A, Gidding SS, Terry JG, et al
    Association of Abdominal Muscle Composition with Prediabetes and Diabetes: The CARDIA Study.
    Diabetes Obes Metab. 2018 Aug 29. doi: 10.1111/dom.13513.
    PubMed     Abstract available


  413. YU E, Ruiz-Canela M, Razquin C, Guasch-Ferre M, et al
    Changes in Arginine are Inversely Associated with Type 2 Diabetes: A Case-Cohort Study in the PREDIMED Trial.
    Diabetes Obes Metab. 2018 Aug 26. doi: 10.1111/dom.13514.
    PubMed     Abstract available


  414. BELL DSH, Goncalves E
    Atrial fibrillation and type 2 diabetes: prevalence, etiology, pathophysiology and effect of anti-diabetic therapies.
    Diabetes Obes Metab. 2018 Aug 24. doi: 10.1111/dom.13512.
    PubMed     Abstract available


  415. RYAN PB, Rosenthal N
    Comment on Ryan, et al. Comparative effectiveness of canagliflozin, SGLT2 inhibitors and non-SGLT2 inhibitors on the risk of hospitalization for heart failure and amputation in patients with type 2 diabetes mellitus: A real-world meta-analysis of 4 ob
    Diabetes Obes Metab. 2018 Aug 23. doi: 10.1111/dom.13509.
    PubMed     Abstract available


  416. ARNOLD SV, Seman L, Tang F, Peri-Okonny PA, et al
    Real-World Opportunity of Empagliflozin to Improve Blood Pressure Control in African Americans with Type 2 Diabetes: An NCDR(R) "Research-to-Practice" Project From the Diabetes Collaborative Registry (DCR).
    Diabetes Obes Metab. 2018 Aug 23. doi: 10.1111/dom.13510.
    PubMed     Abstract available


  417. ARNOLD SV, Yap J, Lam CSP, Tang F, et al
    Management of patients with diabetes and heart failure with reduced ejection fraction: an international comparison.
    Diabetes Obes Metab. 2018 Aug 23. doi: 10.1111/dom.13511.
    PubMed     Abstract available


  418. DORIS J, Millar SA, Idris I, O'Sullivan SE, et al
    Genetic Polymorphisms of the Endocannabinoid System in Obesity and Diabetes.
    Diabetes Obes Metab. 2018 Aug 21. doi: 10.1111/dom.13504.
    PubMed     Abstract available


  419. GARIANI K, Lebowitz D, von Dach E, Kressmann B, et al
    Remission in Diabetic Foot Infections: Duration of Antibiotic Therapy and Other Possible Associated Factors.
    Diabetes Obes Metab. 2018 Aug 21. doi: 10.1111/dom.13507.
    PubMed     Abstract available


  420. WANG W, Ruiz LN, Filippova E, Song KH, et al
    Efficacy and Safety of Once-weekly Dulaglutide Versus Insulin Glargine in Mainly Asian Patients with Type 2 Diabetes Mellitus on Metformin and/or a Sulfonylurea: a 52-week Open-label, Randomized Phase 3 Trial.
    Diabetes Obes Metab. 2018 Aug 21. doi: 10.1111/dom.13506.
    PubMed     Abstract available


  421. BLEVINS TC, Barve A, Sun B, Raiter Y, et al
    Efficacy and Safety of MYL-1501D Versus Insulin Glargine in Patients With Type 2 Diabetes After 24 Weeks: Results of the Phase 3 INSTRIDE 2 Study.
    Diabetes Obes Metab. 2018 Aug 15. doi: 10.1111/dom.13495.
    PubMed     Abstract available


  422. PARKER ED, Wittbrodt ET, McPheeters JT, Frias JP, et al
    Comparison of Healthcare Resource Utilization and Costs in Type 2 Diabetes Patients Initiating Dapagliflozin versus Sitagliptin.
    Diabetes Obes Metab. 2018 Aug 12. doi: 10.1111/dom.13502.
    PubMed     Abstract available


  423. KORSMO-HAUGEN HK, Brurberg KG, Mann J, Aas AM, et al
    Carbohydrate quantity in the dietary management of type 2 diabetes - a systematic review and meta-analysis.
    Diabetes Obes Metab. 2018 Aug 11. doi: 10.1111/dom.13499.
    PubMed     Abstract available


  424. KAKU K, Haneda M, Tanaka Y, Lee G, et al
    Linagliptin as add-on to empagliflozin in a fixed-dose combination in Japanese patients with type 2 diabetes: Glycaemic efficacy and safety profile in a two-part, randomized, placebo-controlled trial.
    Diabetes Obes Metab. 2018 Aug 9. doi: 10.1111/dom.13496.
    PubMed     Abstract available


  425. CHEN HF, Ho CA, Li CY
    Risk of heart failure in type 2 diabetes population: Comparison with non-diabetes subjects with and without coronary heart diseases.
    Diabetes Obes Metab. 2018 Aug 8. doi: 10.1111/dom.13493.
    PubMed     Abstract available


  426. BAILEY CJ, Marx N
    Cardiovascular protection in type 2 diabetes: insights from recent outcome trials.
    Diabetes Obes Metab. 2018 Aug 8. doi: 10.1111/dom.13492.
    PubMed     Abstract available


  427. CHRISTENSEN P, Meinert Larsen T, Westerterp-Plantenga M, Macdonald I, et al
    Men and women respond differently to rapid weight loss: Metabolic outcomes of a multi-centre intervention study after a low-energy diet in 2500 overweight, individuals with pre-diabetes (PREVIEW).
    Diabetes Obes Metab. 2018 Aug 7. doi: 10.1111/dom.13466.
    PubMed     Abstract available


  428. ELBAZ-GREENER G, Bloch O, Kumets I, Blatt A, et al
    Endogenous GLP-1 system response is impaired during St-elevation myocardial infarction in type 2 diabetes patients.
    Diabetes Obes Metab. 2018 Aug 6. doi: 10.1111/dom.13490.
    PubMed     Abstract available


  429. BAE JC, Min KW, Kim YH, Kim KA, et al
    Efficacy and safety of fixed-dose comBination therApy with gemigLiptin (50 mg) and rosuvAstatiN (20 mg) Compared with Each monotherapy in patients with type 2 diabetes and dyslipidaemia (BALANCE): A multicentre, randomized, double-blind, controlled, p
    Diabetes Obes Metab. 2018 Aug 6. doi: 10.1111/dom.13491.
    PubMed     Abstract available


  430. MATIKAINEN N, Soderlund S, Bjornson E, Pietilainen K, et al
    Liraglutide treatment improves postprandial lipid metabolism and cardiometabolic risk factors in humans with adequately controlled type 2 diabetes: A single-centre randomised controlled study.
    Diabetes Obes Metab. 2018 Aug 2. doi: 10.1111/dom.13487.
    PubMed     Abstract available


  431. NEYMAN A, Nelson J, Tersey S, Mirmira RG, et al
    Persistent Elevations in Circulating INS DNA Among Subjects with Longstanding Type 1 Diabetes.
    Diabetes Obes Metab. 2018 Aug 2. doi: 10.1111/dom.13489.
    PubMed     Abstract available


  432. OUCHI M, Oba K, Suganami H, Yoshida A, et al
    This is in reply to the Letter by Kahathuduwa et al. titled "Unaccounted for regression to the mean renders conclusion of article titled 'Uric acid lowering in relation to HbA1c reductions with the SGLT2 inhibitor Tofogliflozin' unsubstantiated".
    Diabetes Obes Metab. 2018;20:2041-2042.
    PubMed    


  433. ELVERT R, Herling AW, Bossart M, Weiss T, et al
    Running on mixed fuel-dual agonistic approach of GLP-1 and GCG receptors leads to beneficial impact on body weight and blood glucose control: A comparative study between mice and non-human primates.
    Diabetes Obes Metab. 2018;20:1836-1851.
    PubMed     Abstract available


  434. MORALES J, Assumpcao-Morales M
    The 2018 update of the American College of Physicians glycaemic management recommendations: An invitation to continued inertia?
    Diabetes Obes Metab. 2018;20:1809-1811.
    PubMed     Abstract available


    July 2018
  435. LIAN J, McGhee SM, So C, Chau J, et al
    Long-term cost-effectiveness of Patient Empowerment Programme for Type 2 Diabetes Mellitus in primary care.
    Diabetes Obes Metab. 2018 Jul 29. doi: 10.1111/dom.13485.
    PubMed     Abstract available


  436. AVGERINOS I, Karagiannis T, Malandris K, Liakos A, et al
    Glucagon-like peptide 1 receptor agonists and microvascular outcomes in type 2 diabetes: a systematic review and meta-analysis.
    Diabetes Obes Metab. 2018 Jul 29. doi: 10.1111/dom.13484.
    PubMed     Abstract available


  437. RENARD E, Tubiana-Rufi N, Bonnemaison-Gilbert E, Coutant R, et al
    Closed-Loop Driven by Control-to-Range Algorithm Outperforms Threshold-Low-Glucose-Suspend Insulin Delivery on Glucose Control Albeit not on Nocturnal Hypoglycemia in Pre-pubertal Patients with Type 1 Diabetes in Supervised Hotel Setting.
    Diabetes Obes Metab. 2018 Jul 25. doi: 10.1111/dom.13482.
    PubMed     Abstract available


  438. MOTTALIB A, Tomah S, Hafida S, Elseaidy T, et al
    Intensive Multidisciplinary Weight Management in Patients with Type 1 Diabetes and Obesity: a 1-Year Retrospective Matched Cohort Study.
    Diabetes Obes Metab. 2018 Jul 25. doi: 10.1111/dom.13478.
    PubMed     Abstract available


  439. SCHMEDT N, Andersohn F, Walker J, Garbe E, et al
    Sodium-glucose co-transporter-2 inhibitors and the risk of fractures of the upper or lower limbs in patients with type 2 diabetes: a nested case-control study.
    Diabetes Obes Metab. 2018 Jul 25. doi: 10.1111/dom.13480.
    PubMed    


  440. TANG H, Yang K, Song Y, Han J, et al
    Meta-analysis of the association between sodium-glucose cotransporter 2 inhibitors and risk of skin cancer among patients with type 2 diabetes.
    Diabetes Obes Metab. 2018 Jul 23. doi: 10.1111/dom.13474.
    PubMed     Abstract available


  441. KU EJ, Lee DH, Jeon HJ, Oh TK, et al
    Effectiveness and safety of empagliflozin-based quadruple therapy compared with insulin glargine-based therapy in patients with inadequately controlled type 2 diabetes: an observational study in clinical practice.
    Diabetes Obes Metab. 2018 Jul 23. doi: 10.1111/dom.13476.
    PubMed     Abstract available


  442. DAWWAS GK, Smith SM, Park H
    Cardiovascular Outcomes of Sodium Glucose Cotransporter-2 Inhibitors in Patients with Type 2 Diabetes.
    Diabetes Obes Metab. 2018 Jul 23. doi: 10.1111/dom.13477.
    PubMed     Abstract available


  443. SCOTT R, Morgan J, Zimmer Z, Lam RLH, et al
    A Randomized Clinical Trial of the Efficacy and Safety of Sitagliptin Compared with Dapagliflozin in Patients with Type 2 Diabetes Mellitus and Mild Renal Insufficiency: The CompoSIT-R Study.
    Diabetes Obes Metab. 2018 Jul 18. doi: 10.1111/dom.13473.
    PubMed     Abstract available


  444. BRUCE DG, Davis WA, Davis TM
    Glycaemic control and mortality in older people with type 2 diabetes: The Fremantle Diabetes Study Phase II.
    Diabetes Obes Metab. 2018 Jul 13. doi: 10.1111/dom.13469.
    PubMed     Abstract available


  445. JAVIER ESCALADA F, Halimi S, Senior PA, Bonnemaire M, et al
    Glycemic control and hypoglycemia benefits with insulin glargine 300 U/mL (Gla-300) extend to people with type 2 diabetes and mild-to-moderate renal impairment.
    Diabetes Obes Metab. 2018 Jul 13. doi: 10.1111/dom.13470.
    PubMed     Abstract available


  446. IDZERDA NMA, Persson F, Pena MJ, Brenner BM, et al
    NT-proBNP predicts the cardio-renal response to aliskiren in patients with type 2 diabetes at high renal and cardiovascular risk.
    Diabetes Obes Metab. 2018 Jul 10. doi: 10.1111/dom.13465.
    PubMed     Abstract available


  447. KADOWAKI T, Sarai N, Hirakawa T, Taki K, et al
    Persistence of oral antidiabetic treatment for type 2 diabetes characterized by drug class, patient characteristics, and severity of renal impairment: A Japanese database analysis.
    Diabetes Obes Metab. 2018 Jul 4. doi: 10.1111/dom.13463.
    PubMed    


  448. ROSENSTOCK J, Handelsman Y, Vidal J, Ampudia Blasco FJ, et al
    Propensity score-matched comparative analyses of simultaneously administered fixed-ratio iGlarLixi (LixiLan) vs sequential administration of insulin glargine and lixisenatide in uncontrolled type 2 diabetes.
    Diabetes Obes Metab. 2018 Jul 4. doi: 10.1111/dom.13462.
    PubMed     Abstract available


  449. WANG JL, Dong YH, Ko WC, Chang CH, et al
    Thiazolidinediones and reduced risk of incident bacterial abscess in adults with type 2 diabetes: a population-based cohort study.
    Diabetes Obes Metab. 2018 Jul 4. doi: 10.1111/dom.13461.
    PubMed     Abstract available


  450. HARJUTSALO V, Thomas MC, Forsblom C, Groop PH, et al
    Risk of coronary artery disease and stroke according to sex and presence of diabetic nephropathy in type 1 diabetes.
    Diabetes Obes Metab. 2018 Jul 2. doi: 10.1111/dom.13456.
    PubMed     Abstract available


  451. RIDDERSTRALE M, Rosenstock J, Andersen KR, Woerle HJ, et al
    Empagliflozin compared with glimepiride in metformin-treated patients with type 2 diabetes: 208-week data from a masked randomized controlled trial.
    Diabetes Obes Metab. 2018 Jul 2. doi: 10.1111/dom.13457.
    PubMed     Abstract available


  452. GUO L, Chen L, Chang B, Yang L, et al
    A randomized, open-label, multicentre, parallel-controlled study comparing the efficacy and safety of biphasic insulin aspart 30 plus metformin with biphasic insulin aspart 30 monotherapy for type 2 diabetes patients inadequately controlled with oral
    Diabetes Obes Metab. 2018 Jul 2. doi: 10.1111/dom.13454.
    PubMed     Abstract available


    June 2018
  453. ZULLO AR, Hersey M, Lee Y, Sharmin S, et al
    Outcomes of "Diabetes-Friendly" versus "Diabetes-Unfriendly" Beta-blockers in Older Nursing Home Residents with Diabetes after Acute Myocardial Infarction.
    Diabetes Obes Metab. 2018 Jun 28. doi: 10.1111/dom.13451.
    PubMed     Abstract available


  454. MULLER-WIELAND D, Kellerer M, Cypryk K, Skripova D, et al
    Efficacy and Safety of Dapagliflozin or Dapagliflozin Plus Saxagliptin Versus Glimepiride as Add-on to Metformin in Patients With Type 2 Diabetes.
    Diabetes Obes Metab. 2018 Jun 27. doi: 10.1111/dom.13437.
    PubMed     Abstract available


  455. FRIER BM, Landgraf W, Zhang M, Bolli GB, et al
    Hypoglycaemia risk in the first eight weeks of titration with insulin glargine 100 U/mL in previously insulin-naive people with type 2 diabetes mellitus.
    Diabetes Obes Metab. 2018 Jun 25. doi: 10.1111/dom.13450.
    PubMed     Abstract available


  456. SPILLER S, Bluher M, Hoffmann R
    Plasma levels of free fatty acids correlate with type 2 diabetes mellitus.
    Diabetes Obes Metab. 2018 Jun 25. doi: 10.1111/dom.13449.
    PubMed     Abstract available


  457. SULLIVAN SD, Bailey TS, Roussel R, Zhou FL, et al
    Clinical outcomes in real-world patients with type 2 diabetes switching from first- to second-generation basal insulin analogues: Comparative effectiveness of insulin glargine 300 units/mL and insulin degludec in the DELIVER D+ cohort study.
    Diabetes Obes Metab. 2018 Jun 25. doi: 10.1111/dom.13345.
    PubMed     Abstract available


  458. RYAN PB, Buse JB, Schuemie MJ, DeFalco F, et al
    Comparative effectiveness of canagliflozin, SGLT2 inhibitors and non-SGLT2 inhibitors on the risk of hospitalization for heart failure and amputation in patients with type 2 diabetes mellitus: A real-world meta-analysis of 4 observational databases (O
    Diabetes Obes Metab. 2018 Jun 25. doi: 10.1111/dom.13424.
    PubMed     Abstract available


  459. WEIR DL, Abrahamowicz M, Beauchamp ME, Eurich DT, et al
    Acute vs Cumulative Benefits of Metformin use in Patients with Type 2 Diabetes and Heart Failure.
    Diabetes Obes Metab. 2018 Jun 23. doi: 10.1111/dom.13448.
    PubMed     Abstract available


  460. STEPHENSON JJ, Raval AD, Kern DM, Bae JP, et al
    Nonadherence to Basal Insulin Among Patients With Type 2 Diabetes in a US Managed Care Population: Results from a Patient Survey.
    Diabetes Obes Metab. 2018 Jun 21. doi: 10.1111/dom.13446.
    PubMed     Abstract available


  461. SUGIMOTO DH, Dex T, Stager W, Aroda VR, et al
    Efficacy of iGlarLixi, a fixed-ratio combination of insulin glargine and lixisenatide, in patients with type 2 diabetes stratified as high and low risk according to HEDIS measures.
    Diabetes Obes Metab. 2018 Jun 19. doi: 10.1111/dom.13438.
    PubMed     Abstract available


  462. ALFREDSSON J, Green JB, Stevens SR, Reed SD, et al
    Sex differences in management and outcomes of patients with type 2 diabetes and cardiovascular disease: A report from TECOS.
    Diabetes Obes Metab. 2018 Jun 19. doi: 10.1111/dom.13377.
    PubMed     Abstract available


  463. MELMER A, Kempf P, Lunger L, Pieber TR, et al
    Short-term effects of dapagliflozin on insulin sensitivity, postprandial glucose excursion, and ketogenesis in type 1 diabetes - a randomized, placebo-controlled, double blind, cross-over pilot study.
    Diabetes Obes Metab. 2018 Jun 19. doi: 10.1111/dom.13439.
    PubMed     Abstract available


  464. JAIKUMKAO K, Pongchaidecha A, Chueakula N, Thongnak LO, et al
    Dapagliflozin, a SGLT2 inhibitor, slows the progression of renal complications through the suppression of renal inflammation, ER stress, and apoptosis in pre-diabetic rats.
    Diabetes Obes Metab. 2018 Jun 19. doi: 10.1111/dom.13441.
    PubMed     Abstract available


  465. ANDERSEN G, Meiffren G, Lamers D, DeVries JH, et al
    Ultra-rapid BioChaperone Lispro Improves post-prandial Blood Glucose Excursions versus Insulin Lispro in a 14-day crossover Treatment Study in Patients with Type 1 Diabetes.
    Diabetes Obes Metab. 2018 Jun 19. doi: 10.1111/dom.13442.
    PubMed     Abstract available


  466. KAZIERAD DJ, Chidsey K, Somayaji VR, Bergman AJ, et al
    Efficacy and Safety of the Glucagon Receptor Antagonist PF-06291874: A 12-Week, Randomized, Dose-Response Study in Patients With Type 2 Diabetes Mellitus on Background Metformin Therapy.
    Diabetes Obes Metab. 2018 Jun 19. doi: 10.1111/dom.13440.
    PubMed     Abstract available


  467. YAN Z, Shyr ZA, Fortunato M, Welscher A, et al
    High Fat Diet induced Remission of Diabetes in a subset of KATP -GOF Insulin Secretory-Deficient mice.
    Diabetes Obes Metab. 2018 Jun 12. doi: 10.1111/dom.13423.
    PubMed     Abstract available


  468. KORSATKO S, Jensen L, Brunner M, Sach-Friedl S, et al
    Effect of once-weekly semaglutide on the counterregulatory response to hypoglycaemia in subjects with type 2 diabetes: a randomised, placebo-controlled, double-blind, crossover trial.
    Diabetes Obes Metab. 2018 Jun 12. doi: 10.1111/dom.13422.
    PubMed     Abstract available


  469. RABBONE I, Minuto N, Toni S, Lombardo F, et al
    Insulin pump breakdown and infusion set failure in Italian children with type 1 diabetes: 1-year prospective observational study with suggestions to minimize clinical impact.
    Diabetes Obes Metab. 2018 Jun 12. doi: 10.1111/dom.13419.
    PubMed     Abstract available


  470. TSURUTANI Y, Nakai K, Inoue K, Kosuke A, et al
    Comparative study of ipragliflozin with sitagliptin on multiple metabolic changes in Japanese patients with type 2 diabetes: a multicenter, randomized, prospective, open-label, active-controlled study.
    Diabetes Obes Metab. 2018 Jun 12. doi: 10.1111/dom.13421.
    PubMed     Abstract available


  471. FIORETTO P, Del Prato S, Buse JB, Goldenberg R, et al
    Efficacy and Safety of Dapagliflozin in Patients with Type 2 Diabetes and Moderate Renal Impairment (Chronic Kidney Disease Stage 3A): The DERIVE Study.
    Diabetes Obes Metab. 2018 Jun 11. doi: 10.1111/dom.13413.
    PubMed     Abstract available


  472. TERAUCHI Y, Riddle MC, Hirose T, Koyama M, et al
    Glycaemic control, hypoglycaemia, and weight change with insulin glargine 300 U/mL versus insulin glargine 100 U/mL in Japanese adults with type 2 diabetes: a 12-month comparison by concomitant sulphonylurea and/or glinide use.
    Diabetes Obes Metab. 2018 Jun 11. doi: 10.1111/dom.13414.
    PubMed     Abstract available


  473. EMANUEL AL, de Clercq NC, Koopen AM, van Poelgeest E, et al
    Iloprost infusion prevents the insulin-induced reduction in skeletal muscle microvascular blood volume but does not enhance peripheral glucose uptake in type 2 diabetic patients.
    Diabetes Obes Metab. 2018 Jun 8. doi: 10.1111/dom.13410.
    PubMed     Abstract available


  474. NIMRI R, Dassau E, Segall T, Muller I, et al
    Adjusting insulin doses in patients with type 1 diabetes that use insulin pump and continuous glucose monitoring - Variations among countries and physicians.
    Diabetes Obes Metab. 2018 Jun 8. doi: 10.1111/dom.13408.
    PubMed     Abstract available


  475. FARR OM, Mantzoros CS
    Obese individuals with type 2 diabetes demonstrate decreased activation of the salience-related insula and increased activation of the emotion/salience-related amygdala to visual food cues compared to non-obese individuals with diabetes: a preliminary
    Diabetes Obes Metab. 2018 Jun 8. doi: 10.1111/dom.13403.
    PubMed     Abstract available


  476. REZNIK Y, Habteab A, Castaneda J, Shin J, et al
    Contribution of basal and postprandial hyperglycemia in type 2 diabetes patients treated by an intensified insulin regimen: impact of pump therapy in the OPT2MISE trial.
    Diabetes Obes Metab. 2018 Jun 4. doi: 10.1111/dom.13398.
    PubMed     Abstract available


  477. HANS DEVRIES J, Desouza C, Bellary S, Unger J, et al
    Achieving glycaemic control without weight gain, hypoglycaemia, or gastrointestinal adverse events in type 2 diabetes in the SUSTAIN clinical trial programme.
    Diabetes Obes Metab. 2018 Jun 4. doi: 10.1111/dom.13396.
    PubMed     Abstract available


  478. HAN KA, Chon S, Chung CH, Lim S, et al
    Efficacy and safety of ipragliflozin as an add-on therapy to sitagliptin and metformin in Korean patients with inadequately controlled type 2 diabetes mellitus: a randomized controlled trial.
    Diabetes Obes Metab. 2018 Jun 4. doi: 10.1111/dom.13394.
    PubMed     Abstract available


  479. KAKU K, Kuroda S, Ishida K, Umeda Y, et al
    Efficacy and safety of trelagliptin in combination with insulin therapy in Japanese patients with type 2 diabetes: results from a randomized, phase IV study.
    Diabetes Obes Metab. 2018 Jun 4. doi: 10.1111/dom.13397.
    PubMed     Abstract available


  480. JALVING AC, Gant CM, Binnenmars SH, Soedamah-Muthu SS, et al
    Glycemic Control In The Diabetes And Lifestyle Cohort Twente - A Cross-Sectional Assessment Of Lifestyle And Pharmacological Management On Hba1c Target Achievement.
    Diabetes Obes Metab. 2018 Jun 4. doi: 10.1111/dom.13399.
    PubMed     Abstract available


  481. KREBS JD, Arahill J, Cresswell P, Weatherall M, et al
    The effect of additional mealtime insulin bolus using an insulin-to-protein ratio compared to to usual carbohydrate counting on postprandial glucose in those with Type 1 diabetes who usually follow a carbohydrate-restricted diet: a randomised cross-ov
    Diabetes Obes Metab. 2018 Jun 1. doi: 10.1111/dom.13392.
    PubMed     Abstract available


    May 2018
  482. GANDA OP, Plutzky J, Sanganalmath SK, Bujas-Bobanovic M, et al
    Efficacy and safety of alirocumab among individuals with diabetes mellitus and atherosclerotic cardiovascular disease in the ODYSSEY phase 3 trials.
    Diabetes Obes Metab. 2018 May 26. doi: 10.1111/dom.13384.
    PubMed     Abstract available


  483. NORONHA JC, Braunstein CR, Glenn A, Khan TA, et al
    Effect of Small Doses of Fructose and Allulose on Postprandial Glucose Metabolism in Type 2 Diabetes: A Double-blind, Randomized, Controlled, Acute Feeding Equivalence Trial.
    Diabetes Obes Metab. 2018 May 24. doi: 10.1111/dom.13374.
    PubMed     Abstract available


  484. DRUMMOND RS, Malkin S, Du Preez M, Lee XY, et al
    Management of type 2 diabetes with Fixed-Ratio combination insulin degludec/liraglutide (IDEGLIRA) versus Basal-Bolus therapy (INSULIN GLARGINE U100 PLUS INSULIN ASPART): A Short-Term Cost-Effectiveness analysis in the UK setting.
    Diabetes Obes Metab. 2018 May 24. doi: 10.1111/dom.13375.
    PubMed     Abstract available


  485. CAO B, Rosenblat JD, Brietzke E, Park C, et al
    Comparative Efficacy and Acceptability of Anti-Diabetic Agents for Alzheimer's Disease and Mild Cognitive Impairment: A Systematic Review and Network Meta-analysis.
    Diabetes Obes Metab. 2018 May 23. doi: 10.1111/dom.13373.
    PubMed     Abstract available


  486. KAWASAKI R, Konta T, Nishida K
    Lipid-lowering medication use is associated with decreased risk of diabetic retinopathy and its treatments in patients with type 2 diabetes: a real-world observational analysis of a health claims database.
    Diabetes Obes Metab. 2018 May 22. doi: 10.1111/dom.13372.
    PubMed     Abstract available


  487. BELL DSH, Goncalves E
    Should we still be utilizing warfarin in the type 2 diabetic patient?
    Diabetes Obes Metab. 2018 May 22. doi: 10.1111/dom.13371.
    PubMed     Abstract available


  488. LESLIE RD, Pozzilli P, Peters AL, Buzzetti R, et al
    Response to the comment on Dulaglutide treatment results in effective glycaemic control in latent autoimmune diabetes in adults (LADA): A post-hoc analysis of the AWARD-2,-4 and -5 Trials.
    Diabetes Obes Metab. 2018 May 20. doi: 10.1111/dom.13366.
    PubMed     Abstract available


  489. SUZUKI R, Eiki JI, Moritoyo T, Furihata K, et al
    Effect of Short Term Treatment with Sitagliptin or Glibenclamide on Daily Glucose Fluctuation in Drug-naive Japanese Patients with Type 2 Diabetes Mellitus.
    Diabetes Obes Metab. 2018 May 17. doi: 10.1111/dom.13364.
    PubMed     Abstract available


  490. KAWAMORI R, Haneda M, Suzaki K, Cheng G, et al
    Empagliflozin as add-on to linagliptin in a fixed-dose combination in Japanese patients with type 2 diabetes: Glycemic efficacy and safety profile in a 52-week, randomized, placebo-controlled trial.
    Diabetes Obes Metab. 2018 May 15. doi: 10.1111/dom.13352.
    PubMed     Abstract available


  491. HOME PD, Lam RLH, Carofano WL, Golm GT, et al
    Efficacy and safety of MK-1293 insulin glargine compared with originator insulin glargine (Lantus) in type 1 diabetes: a randomized, open-label clinical trial.
    Diabetes Obes Metab. 2018 May 15. doi: 10.1111/dom.13354.
    PubMed     Abstract available


  492. AHREN B, Atkin SL, Charpentier G, Warren ML, et al
    Semaglutide induces weight loss in subjects with type 2 diabetes regardless of baseline BMI or gastrointestinal adverse events in SUSTAIN 1-5 trials.
    Diabetes Obes Metab. 2018 May 15. doi: 10.1111/dom.13353.
    PubMed     Abstract available


  493. SHIMADA A, Hanafusa T, Yasui A, Lee G, et al
    Empagliflozin as adjunct to insulin in Japanese participants with type 1 diabetes: Results of a 4-week, double-blind, randomized, placebo-controlled phase 2 trial.
    Diabetes Obes Metab. 2018 May 15. doi: 10.1111/dom.13351.
    PubMed     Abstract available


  494. HOLLANDER PA, Carofano WL, Lam RLH, Golm GT, et al
    Efficacy and safety of MK-1293 insulin glargine compared with originator insulin glargine (Lantus) in type 2 diabetes: a randomized, open-label clinical trial.
    Diabetes Obes Metab. 2018 May 14. doi: 10.1111/dom.13363.
    PubMed     Abstract available


  495. ANDREADIS P, Karagiannis T, Malandris K, Avgerinos I, et al
    Semaglutide for type 2 diabetes mellitus: a systematic review and meta-analysis.
    Diabetes Obes Metab. 2018 May 13. doi: 10.1111/dom.13361.
    PubMed     Abstract available


  496. BAILEY CJ
    European Medicines Agency: approval of new glucose-lowering medicines for type 2 diabetes.
    Diabetes Obes Metab. 2018 May 13. doi: 10.1111/dom.13360.
    PubMed     Abstract available


  497. PETRI KCC, Ingwersen SH, Flint A, Zacho J, et al
    Exposure-response analysis for evaluation of semaglutide dose levels in type 2 diabetes.
    Diabetes Obes Metab. 2018 May 11. doi: 10.1111/dom.13358.
    PubMed     Abstract available


  498. CURTIN F, Bernard C, Levet S, Perron H, et al
    A new therapeutic approach for type 1 diabetes: rationale for GNbAC1 an anti-HERV-W-Env monoclonal antibody.
    Diabetes Obes Metab. 2018 May 10. doi: 10.1111/dom.13357.
    PubMed     Abstract available


  499. BLIND E, Janssen H, Dunder K, de Graeff PA, et al
    The European Medicines Agency's Approval of New Medicines for Type 2 Diabetes.
    Diabetes Obes Metab. 2018 May 8. doi: 10.1111/dom.13349.
    PubMed     Abstract available


  500. FITZPATRICK C, Chatterjee S, Seidu S, Bodicoat DH, et al
    Association of hypoglycaemia and cardiac arrhythmia risk in patients with diabetes mellitus: A systematic review and meta-analysis.
    Diabetes Obes Metab. 2018 May 8. doi: 10.1111/dom.13348.
    PubMed     Abstract available


  501. CURTIS HJ, Dennis JM, Shields BM, Walker AJ, et al
    Time Trends and Geographical Variation in Prescribing of Drugs for Diabetes in England 1998-2017.
    Diabetes Obes Metab. 2018 May 7. doi: 10.1111/dom.13346.
    PubMed     Abstract available


  502. MAIORINO MI, Chiodini P, Bellastella G, Scappaticcio L, et al
    Free and fixed-ratio combinations of basal insulin and GLP-1 receptor agonists versus basal insulin intensification in type 2 diabetes: A systematic review and meta-analysis of randomized controlled trials.
    Diabetes Obes Metab. 2018 May 7. doi: 10.1111/dom.13343.
    PubMed     Abstract available


  503. OVERBEEK J, Heintjes E, Huisman E, Tikkanen C, et al
    Clinical Effectiveness of Liraglutide versus Basal Insulin in a Real-world Setting: Evidence for Improved Glycaemic and Weight Control in Obese Patients with Type 2 Diabetes.
    Diabetes Obes Metab. 2018 May 3. doi: 10.1111/dom.13335.
    PubMed     Abstract available


  504. HUANG CJ, Wang WT, Sung SH, Chen CH, et al
    Blood Glucose Reduction by Diabetic Drugs with Minimal Hypoglycemia Risk for Cardiovascular Outcomes: Evidence from Meta-regression Analysis of Randomized Controlled Trials.
    Diabetes Obes Metab. 2018 May 2. doi: 10.1111/dom.13342.
    PubMed     Abstract available


    April 2018
  505. CHEN YH, Huang CN, Cho YM, Li P, et al
    Efficacy and safety of dulaglutide monotherapy compared to glimepiride in East Asian patients with type 2 diabetes in a multicenter, double-blind, randomized, parallel-arm, active comparator, phase 3 trial.
    Diabetes Obes Metab. 2018 Apr 30. doi: 10.1111/dom.13340.
    PubMed     Abstract available


  506. GOLDENBERG RM, Assimakopoulos P, Gilbert JD, Gottesman IS, et al
    A Practical Approach and Algorithm for Intensifying Beyond Basal Insulin in Type 2 Diabetes.
    Diabetes Obes Metab. 2018 Apr 29. doi: 10.1111/dom.13337.
    PubMed     Abstract available


  507. ZHU XX, Zhu DL, Li XY, Li YL, et al
    Dorzagliatin (HMS5552), a Novel Dual Acting Glucokinase Activator, Improves Glycemic Control and Pancreatic beta-cell Function in Patients with Type 2 Diabetes: A 28-day Treatment Study Using Biomarker-Guided Patient Selection.
    Diabetes Obes Metab. 2018 Apr 29. doi: 10.1111/dom.13338.
    PubMed     Abstract available


  508. PANDEYA N, Huxley RR, Chung HF, Dobson AJ, et al
    Female reproductive history and risk of type 2 diabetes: a prospective analysis of 126,721 women.
    Diabetes Obes Metab. 2018 Apr 25. doi: 10.1111/dom.13336.
    PubMed     Abstract available


  509. WARREN M, Chaykin L, Trachtenbarg D, Nayak G, et al
    Semaglutide as a therapeutic option for elderly patients with type 2 diabetes: pooled analysis of the SUSTAIN 1-5 trials.
    Diabetes Obes Metab. 2018 Apr 23. doi: 10.1111/dom.13331.
    PubMed     Abstract available


  510. LIU DM, Mosialou I, Liu JM
    Bone: another potential target to treat, prevent and predict diabetes.
    Diabetes Obes Metab. 2018 Apr 23. doi: 10.1111/dom.13330.
    PubMed     Abstract available


  511. COLLIER A, Connelly PJ, Hair M, Cameron L, et al
    Mortality risk is still higher in people with type 1 diabetes: a population-based cohort study (The Ayrshirre Diabetes fOllow-up Cohort (ADOC) study).
    Diabetes Obes Metab. 2018 Apr 23. doi: 10.1111/dom.13334.
    PubMed     Abstract available


  512. SIDORENKOV G, van Boven JFM, Hoekstra T, Nijpels G, et al
    HbA1c response after insulin initiation in patients with type 2 diabetes in real-life: identifying distinct subgroups.
    Diabetes Obes Metab. 2018 Apr 23. doi: 10.1111/dom.13332.
    PubMed     Abstract available


  513. OUT M, Top WMC, Lehert P, Schalkwijk CA, et al
    Long-term treatment with metformin in type 2 diabetes and vitamin D levels: A post hoc analysis of a randomised placebo-controlled trial.
    Diabetes Obes Metab. 2018 Apr 17. doi: 10.1111/dom.13327.
    PubMed    


  514. BLEVINS TC, Barve A, Sun B, Ankersen M, et al
    Efficacy and Safety of MYL-1501D Versus Insulin Glargine in Patients With Type 1 Diabetes After 52 Weeks: Results of the Phase 3 INSTRIDE 1 Study.
    Diabetes Obes Metab. 2018 Apr 15. doi: 10.1111/dom.13322.
    PubMed     Abstract available


  515. ANDERSEN ES, Lund A, Bagger JI, Andreasen C, et al
    Is glucagon-like peptide-1 fully protected by dipeptidyl peptidase 4 inhibitor administration in patients with type 2 diabetes?
    Diabetes Obes Metab. 2018 Apr 14. doi: 10.1111/dom.13321.
    PubMed     Abstract available


  516. PONTIROLI AE, Ceriani V
    Intranasal glucagon for hypoglycaemia in diabetic patients. An old dream is becoming reality?
    Diabetes Obes Metab. 2018 Apr 13. doi: 10.1111/dom.13317.
    PubMed     Abstract available


  517. BARNETT AH, Arnoldini S, Hunt B, Subramanian G, et al
    Switching from sitagliptin to liraglutide to manage patients with type 2 diabetes in the UK: A Long-Term Cost-Effectiveness analysis.
    Diabetes Obes Metab. 2018 Apr 13. doi: 10.1111/dom.13318.
    PubMed     Abstract available


  518. FARNGREN J, Persson M, Ahren B
    Effects on the glucagon response to hypoglycaemia during DPP-4 inhibition in elderly subjects with type 2 diabetes-a randomized, placebo-controlled study.
    Diabetes Obes Metab. 2018 Apr 12. doi: 10.1111/dom.13316.
    PubMed     Abstract available


    March 2018
  519. HEERSPINK HJL, Andress DL, Bakris G, Brennan JJ, et al
    Baseline characteristics and enrichment results of the Study Of diabetic Nephropathy with AtRasentan (SONAR) trial.
    Diabetes Obes Metab. 2018 Mar 31. doi: 10.1111/dom.13315.
    PubMed     Abstract available


  520. MATHIEU C, Del Prato S, Botros FT, Thieu VT, et al
    Effect of Once Weekly Dulaglutide by Baseline Beta-cell Function in People with Type 2 Diabetes in the AWARD Programme.
    Diabetes Obes Metab. 2018 Mar 30. doi: 10.1111/dom.13313.
    PubMed     Abstract available


  521. VOORMOLEN DN, DeVries JH, Sanson RME, Heringa MP, et al
    Continuous Glucose Monitoring during Diabetic Pregnancy (GlucoMOMS); a multicentre randomised controlled trial.
    Diabetes Obes Metab. 2018 Mar 30. doi: 10.1111/dom.13310.
    PubMed     Abstract available


  522. RADHOLM K, Chalmers J, Ohkuma T, Peters S, et al
    Use of the waist-to-height-ratio to predict cardiovascular risk in patients with diabetes: results from ADVANCE-ON.
    Diabetes Obes Metab. 2018 Mar 30. doi: 10.1111/dom.13311.
    PubMed     Abstract available


  523. BECKER RHA
    Comment to Heise, T, Norskov, M, Nosek, L, Kaplan, K, Famulla, S and Haahr, H. L. (2017), Insulin degludec: lower day-to-day and within-day variability in pharmacodynamic response compared to insulin glargine U300 in type 1 diabetes. Diabetes Obes Met
    Diabetes Obes Metab. 2018 Mar 29. doi: 10.1111/dom.13308.
    PubMed     Abstract available


  524. HOU C, Xu Q, Diao S, Hewitt J, et al
    Mobile phone applications and self-management of diabetes: a systematic review with meta-analysis, meta-regression of 21 randomized trials, and GRADE.
    Diabetes Obes Metab. 2018 Mar 27. doi: 10.1111/dom.13307.
    PubMed     Abstract available


  525. ORSI E, Solini A, Bonora E, Fondelli C, et al
    Haemoglobin A1c variability is a strong, independent predictor of all-cause mortality in patients with type 2 diabetes.
    Diabetes Obes Metab. 2018 Mar 26. doi: 10.1111/dom.13306.
    PubMed     Abstract available


  526. ARNOLD SV, Kosiborod M, Wang J, Fenici P, et al
    Burden of Cardio-Renal-Metabolic Conditions in Adults with Type 2 Diabetes within the Diabetes Collaborative Registry.
    Diabetes Obes Metab. 2018 Mar 25. doi: 10.1111/dom.13303.
    PubMed     Abstract available


  527. RUAN Y, Bally L, Thabit H, Leelarathna L, et al
    Hypoglycaemia Incidence and Recovery During Home Use of Hybrid Closed-Loop Insulin Delivery in Adults with Type 1 Diabetes.
    Diabetes Obes Metab. 2018 Mar 25. doi: 10.1111/dom.13304.
    PubMed     Abstract available


  528. REED SD, Li Y, Leal J, Radican L, et al
    Longitudinal Medical Resources and Costs Among Type 2 Diabetes Patients Participating in the Trial Evaluating Cardiovascular Outcomes with Sitagliptin (TECOS).
    Diabetes Obes Metab. 2018 Mar 23. doi: 10.1111/dom.13292.
    PubMed     Abstract available


  529. FRIAS JP, Hardy E, Ahmed A, Ohman P, et al
    Effects of exenatide once weekly plus dapagliflozin, exenatide once weekly, or dapagliflozin added to metformin monotherapy in subgroups of patients with type 2 diabetes in the DURATION-8 randomized controlled trial.
    Diabetes Obes Metab. 2018 Mar 23. doi: 10.1111/dom.13296.
    PubMed     Abstract available


  530. GUO M, Ding J, Li J, Wang J, et al
    SGLT2 inhibitors and stroke risk in patients with type 2 diabetes: a systematic review and meta-analysis.
    Diabetes Obes Metab. 2018 Mar 23. doi: 10.1111/dom.13295.
    PubMed     Abstract available


  531. LI D, Shi W, Wang T, Tang H, et al
    SGLT2 inhibitor plus DPP-4 inhibitor as combination therapy for type 2 diabetes: A systematic review and meta-analysis.
    Diabetes Obes Metab. 2018 Mar 23. doi: 10.1111/dom.13294.
    PubMed     Abstract available


  532. PICHE ME, Laberge AS, Brassard P, Arsenault BJ, et al
    Rosiglitazone lowers resting and blood pressure response to exercise in men with type 2 diabetes: a 1 year randomized study.
    Diabetes Obes Metab. 2018 Mar 23. doi: 10.1111/dom.13293.
    PubMed     Abstract available


  533. KIM YG, Jeon JY, Han SJ, Kim DJ, et al
    Sodium-glucose co-transporter 2 inhibitors and the risk for diabetic ketoacidosis in patients with type 2 diabetes mellitus: A nationwide population-based cohort study.
    Diabetes Obes Metab. 2018 Mar 22. doi: 10.1111/dom.13297.
    PubMed     Abstract available


  534. MASTRACCI TL, Turatsinze JV, Book BK, Restrepo IA, et al
    Distinct Gene Expression Pathways in Islets from Individuals with Short- and Long-Duration Type 1 Diabetes.
    Diabetes Obes Metab. 2018 Mar 22. doi: 10.1111/dom.13298.
    PubMed     Abstract available


  535. LAUBNER K, Riedel N, Fink K, Holl RW, et al
    Comparative efficacy and safety of the duodenal-jejunal bypass liner in obese patients with type 2 diabetes mellitus - a case control study.
    Diabetes Obes Metab. 2018 Mar 22. doi: 10.1111/dom.13300.
    PubMed     Abstract available


  536. YANG YS, Lim MH, Lee SO, Roh E, et al
    Fimasartan increases glucose-stimulated insulin secretion in patients with type 2 diabetes and hypertension compared with amlodipine.
    Diabetes Obes Metab. 2018 Mar 15. doi: 10.1111/dom.13282.
    PubMed     Abstract available


  537. JONES AG, McDonald TJ
    Comment on: Dulaglutide treatment results in effective glycaemic control in latent autoimmune diabetes in adults (LADA): A post-hoc analysis of the AWARD-2, -4 and -5 Trials.
    Diabetes Obes Metab. 2018 Mar 14. doi: 10.1111/dom.13290.
    PubMed     Abstract available


  538. MONTVIDA O, Shaw J, Blonde L, Paul SK, et al
    Long-term sustainability of glycaemic achievements with second-line anti-diabetic therapies in patients with type 2 diabetes: A real-world study.
    Diabetes Obes Metab. 2018 Mar 14. doi: 10.1111/dom.13288.
    PubMed     Abstract available


  539. POP LM, Mari A, Zhao TJ, Mitchell L, et al
    Roux-en-Y Gastric Bypass Compared to Equivalent Diet Restriction: Mechanistic Insights into Diabetes Remission.
    Diabetes Obes Metab. 2018 Mar 13. doi: 10.1111/dom.13287.
    PubMed     Abstract available


  540. BRIL F, Millan L, Kalavalpalli S, McPhaul MJ, et al
    Use of a Metabolomic Approach to Non-invasively Diagnose Nonalcoholic Fatty Liver Disease in Patients with Type 2 Diabetes Mellitus.
    Diabetes Obes Metab. 2018 Mar 12. doi: 10.1111/dom.13285.
    PubMed     Abstract available


  541. MOHANDAS C, Bonadonna R, Shojee-Moradie F, Jackson N, et al
    Ethnic differences in insulin secretory function between Black African and White European men with early type 2 diabetes.
    Diabetes Obes Metab. 2018 Mar 8. doi: 10.1111/dom.13283.
    PubMed     Abstract available


  542. JUNG HY, Kim B, Ji Y, Ryu HG, et al
    Amodiaquine improves insulin resistance and lipid metabolism in diabetic model mice.
    Diabetes Obes Metab. 2018 Mar 8. doi: 10.1111/dom.13284.
    PubMed     Abstract available


  543. SEAQUIST ER, Dulude H, Zhang XM, Rabasa-Lhoret R, et al
    A prospective study evaluating the use of nasal glucagon for the treatment of moderate to severe hypoglycemia in adults with type 1 diabetes in a real-world setting.
    Diabetes Obes Metab. 2018 Mar 5. doi: 10.1111/dom.13278.
    PubMed     Abstract available


  544. CEA-SORIANO L, Garcia-Rodriguez LA, Brodovicz KG, Masso Gonzalez E, et al
    Safety of Non-insulin glucose-lowering drugs in pregnant women with pre-gestational diabetes: a cohort study.
    Diabetes Obes Metab. 2018 Mar 2. doi: 10.1111/dom.13275.
    PubMed     Abstract available


  545. ALSALIM W, Persson M, Ahren B
    Different Glucagon Effects During DPP-4 Inhibition versus SGLT-2 Inhibition in Metformin-Treated Type 2 Diabetes Subjects.
    Diabetes Obes Metab. 2018 Mar 2. doi: 10.1111/dom.13276.
    PubMed     Abstract available


  546. BJORNSTAD P, Maahs DM, Roncal CA, Snell-Bergeon JK, et al
    Role of Bicarbonate Supplementation on Urine Uric Acid Crystals and Diabetic Tubulopathy in Adults with Type 1 Diabetes: A Brief Report.
    Diabetes Obes Metab. 2018 Mar 2. doi: 10.1111/dom.13274.
    PubMed     Abstract available


  547. HENRY RR, Muller-Wieland D, Taub PR, Bujas-Bobanovic M, et al
    Effect of alirocumab on lipids and lipoproteins in individuals with metabolic syndrome and without diabetes: Pooled data from 10 phase 3 trials.
    Diabetes Obes Metab. 2018 Mar 1. doi: 10.1111/dom.13273.
    PubMed     Abstract available


    February 2018
  548. HARASHIMA SI, Inagaki N, Kondo K, Maruyama N, et al
    Efficacy and safety of canagliflozin as add-on therapy to a glucagon-like peptide-1 receptor agonist in Japanese patients with type 2 diabetes mellitus: a 52-week, open-label, phase IV study.
    Diabetes Obes Metab. 2018 Feb 23. doi: 10.1111/dom.13267.
    PubMed     Abstract available


  549. GUJA C, Frias JP, Somogyi A, Jabbour S, et al
    Effect of exenatide QW or placebo, both added to titrated insulin glargine, in uncontrolled type 2 diabetes: the DURATION-7 randomized study.
    Diabetes Obes Metab. 2018 Feb 23. doi: 10.1111/dom.13266.
    PubMed     Abstract available


  550. YAMADA T, Shojima N, Noma H, Yamauchi T, et al
    Sodium-glucose co-transporter 2 (SGLT2) inhibitors as add-on therapy to insulin for type 1 diabetes mellitus: Systematic review and meta-analysis of randomized controlled trials.
    Diabetes Obes Metab. 2018 Feb 16. doi: 10.1111/dom.13260.
    PubMed     Abstract available


  551. HALUZIK M, Fulcher G, Pieber TR, Bardtrum L, et al
    Insulin degludec/insulin aspart lowers fasting plasma glucose and rates of confirmed and nocturnal hypoglycaemia independent of baseline HbA1c levels, disease duration or BMI: A pooled meta-analysis of phase 3 studies in patients with type 2 diabetes.
    Diabetes Obes Metab. 2018 Feb 16. doi: 10.1111/dom.13261.
    PubMed     Abstract available


  552. JUNG CH, Rhee EJ, Lee WY, Min KW, et al
    A 52-week extension study of switching from gemigliptin vs. sitagliptin to gemigliptin only as an add-on to patients with type 2 diabetes inadequately controlled on metformin alone.
    Diabetes Obes Metab. 2018 Feb 13. doi: 10.1111/dom.13256.
    PubMed     Abstract available


  553. RAY KK, Leiter LA, Muller-Wieland D, Cariou B, et al
    Alirocumab versus usual lipid-lowering care as add-on to statin therapy in individuals with type 2 diabetes and mixed dyslipidaemia: The ODYSSEY DM-DYSLIPIDEMIA randomized trial.
    Diabetes Obes Metab. 2018 Feb 13. doi: 10.1111/dom.13257.
    PubMed     Abstract available


  554. PANTALONE KM, Patel H, Yu M, Lando LF, et al
    Dulaglutide 1.5 mg as an Add-on Option for Patients Uncontrolled on Insulin: Subgroup Analysis by Age, Duration of Diabetes and Baseline HbA1c.
    Diabetes Obes Metab. 2018 Feb 12. doi: 10.1111/dom.13252.
    PubMed     Abstract available


  555. WONG CKH, Jiao F, Tang EHM, Tong T, et al
    Direct medical costs of diabetes mellitus in the year of mortality and year before mortality.
    Diabetes Obes Metab. 2018 Feb 12. doi: 10.1111/dom.13253.
    PubMed     Abstract available


  556. LAFFIN LJ, Bakris GL
    Results of ACCORDIAN in Accord with Lower Blood Pressure Begetting Lower Mortality in Patients with Diabetes.
    Diabetes Obes Metab. 2018 Feb 9. doi: 10.1111/dom.13249.
    PubMed     Abstract available


  557. BUCKLEY LF, Dixon DL, Wohlford GF 4th, Wijesinghe DS, et al
    Effect of Intensive Blood Pressure Control in Patients with Type 2 Diabetes Mellitus Over 9 Years of Follow-Up: A Subgroup Analysis of High-Risk ACCORDION Trial Participants.
    Diabetes Obes Metab. 2018 Feb 9. doi: 10.1111/dom.13248.
    PubMed     Abstract available


  558. BALDASSARRE MPA, Andersen A, Consoli A, Knop FK, et al
    Cardiovascular biomarkers in clinical studies of type 2 diabetes.
    Diabetes Obes Metab. 2018 Feb 8. doi: 10.1111/dom.13247.
    PubMed     Abstract available


  559. GORMSEN LC, Sondergaard E, Christensen NL, Jakobsen S, et al
    Metformin does not Affect Postabsorptive Hepatic Free Fatty Acid Uptake, Oxidation or Resecretion in Humans: A 3-months Placebo Controlled Clinical Trial in Patients with Type 2 Diabetes and Healthy Controls.
    Diabetes Obes Metab. 2018 Feb 6. doi: 10.1111/dom.13244.
    PubMed     Abstract available


  560. HEERSPINK HJL, Andress DL, Bakris G, Brennan JJ, et al
    Rationale and protocol of the Study of Diabetic Nephropathy with Atrasentan (SONAR) trial: A clinical trial design novel to diabetic nephropathy.
    Diabetes Obes Metab. 2018 Feb 6. doi: 10.1111/dom.13245.
    PubMed     Abstract available


  561. KHUNTI K, Kosiborod M, Ray KK
    Legacy benefits of blood glucose, blood pressure and lipid control in people with diabetes and cardiovascular disease: Time to overcome multifactorial therapeutic inertia?
    Diabetes Obes Metab. 2018 Feb 6. doi: 10.1111/dom.13243.
    PubMed     Abstract available


  562. MALMSTROM H, Walldius G, Carlsson S, Grill V, et al
    Elevations of metabolic risk factors 20 years or more before diagnosis of type 2 diabetes - experience from the AMORIS study.
    Diabetes Obes Metab. 2018 Feb 5. doi: 10.1111/dom.13241.
    PubMed     Abstract available


  563. TRAN S, Retnakaran R, Zinman B, Kramer CK, et al
    Efficacy of glucagon-like peptide-1 receptor agonists compared to dipeptidyl peptidase-4 inhibitors for the management of type 2 diabetes: A meta-analysis of randomized clinical trials.
    Diabetes Obes Metab. 2018;20 Suppl 1:68-76.
    PubMed     Abstract available


  564. DANDONA P, Ghanim H, Chaudhuri A
    Incretins: Beyond type 2 diabetes.
    Diabetes Obes Metab. 2018;20 Suppl 1:59-67.
    PubMed     Abstract available


    January 2018
  565. THUESEN ACB, Vaag A
    Perspectives on diabetes mortality due to residual confounding and reverse causality by common disease.
    Diabetes Obes Metab. 2018 Jan 30. doi: 10.1111/dom.13238.
    PubMed     Abstract available


  566. POZZILLI P, Leslie RD, Peters AL, Buzzetti R, et al
    Dulaglutide Treatment Results in Effective Glycemic Control in Latent Autoimmune Diabetes in Adults (LADA): A Post-Hoc Analysis of the AWARD-2, -4, and -5 Trials.
    Diabetes Obes Metab. 2018 Jan 27. doi: 10.1111/dom.13237.
    PubMed     Abstract available


  567. CAO YX, Liu HH, Dong QT, Li S, et al
    Effect of the PCSK9-monoclonal antibodies on new-onset diabetes mellitus and glucose metabolism: a systematic review and meta-analysis.
    Diabetes Obes Metab. 2018 Jan 27. doi: 10.1111/dom.13235.
    PubMed     Abstract available


  568. RETNAKARAN R, Choi H, Ye C, Kramer CK, et al
    A 2-year Trial of Intermittent Insulin Therapy versus Metformin for the Preservation of Beta-cell Function after Initial Short-term Intensive Insulin Induction in early Type 2 Diabetes.
    Diabetes Obes Metab. 2018 Jan 27. doi: 10.1111/dom.13236.
    PubMed     Abstract available


  569. TANG H, Li G, Zhao Y, Wang F, et al
    Comparisons of diabetic retinopathy events associated with glucose-lowering drugs in patients with type 2 diabetes mellitus: a network meta-analysis.
    Diabetes Obes Metab. 2018 Jan 25. doi: 10.1111/dom.13232.
    PubMed     Abstract available


  570. LIU H, Wang L, Zhang S, Leng J, et al
    One-year weight losses in the Tianjin Gestational Diabetes Mellitus Prevention Program: A Randomized Clinical Trial.
    Diabetes Obes Metab. 2018 Jan 23. doi: 10.1111/dom.13225.
    PubMed     Abstract available


  571. KREBS JD, Weatherall M, Corley B, Wiltshire E, et al
    Optimising the management of hypoglycaemia in people with Type 2 Diabetes. A randomised crossover comparison of a weight-based protocol compared with two fixed-dose glucose regimens.
    Diabetes Obes Metab. 2018 Jan 23. doi: 10.1111/dom.13231.
    PubMed     Abstract available


  572. KOFFERT J, Stahle M, Karlsson H, Iozzo P, et al
    Morbid obesity and type 2 diabetes alter intestinal fatty acid uptake and blood flow.
    Diabetes Obes Metab. 2018 Jan 20. doi: 10.1111/dom.13228.
    PubMed     Abstract available


  573. APPERLOO EM, Pena MJ, de Zeeuw D, Denig P, et al
    Individual variability in response to renin-angiotensin-aldosterone system inhibition predicts cardiovascular outcome in patients with type 2 diabetes: a primary care cohort study.
    Diabetes Obes Metab. 2018 Jan 18. doi: 10.1111/dom.13226.
    PubMed     Abstract available


  574. POLIDORI D, Iijima H, Goda M, Maruyama N, et al
    Intra- and Inter-Subject Variability for Increases in Serum Ketone Bodies in Patients With Type 2 Diabetes Treated With the Sodium Glucose Co-transporter 2 Inhibitor Canagliflozin.
    Diabetes Obes Metab. 2018 Jan 17. doi: 10.1111/dom.13224.
    PubMed     Abstract available


  575. DORENBOS E, Drummen M, Rijks J, Adam T, et al
    PREVIEW: Prevention of diabetes through lifestyle intervention in a multicentre study in Europe in children (10-17y). Design, methods, and baseline results.
    Diabetes Obes Metab. 2018 Jan 11. doi: 10.1111/dom.13216.
    PubMed     Abstract available


  576. ILANY J, Bhandari H, Nabriski D, Toledano Y, et al
    Effect of prandial treatment timing adjustment, based on continuous glucose monitoring, in patients with type 2 diabetes uncontrolled on once daily basal insulin: a randomized, phase IV study.
    Diabetes Obes Metab. 2018 Jan 8. doi: 10.1111/dom.13214.
    PubMed     Abstract available


  577. PORKSEN NK, Linnebjerg H, Lam ECQ, Garhyan P, et al
    Basal Insulin Peglispro Increases Lipid Oxidation, Metabolic Flexibility, Thermogenesis And Ketone Bodies Compared To Insulin Glargine In Subjects With Type 1 Diabetes Mellitus.
    Diabetes Obes Metab. 2018 Jan 8. doi: 10.1111/dom.13215.
    PubMed     Abstract available


  578. MATHIEU C, Bode BW, Franek E, Philis-Tsimikas A, et al
    Efficacy and safety of fast-acting insulin aspart in comparison with insulin aspart in type 1 diabetes (onset 1): a 52-week, randomized, treat-to-target, phase 3 trial.
    Diabetes Obes Metab. 2018 Jan 8. doi: 10.1111/dom.13205.
    PubMed     Abstract available


  579. TERAUCHI Y, Tamura M, Senda M, Gunji R, et al
    Long-term safety and efficacy of tofogliflozin add-on to insulin in patients with type 2 diabetes: results from a 52-week, multicenter, randomized, double-blind, open-label extension, Phase 4 study in Japan (J-STEP/INS).
    Diabetes Obes Metab. 2018 Jan 5. doi: 10.1111/dom.13213.
    PubMed     Abstract available


  580. JABBOUR SA, Frias JP, Guja C, Hardy E, et al
    Effects of exenatide once weekly plus dapagliflozin, exenatide once weekly, or dapagliflozin added to metformin monotherapy on body weight, systolic blood pressure, and triglycerides in patients with type 2 diabetes in the DURATION-8 study.
    Diabetes Obes Metab. 2018 Jan 5. doi: 10.1111/dom.13206.
    PubMed     Abstract available


  581. MENEGHINI LF, Lee L, Gupta S, Preblick R, et al
    The association of hypoglycaemia severity and clinical, patient-reported and economic outcomes in US patients with type 2 diabetes using basal insulin.
    Diabetes Obes Metab. 2018 Jan 5. doi: 10.1111/dom.13208.
    PubMed     Abstract available


  582. PACKER M
    Have We Really Demonstrated the Cardiovascular Safety of Antihyperglycemic Drugs? Rethinking the Concepts of Macrovascular and Microvascular Disease in Type 2 Diabetes.
    Diabetes Obes Metab. 2018 Jan 5. doi: 10.1111/dom.13207.
    PubMed     Abstract available


    December 2017
  583. PETTUS J, Reeds D, Santos Cavaiola T, Boeder S, et al
    Effect of a Glucagon Receptor Antibody (REMD-477) in Type 1 Diabetes: A Randomized Controlled Trial.
    Diabetes Obes Metab. 2017 Dec 28. doi: 10.1111/dom.13202.
    PubMed     Abstract available


  584. ZHOU FL, Xie L, Pan C, Wang Y, et al
    Relationship between treatment persistence and A1C trends among patients with type 2 diabetes newly initiated on basal insulin.
    Diabetes Obes Metab. 2017 Dec 26. doi: 10.1111/dom.13200.
    PubMed     Abstract available


  585. WINDING KM, Munch GW, Iepsen UW, Van Hall G, et al
    The effect of low-volume high-intensity interval training versus endurance training on glycemic control in individuals with type 2 diabetes.
    Diabetes Obes Metab. 2017 Dec 22. doi: 10.1111/dom.13198.
    PubMed     Abstract available


  586. ZHOU FL, Ye F, Berhanu P, Gupta VE, et al
    Real-world evidence on clinical and economic outcomes of switching to insulin glargine 300 Units/mL vs other basal insulins in patients with type 2 diabetes on basal insulin.
    Diabetes Obes Metab. 2017 Dec 22. doi: 10.1111/dom.13199.
    PubMed     Abstract available


  587. BUMBU A, Moutairou A, Matar O, Fumeron F, et al
    Non-severe hypoglycemia is associated with weight gain in patients with type 1 diabetes: Results from the Diabetes Control and Complication Trial.
    Diabetes Obes Metab. 2017 Dec 22. doi: 10.1111/dom.13197.
    PubMed     Abstract available


  588. CHON S, Rhee SY, Ahn KJ, Baik SH, et al
    Long-term outcome on glycaemic control and beta-cell preservation of early intensive treatment in patients with newly diagnosed Type 2 Diabetes: A Multicentre Randomised Trial.
    Diabetes Obes Metab. 2017 Dec 22. doi: 10.1111/dom.13196.
    PubMed     Abstract available


  589. PRATLEY RE, Eldor R, Raji A, Golm G, et al
    Ertugliflozin Plus Sitagliptin Versus Either Individual Agent Over 52 Weeks in Patients with Type 2 Diabetes Mellitus Inadequately Controlled With Metformin: The VERTIS FACTORIAL Randomized Trial.
    Diabetes Obes Metab. 2017 Dec 21. doi: 10.1111/dom.13194.
    PubMed     Abstract available


  590. WIGHTMAN SS, Sainsbury CAR, Jones GC
    Visit-to-visit HbA1c variability and systolic blood pressure (SBP) variability are significantly and additively associated with mortality in people with type 1 diabetes: an observational study.
    Diabetes Obes Metab. 2017 Dec 21. doi: 10.1111/dom.13193.
    PubMed     Abstract available


  591. PACKER M
    Role of the Sodium-Hydrogen Exchanger in Mediating the Renal Effects of Drugs Commonly Used in the Treatment of Type 2 Diabetes.
    Diabetes Obes Metab. 2017 Dec 11. doi: 10.1111/dom.13191.
    PubMed     Abstract available


  592. ALSALIM W, Goransson O, Carr RD, Bizzotto R, et al
    Effect of a single dose of the DPP-4 inhibitor sitagliptin on beta-cell function and incretin hormone secretion after meal ingestion in healthy volunteers and drug-naive, well-controlled type 2 diabetes subjects.
    Diabetes Obes Metab. 2017 Dec 11. doi: 10.1111/dom.13192.
    PubMed     Abstract available


  593. JI L, Liu J, Yang J, Li Y, et al
    Comparative effectiveness of metformin monotherapy in extended release and immediate release formulations for the treatment of type 2 diabetes in treatment-naive Chinese patients: analysis of results from the CONSENT trial.
    Diabetes Obes Metab. 2017 Dec 11. doi: 10.1111/dom.13190.
    PubMed     Abstract available


  594. PRICE H, Bluher M, Prager R, Phan TM, et al
    Use and effectiveness of a fixed-ratio combination of insulin degludec/liraglutide (IDegLira) in a real-world population with type 2 diabetes: Results from a European, multicentre, retrospective chart review study.
    Diabetes Obes Metab. 2017 Dec 5. doi: 10.1111/dom.13182.
    PubMed     Abstract available


  595. ZACCARDI F, Dhalwani NN, Dales J, Mani H, et al
    Comparison of glucose-lowering agents following dual therapy failure in type 2 diabetes Systematic review and network meta-analysis of randomised controlled trials.
    Diabetes Obes Metab. 2017 Dec 5. doi: 10.1111/dom.13185.
    PubMed     Abstract available


  596. EL KHOURY P, Roussel R, Fumeron F, Abou-Khalil Y, et al
    Plasma PCSK9 and Cardiovascular Events in Type 2 Diabetes.
    Diabetes Obes Metab. 2017 Dec 5. doi: 10.1111/dom.13181.
    PubMed    


  597. HOME P, Calvi-Gries F, Blonde L, Pilorget V, et al
    Clinical correlates of hypoglycaemia over 4 years in people with type 2 diabetes starting insulin: An analysis from the CREDIT study.
    Diabetes Obes Metab. 2017 Dec 5. doi: 10.1111/dom.13179.
    PubMed     Abstract available


    November 2017
  598. SISKIND D, Russell AW, Gamble C, Winckel K, et al
    Treatment of clozapine-associated obesity and diabetes with exenatide (CODEX) in adults with schizophrenia: a randomised controlled trial.
    Diabetes Obes Metab. 2017 Nov 30. doi: 10.1111/dom.13167.
    PubMed     Abstract available


  599. WANG H, Liu Y, Tian Q, Yang J, et al
    Incretin-based therapies and risk of pancreatic cancer in patients with type 2 diabetes: a meta-analysis of randomised controlled trials.
    Diabetes Obes Metab. 2017 Nov 30. doi: 10.1111/dom.13177.
    PubMed     Abstract available


  600. LOUGHLIN AM, Qiao Q, Nunes AP, Ohman P, et al
    Effectiveness and tolerability of therapy with exenatide once-weekly versus basal insulin among injectable-naive elderly or renal impaired patients with type 2 diabetes in the United States.
    Diabetes Obes Metab. 2017 Nov 30. doi: 10.1111/dom.13175.
    PubMed     Abstract available


  601. HART HUBERTA E, Rutten Guy E, Bontje Kyra N, Vos Rimke C, et al
    Overtreatment of older patients with type 2 diabetes mellitus in primary care.
    Diabetes Obes Metab. 2017 Nov 30. doi: 10.1111/dom.13174.
    PubMed     Abstract available


  602. BOTHA S, Forde L, MacNaughton S, Shearer R, et al
    The effect of non-surgical weight management on weight and glycaemic control in people with type 2 diabetes: a comparison of interventional and non-interventional outcomes at three years.
    Diabetes Obes Metab. 2017 Nov 27. doi: 10.1111/dom.13171.
    PubMed     Abstract available


  603. TAY J, Thompson CH, Luscombe-Marsh ND, Wycherley TP, et al
    Effects of an energy-restricted low-carbohydrate, high unsaturated fat/low saturated fat diet versus a high carbohydrate, low fat diet in type 2 diabetes: a 2 year randomized clinical trial.
    Diabetes Obes Metab. 2017 Nov 27. doi: 10.1111/dom.13164.
    PubMed     Abstract available


  604. VILSBOLL T, Bain SC, Leiter LA, Lingvay I, et al
    Semaglutide, reduction in HbA1c and the risk of diabetic retinopathy.
    Diabetes Obes Metab. 2017 Nov 27. doi: 10.1111/dom.13172.
    PubMed     Abstract available


  605. YE M, Robson PJ, Eurich DT, Vena JE, et al
    Systemic Use of Antibiotics and Risk of Diabetes in Adults: A Nested Case-control Study of Alberta's Tomorrow Project.
    Diabetes Obes Metab. 2017 Nov 20. doi: 10.1111/dom.13163.
    PubMed     Abstract available


  606. CHEN Y, Liu X, Li Q, Ma J, et al
    Saxagliptin add-on therapy in Chinese patients with type 2 diabetes inadequately controlled by insulin with or without metformin: results from the SUPER study, a randomized, double-blind, placebo-controlled trial.
    Diabetes Obes Metab. 2017 Nov 16. doi: 10.1111/dom.13161.
    PubMed     Abstract available


  607. MCGOVERN A, Tippu Z, Hinton W, Munro N, et al
    A comparison of adherence and persistence by medication class in type 2 diabetes: A systematic review and meta-analysis.
    Diabetes Obes Metab. 2017 Nov 14. doi: 10.1111/dom.13160.
    PubMed     Abstract available


  608. TONG L, Pan C, Wang H, Bertolini M, et al
    Impact of delaying treatment intensification with a glucagon-like peptide-1 receptor agonist in patients with type 2 diabetes uncontrolled on basal insulin: a longitudinal study of a US administrative claims database.
    Diabetes Obes Metab. 2017 Nov 8. doi: 10.1111/dom.13156.
    PubMed     Abstract available


  609. CHAN LKY, Wang Y, Ng EKW, Leung PS, et al
    NHE3 Blockade Ameliorates Type 2 Diabetes Mellitus via Inhibition of SGLT1-Mediated Glucose Absorption in the Small Intestine.
    Diabetes Obes Metab. 2017 Nov 7. doi: 10.1111/dom.13151.
    PubMed     Abstract available


  610. INAGAKI N, Harashima SI, Kaku K, Kondo K, et al
    Long-term efficacy and safety of canagliflozin in combination with insulin in Japanese patients with type 2 diabetes mellitus.
    Diabetes Obes Metab. 2017 Nov 7. doi: 10.1111/dom.13152.
    PubMed     Abstract available


  611. JOURDAN T, Park JK, Varga ZV, Paloczi J, et al
    Cannabinoid-1 receptor deletion in podocytes mitigates both glomerular and tubular dysfunction in a mouse model of diabetic nephropathy.
    Diabetes Obes Metab. 2017 Nov 6. doi: 10.1111/dom.13150.
    PubMed     Abstract available


  612. SIEGMUND T, Tentolouris N, Knudsen ST, Lapolla A, et al
    A European, multicentre, retrospective, non-interventional study (EU-TREAT) of the effectiveness of insulin degludec after switching basal insulin in a population with type 1 or type 2 diabetes.
    Diabetes Obes Metab. 2017 Nov 6. doi: 10.1111/dom.13149.
    PubMed     Abstract available


  613. CHEN K, Kang D, Yu M, Zhang R, et al
    Direct head-to-head comparison of glycemic durability of dipeptidyl peptidase-4 inhibitors and sulphonylureas in patients with type 2 diabetes mellitus: a meta-analysis of long-term randomized controlled trials.
    Diabetes Obes Metab. 2017 Nov 2. doi: 10.1111/dom.13147.
    PubMed     Abstract available


  614. HERTROIJS DF, Elissen AM, Brouwers MC, Schaper NC, et al
    A risk score of BMI, HbA1c and triglycerides predicts future glycemic control in type 2 diabetes.
    Diabetes Obes Metab. 2017 Nov 2. doi: 10.1111/dom.13148.
    PubMed     Abstract available


    October 2017
  615. WITTBRODT E, Kong AM, Moore-Schiltz L, Juneau P, et al
    All-Cause and Diabetes-Related Healthcare Costs among U.S. Adults with Type 2 Diabetes Initiating Exenatide Once Weekly or Insulin Glargine.
    Diabetes Obes Metab. 2017 Oct 30. doi: 10.1111/dom.13145.
    PubMed     Abstract available


  616. SKOG O, Korsgren O
    On the etiology of type 1 diabetes: Physiological growth in children impacts disease progression.
    Diabetes Obes Metab. 2017 Oct 30. doi: 10.1111/dom.13144.
    PubMed     Abstract available


  617. KHUNTI K, Kosiborod M
    SGLT 2 inhibitors and cardiovascular outcome studies in Type 2 diabetes: From efficacy to effectiveness.
    Diabetes Obes Metab. 2017 Oct 27. doi: 10.1111/dom.13142.
    PubMed     Abstract available


  618. CASPARD H, Jabbour S, Hammar N, Fenici P, et al
    Recent Trends in the Prevalence of Type 2 Diabetes and the Association With Abdominal Obesity Lead to Growing Health Disparities in the United States.
    Diabetes Obes Metab. 2017 Oct 27. doi: 10.1111/dom.13143.
    PubMed     Abstract available


  619. GEYER MC, Rayner CK, Horowitz M, Couper JJ, et al
    Targeting Postprandial Glycaemia in Children with Diabetes: Opportunities and Challenges.
    Diabetes Obes Metab. 2017 Oct 26. doi: 10.1111/dom.13141.
    PubMed     Abstract available


  620. HUANG J, Yang Y, Hu R, Chen L, et al
    Anti-interleukin-1 therapy has mild hypoglycemic effect in type 2 diabetes.
    Diabetes Obes Metab. 2017 Oct 26. doi: 10.1111/dom.13140.
    PubMed     Abstract available


  621. SHAH A, Levesque K, Pierini E, Rojas B, et al
    Effect of Sitagliptin on Glucose Control in Type 2 Diabetes Mellitus after Roux-en-Y Gastric Bypass Surgery.
    Diabetes Obes Metab. 2017 Oct 26. doi: 10.1111/dom.13139.
    PubMed     Abstract available


  622. HWANG YC, Morrow DA, Cannon CP, Liu Y, et al
    High-sensitivity C-reactive Protein, Low-Density Lipoprotein Cholesterol, and Cardiovascular Outcomes in Patients with Type 2 Diabetes in the EXAMINE (Examination of Cardiovascular Outcomes With Alogliptin Versus Standard of Care) Trial.
    Diabetes Obes Metab. 2017 Oct 24. doi: 10.1111/dom.13136.
    PubMed     Abstract available


  623. TANG T, Abbott S, le Roux CW, Wilson V, et al
    Preoperative Weight Loss With GLP-1 Receptor Agonist Treatment Predicts Greater Weight Loss Achieved by the Combination of Medical Weight Management And Bariatric Surgery In Patients With Type 2 Diabetes: A Longitudinal Analysis.
    Diabetes Obes Metab. 2017 Oct 20. doi: 10.1111/dom.13131.
    PubMed     Abstract available


  624. HENRY R, Rosenstock J, McCarthy JF, Carls G, et al
    Treatment Satisfaction with ITCA 650, a Novel Drug-device Delivering Continuous Exenatide versus Twice-Daily Injections of Exenatide in Type 2 Diabetics on Metformin.
    Diabetes Obes Metab. 2017 Oct 20. doi: 10.1111/dom.13133.
    PubMed     Abstract available


  625. TOP W, Stehouwer C, Lehert P, Kooy A, et al
    Metformin and beta cell function in insulin-treated patients with type 2 diabetes : a randomized placebo-controlled 4.3 year trial.
    Diabetes Obes Metab. 2017 Oct 2. doi: 10.1111/dom.13123.
    PubMed     Abstract available


    September 2017
  626. JABBOUR S, Seufert J, Scheen A, Bailey CJ, et al
    Dapagliflozin in patients with type 2 diabetes mellitus: a pooled analysis of safety data from Phase 2b/3 clinical trials.
    Diabetes Obes Metab. 2017 Sep 26. doi: 10.1111/dom.13124.
    PubMed     Abstract available


  627. MARFELLA R, Sardu C, Calabro P, Siniscalchi M, et al
    Non-ST-Elevation Myocardial Infarction (NSTEMI) outcome in type 2 diabetic patients with non-obstructive coronary artery stenosis: effects of incretin treatment.
    Diabetes Obes Metab. 2017 Sep 26. doi: 10.1111/dom.13122.
    PubMed     Abstract available


  628. PANG B, Zhao LH, Li XL, Song J, et al
    Different intervention strategies for preventing type 2 diabetes mellitus in China: A systematic review and network meta-analysis of randomized controlled trials.
    Diabetes Obes Metab. 2017 Sep 23. doi: 10.1111/dom.13121.
    PubMed     Abstract available


  629. HULST AH, Polderman JAW, Ouweneel E, Pijl AJ, et al
    Perioperative continuation of metformin does not improve glycemic control in patients with type 2 diabetes; a randomized controlled trial.
    Diabetes Obes Metab. 2017 Sep 20. doi: 10.1111/dom.13118.
    PubMed     Abstract available


  630. DOU J, Ma J, Liu J, Wang C, et al
    Efficacy and Safety of Saxagliptin in Combination with Metformin as Initial Therapy in Chinese Patients with Type 2 diabetes: Results from the START Study, a Multicenter, Randomized, Double-blind, Active-controlled, Phase 3 Trial.
    Diabetes Obes Metab. 2017 Sep 19. doi: 10.1111/dom.13117.
    PubMed     Abstract available


  631. DAGOGO-JACK S, Liu J, Eldor R, Amorin G, et al
    Efficacy and safety of the addition of ertugliflozin in patients with type 2 diabetes mellitus inadequately controlled with metformin and sitagliptin: the VERTIS SITA2 placebo-controlled randomized study.
    Diabetes Obes Metab. 2017 Sep 17. doi: 10.1111/dom.13116.
    PubMed     Abstract available


  632. LEITER LA, Cariou B, Muller-Wieland D, Colhoun HM, et al
    Efficacy and safety of alirocumab in insulin-treated individuals with type 1 or type 2 diabetes and high cardiovascular risk: The ODYSSEY DM-INSULIN randomized trial.
    Diabetes Obes Metab. 2017 Sep 14. doi: 10.1111/dom.13114.
    PubMed     Abstract available


  633. YUAN Z, DeFalco FJ, Ryan PB, Schuemie MJ, et al
    Risk of Lower Extremity Amputations in Patients With Type 2 Diabetes Mellitus Treated With SGLT2 Inhibitors in the United States: A Retrospective Cohort Study.
    Diabetes Obes Metab. 2017 Sep 12. doi: 10.1111/dom.13115.
    PubMed     Abstract available


    March 2017
  634. NEAL B, Perkovic V, Matthews DR, Mahaffey KW, et al
    Rationale, design and baseline characteristics of the CANagliflozin cardioVascular Assessment Study-Renal (CANVAS-R): A randomized, placebo-controlled trial.
    Diabetes Obes Metab. 2017;19:387-393.
    PubMed     Abstract available


  635. DRIESSEN JH, van den Bergh JP, van Onzenoort HA, Henry RM, et al
    Long-term use of dipeptidyl peptidase-4 inhibitors and risk of fracture: A retrospective population-based cohort study.
    Diabetes Obes Metab. 2017;19:421-428.
    PubMed     Abstract available


  636. KOZLOVSKI P, Fonseca M, Mohan V, Lukashevich V, et al
    Effect of race and ethnicity on vildagliptin efficacy: A pooled analysis of phase II and III studies.
    Diabetes Obes Metab. 2017;19:429-435.
    PubMed     Abstract available


  637. CAMASTRA S, Astiarraga B, Tura A, Frascerra S, et al
    Effect of exenatide on postprandial glucose fluxes, lipolysis, and ss-cell function in non-diabetic, morbidly obese patients.
    Diabetes Obes Metab. 2017;19:412-420.
    PubMed     Abstract available


  638. KNAPEN LM, de Jong RG, Driessen JH, Keulemans YC, et al
    Use of incretin agents and risk of acute and chronic pancreatitis: A population-based cohort study.
    Diabetes Obes Metab. 2017;19:401-411.
    PubMed     Abstract available


  639. BAIN S, Druyts E, Balijepalli C, Baxter CA, et al
    Cardiovascular events and all-cause mortality associated with sulphonylureas compared with other antihyperglycaemic drugs: A Bayesian meta-analysis of survival data.
    Diabetes Obes Metab. 2017;19:329-335.
    PubMed     Abstract available


  640. BETTGE K, Kahle M, Abd El Aziz MS, Meier JJ, et al
    Occurrence of nausea, vomiting and diarrhoea reported as adverse events in clinical trials studying glucagon-like peptide-1 receptor agonists: A systematic analysis of published clinical trials.
    Diabetes Obes Metab. 2017;19:336-347.
    PubMed     Abstract available


Thank you for your interest in scientific medicine.


AMEDEO Diabetes is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.

Design: